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On the brain: 
 
“The brain is the organ of destiny.  It holds within its humming mechanism secrets that will 
determine the future of the human race.” 
 












"Once the development was ended, the founts of growth and regeneration of the axons and 
dendrites dried up irrevocably.  In the adult centers, the nerve paths are something fixed, ended, 
and immutable.  Everything may die, nothing may be regenerated.  It is for the science of the 
future to change, if possible, this harsh decree." 
 










On graduate school: 
 
"It's supposed to be hard.  If it wasn't hard, everyone would do it.  The hard...is what makes it 
great."  
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 Depending on location and severity, injury to the adult mammalian central nervous 
system (CNS) typically results in neurological deficits ranging from mild motor impairment to 
complete paralysis.  As the regenerative capacity of severed axons is extremely limited, there is a 
great unmet need for strategies that promote neural tissue growth and repair.  There are two 
major extrinsic barriers to axon regeneration in the injured CNS: myelin-associated inhibitors 
(MAIs) and chondroitin sulfate proteoglycans (CSPGs).  MAIs and CSPGs bind to axonal 
receptors and initiate signaling cascades to prevent significant regenerative growth; thus, these 
receptors represent potential targets for therapeutic intervention.  
 The Nogo receptors (NgR1, NgR2, and NgR3) form a small subfamily of proteins, of 
which NgR1 and NgR2 have been shown to act as receptors for MAIs.  Here we report on a 
novel interaction between select members of the Nogo receptor family and CSPGs.  NgR1 and 
NgR3 bind with high affinity and selectivity to the sugar moiety of CSPGs.  In vitro, primary 
neurons isolated from mice lacking both NgR1 and NgR3 (NgR13–/–) grow longer neurites on 
substrate-adsorbed CSPGs than neurons isolated from controls.  NgR13–/– double mutants, but 
not single mutants, show enhanced axonal regeneration of retinal ganglion cell (RGC) fibers 
following optic nerve crush injury in vivo.  When combined with activation of RGC intrinsic 
growth programs, genetic manipulations result in a further increase in optic nerve regeneration.  
These results thus identify NgR1 and NgR3 as novel CSPG receptors and provide unexpected 




at examining whether the regenerating fibers of NgR13–/– mice are electrically active and able to 
reach their pre-injury synaptic targets. 
 We have also identified the low-density lipoprotein receptor-related protein 1 (LRP1) as a 
novel receptor for one of the MAIs, the myelin-associated glycoprotein (MAG).  In addition to 
its established role in neuronal growth inhibition, MAG has recently been shown to protect 
neurons from axonal degeneration and excitotoxicity.  Here we performed a comprehensive 
dissection of the growth-inhibitory and protective functions of MAG and identified distinct 
receptor-signaling systems that mediate these two functions.  On the receptor level, we show that 
paired immunoglobulin (Ig)-like receptor B (PirB) and LRP1 mediate MAG-induced neurite 
outgrowth inhibition in a cell type-specific manner, whereas NgR1 mediates MAG-induced 
neuroprotection.  Loss of NgR1 results in increased vulnerability to acrylamide toxicity, as 
determined by rotarod performance and compound action potential recordings of the sciatic 
nerve.  NgR1-/- mice also show increased susceptibility to kainic acid-induced epileptic seizures.  
Additionally, we find that MAG growth inhibition requires negative regulation of the PI3K-
AKT-mTOR pathway, whereas MAG protection involves blockade of calpain-induced cleavage 
of the neuronal cytoskeleton.  Finally, structural analysis shows that the neuroprotective activity 
resides within the N-terminal portion of the MAG ectodomain, whereas the growth-inhibitory 
activity resides near the C-terminus.  Collectively, we provide novel insights into the molecular 








Can development be recapitulated in the adult? 
Current strategies and future challenges for mammalian axon regeneration 
 
1.1 Abstract 
 A devastating form of central nervous system (CNS) injury is traumatic injury to the 
spinal cord.  The National Spinal Cord Injury Statistical Center at the University of Alabama 
estimates the number of Americans living with spinal cord injury (SCI) to be around 250,000 
(with ~11,000 new injuries every year).  In higher vertebrates, including humans, the 
regenerative capacity of severed axons in the adult CNS is extremely limited.  Therapeutic 
interventions are sparse, and the prognosis for significant or complete recovery following 
moderate to severe SCI is poor.  Many neurons located above and below the injury site in the 
spinal cord survive for several years after SCI; their axons, however, are severed or damaged and 
fail to propagate information in the form of electrical impulses past the site of injury.  A decrease 
or complete loss of axon potential propagation results in partial or complete paralysis of the body 
distal to the location of injury.  Thus, a major goal of SCI research is to reestablish neuronal 
connectivity lost as a consequence of injury.  There are several strategies for how this can be 
achieved.  Reinnervation can be accomplished by (1) long-distance regeneration of severed 
axons followed by synapse formation on pre-injury targets, (2) short-distance axonal growth and 




or (3) compensatory sprouting of spared axons that maintain connectivity beyond the injury site.  
Mounting evidence suggests that the limited degree of spontaneous recovery observed following 
CNS injury is a result of compensatory sprouting from spared neuronal systems.  While 
substantial progress has been made in promoting axonal sprouting and regenerative growth in 
CNS-injured rodents, challenges ahead include translation of the most promising advances to 
human subjects with SCI. 
 
1.2 Introduction 
 Accounts of SCI and attempts to treat it date back to ancient times.  The Greek physician 
Hippocrates (460-377 BC) wrote: “there are no treatment options for SCI that resulted in 
paralysis and unfortunately, those patients suffering from such injuries were destined to die.”  
Although survival after injury and surgical options for SCI patients have dramatically improved 
in recent years, moderate to severe SCI that causes substantial functional deficits remains a 
major medical challenge, with limited treatment options and a poor prognosis for complete 
recovery.  Advances in emergency and acute care improve survival rates following SCI and 
increase the number of individuals who have to cope with severe disabilities.  New treatment 
options to promote repair following SCI are urgently needed.   
 Although the spinal cord is well protected by hard bones of segmentally aligned vertebrae 
bodies, the vertebrae column can be fractured or dislocated during a car accident or a severe 
sports injury.  In most cases, SCI is caused by fracture or compression of the vertebral column at 
a specific location, resulting in contusion or transection of neural tissue.  An injury to the spinal 
cord can damage a few, many, or almost all spinally projecting fiber tracts.  Some injuries will 




level at which the SCI is inflicted and the severity of neural tissue damage, it may cause partial 
or full para- or tetraplegia. 
 On a cellular level, compression or disruption of neural tissue leads to transection of 
ascending and descending fiber tracts.  Axons of spinally projecting neurons are bundled into 
specific fiber tracts that propagate electrical impulses that carry sensory information or 
participate in motor coordination.  Axons in fiber tracts are insulated by myelin sheaths to ensure 
rapid propagation of these electrical impulses.  If the axon of a projection neuron is severed, this 
leads to “self-destruction” and total disintegration of the axonal segment located distal (relative 
to the neuronal cell body) to the transection site.  Less severe trauma causes focal demyelination 
with preservation of axonal continuity.  Transection or demyelinating lesions produce a 
reduction or complete block of electrical impulse propagation past the injury site.  The ability of 
partially demyelinated fibers to faithfully carry long trains of complex electrical impulses is 
greatly impaired and leads to various degrees of functional impairments.  Thus, relatively small 
lesions to the adult spinal cord can lead to substantial functional loss.   
 The focus of this chapter is to discuss recent advances in our understanding of the 
biochemical signaling cascades and molecular mechanisms that limit spontaneous regeneration 
of neuronal networks following CNS injury.  Cell surface receptor complexes and intracellular 
signaling pathways implicated in neuronal growth inhibition, as well as new treatment strategies 
for SCI, are summarized. 
 
1.2.1 Spinal Cord Injury Repair: A Complex Problem 
 A SCI is a complex biological and medical problem.  Initial damage caused by the impact 




complex cellular and biochemical cascades that cause cell death and degeneration of neural 
tissue over days and weeks following injury - processes generally referred to as secondary 
damage.  Secondary damage caused by glutamate excitotoxicity and hypoxia happens within 
minutes following SCI and for logistical reasons is difficult to block.  Subsequent waves of cell 
death, inflammatory immune responses, and oxidative damage may be more realistic targets to 
limit secondary damage.   
 Because the molecular and cellular environment of the spinal cord is constantly changing 
from the moment of injury until several weeks to months later, combination therapies need to be 
designed and applied to target specific mechanisms of damage at different time points after 
injury.  Strategies for the repair of injured neural tissue may target neuronal growth, formation of 
new synapses (synaptogenesis), plasticity of newly formed and existing synapses, and axon 
myelination.  Understanding the cellular and molecular mechanisms involved in both the healthy 
and injured spinal cord will hopefully point the way to therapies that prevent secondary damage, 
encourage axons to grow and reconnect past injured areas within the spinal cord, and promote 
adaptive neuronal plasticity.  A more detailed understanding of these processes at the molecular 
level is of great interest biologically and believed to be key to the development of therapeutic 
interventions for SCI. 
 
1.2.2 Severed Axons in the Injured Adult Mammalian CNS Show Poor Regenerative Growth 
 Long-distance axon regeneration often occurs following peripheral nervous system (PNS) 
injury but does not occur spontaneously in the injured adult mammalian CNS (Table 1.1).  Thus, 
in mammals, injured neurons of the PNS and CNS exhibit quite distinct adaptive strategies to 




morphologically more diverse (Gaudet et al., 2011).  Research on many fronts has revealed that 
encouraging axons to grow after injury is a complicated and challenging task.   
 Most CNS neurons have the capacity to extend processes following injury; however, the 
environment in the injured adult brain or spinal cord does not encourage growth (Aguayo et al., 
1978; Aguayo et al., 1981).  This environment not only lacks the growth-promoting molecules 
that are present in the developing CNS, but it also contains substances that actively block axon 
extension (Schwab et al., 1993).  Moreover, intrinsic cell growth programs of mature CNS 
neurons are “more quiescent” compared with developing neurons.  Even when placed in an 
environment that supports neuronal sprouting and process outgrowth, growth rates of mature 
neurons are substantially lower compared with developing neurons (Goldberg et al., 2002).  As 
discussed later, different approaches have been used successfully to promote axonal growth and 
improve behavioral outcomes in the injured adult mammalian CNS.  Treatment strategies fall 
into three general categories: (1) functional depletion of growth-inhibitory environmental cues; 
(2) application of growth-promoting substrates or growth factors; and (3) activation of neuron 
intrinsic growth programs. 
 
1.3 Inhibitors of CNS Axon Regeneration  
 Myelin sheaths produced by oligodendrocytes are wrapped around axons of many CNS 
neurons and facilitate rapid propagation of electrical impulses.  Protein components associated 
with CNS myelin are profoundly inhibitory for neurite outgrowth when presented to cultured 
neurons.  In vivo, myelin-associated inhibitors of growth are thought to contribute to the growth-
inhibitory nature of injured adult mammalian CNS tissue (Hu and Strittmatter, 2004; Schwab et 




at the molecular level, including myelin-associated glycoprotein (MAG), the reticulon family 
member Nogo-A, and oligodendrocyte myelin glycoprotein (OMgp) (Filbin, 2003; Xie and 
Zheng, 2008).  Although most attention has focused on the mechanisms of action of these three 
inhibitors during CNS axon regeneration, it is important to point out that additional growth 
inhibitors are present in adult CNS tissue, many of which are upregulated by injury (Figure 1.1).  
Repulsive or growth-inhibitory molecules belonging to the semaphorin, ephrin, and netrin 
families of axon guidance molecules are present in CNS myelin and contribute to the 
regenerative failure of different types of injured CNS axons (Bolsover et al., 2008; Low et al., 
2008).  Chondroitin sulfate proteoglycans (CSPGs) comprise an important class of growth 
inhibitors (Davies et al., 1999; Snow et al., 1990b).  Different types of CSPGs are broadly 
expressed in the CNS and are important components of the extracellular matrix (Zimmermann 
and Dours-Zimmermann, 2008).  Some CSPG family members, including aggrecan, neurocan, 
and versican, show regional upregulation following injury to the brain or spinal cord (McKeon et 
al., 1995).  Near the injury site, a glial scar starts to form that is composed of reactive astrocytes, 
migrating meningeal cells, and microglia.  Reactive astrocytes express high levels of inhibitory 
CSPGs that block regenerative axonal growth following SCI in rodents (Bradbury et al., 2002; 
Shen et al., 2010).  Additional molecules that may contribute to the growth-inhibitory nature of 
adult mammalian CNS tissue include members of the slit family of inhibitory axon guidance 
cues (Lau and Margolis, 2010), wnt family members (Liu et al., 2008), the lipid sulfatide 
(Winzeler et al., 2011), and blood-derived factors such as fibrinogen (Schachtrup et al., 2007).  
Expression levels and distribution of these growth-inhibitory molecules are regulated by injury.  




functional depletion of any individual inhibitor alone is likely not sufficient to significantly 
enhance regenerative growth of injured CNS neurons. 
                                    
                                                                                                               
1.3.1 Myelin-Associated Inhibitors 
 While the growth-inhibitory nature of CNS myelin is well established, an important 
question concerns the identification and characterization of specific myelin inhibitors at the 
molecular level.  Of equal interest is the identification of the neuronal cell surface receptors 
employed by myelin inhibitors and the characterization of the intracellular signaling cascades 
that are activated upon ligand binding and lead to growth inhibition or axon retraction.  In this 
section, we give an overview of the prototypic myelin inhibitors MAG, Nogo, and OMgp, and 
additional inhibitors of growth found in CNS myelin. 
 
Myelin-associated glycoprotein 
 As discussed above, CNS myelin contains a number of growth-inhibitory factors.  
Biochemical purification of one growth-inhibitory activity identified MAG, a previously known 
myelin component of largely unknown function (McKerracher et al., 1994; Mukhopadhyay et al., 
1994).  MAG (also known as Siglec4a) is a type 1 transmembrane protein and is a member of the 
sialic acid-binding immunoglobulin (Ig) lectins, composed of an extracellular region with five 
Ig-like domains, a transmembrane domain, and a cytoplasmic tail (Filbin, 2003).  A short (S-
MAG) and large (L-MAG) splice form of MAG exist, differing only in the length of the 
cytoplasmic regions (Lai et al., 1987; Salzer et al., 1987).  The lectin activity of MAG complexes 
with terminal sialic acids on gangliosides and sialo-glycoproteins, with preferential binding of 




2001).  The MAG lectin activity critically depends on the presence of a conserved arginine 
residue (Arg118) located in the first Ig-like domain (Tang et al., 1997).  The importance of the 
MAG lectin activity for neuronal growth inhibition has been examined extensively and was 
found to augment the inhibitory action when MAG is presented at limiting concentrations.  At 
high concentrations of MAG, however, the lectin activity is not required for neurite outgrowth 
inhibition in vitro (Tang et al., 1997; Vinson et al., 2001; Vyas et al., 2002).  Of interest, terminal 
sialic acid moieties appear to limit spinal axon growth into implanted peripheral nerve grafts in a 
rat model of brachial plexus avulsion in vivo (Yang et al., 2006).  Moreover, intrathecal infusion 
of sialidase in rats following spinal cord contusion injury enhances axonal sprouting and leads to 
improved behavioral outcomes (Mountney et al., 2010). 
 Of interest for axonal growth and regeneration is the observation that MAG is a 
bifunctional molecule that influences axonal extension in an age-dependent manner.  Initially, 
MAG was shown to mildly promote the neurite outgrowth of postnatal day 1 (P1) dorsal root 
ganglion (DRG) neurons and embryonic day 17 (E17) spinal neurons plated on fibroblast 
monolayers stably expressing recombinant L-MAG (Johnson et al., 1989; Turnley and Bartlett, 
1998).  At more mature stages, these neuronal cell types, as well as several other types of 
primary neurons, are all strongly inhibited by MAG (DeBellard et al., 1996; McKerracher et al., 
1994; Mukhopadhyay et al., 1994).  Despite the well-established growth-inhibitory action of 
MAG in vitro, nervous system regeneration studies in MAG-/- mice showed little or no enhanced 
axonal regeneration following CNS injury (Bartsch et al., 1995; Li et al., 1996).  Following optic 
nerve crush injury in adult MAG-/- mice, no improvement in regeneration of retinal ganglion cell 
(RGC) axons is seen.  Following bilateral transection of the dorsal spinal cord, longitudinal 




(Bartsch et al., 1995).  A subsequent study showed minimal enhancement of corticospinal tract 
(CST) fiber regeneration following dorsal hemisection lesions at the thoracic level in adult  
MAG-/- mice (Li et al., 1996).  Based on these studies, it can be concluded that germline ablation 




 Myelin-associated inhibitory activities with molecular masses of 35- and 250-kDa were 
first described by Caroni and Schwab (Caroni and Schwab, 1988a).  A function-blocking 
monoclonal antibody (called IN-1) was raised against a partially purified inhibitory activity and 
shown to reduce the myelin inhibitory effects toward sensory and sympathetic neurons in vitro 
(Caroni and Schwab, 1988b).  In vivo, IN-1 was found to promote some degree of axonal 
sprouting and regeneration of severed CST axons (Schnell and Schwab, 1990).  Regenerating 
raphespinal and coeruleospinal projections were also increased following IN-1 treatment.  
Importantly, anatomical growth and sprouting in IN-1-treated animals correlated with improved 
recovery of locomotor function (Bregman et al., 1995). 
 Despite the promising results with IN-1 in spinal cord-injured rodents, the antigen(s) 
recognized and neutralized by the IN-1 antibody remained elusive for some time.  Based on 
partial sequence information of the IN-1 antigen, three groups independently identified the 
reticulon family member Nogo-A (also known as RTN4a) as a growth-inhibitory protein (Chen 
et al., 2000; GrandPre et al., 2000; Prinjha et al., 2000).  Recombinant Nogo-A is sufficient to 
inhibit neurite outgrowth in vitro, and the growth-inhibitory activity of Nogo-A is largely 




member as an inhibitor of axonal growth was unexpected, given that other reticulon proteins are 
largely confined to the endoplasmic reticulum (Voeltz et al., 2006).  Nogo appears to be an 
exception as the protein is found on the cell surface of oligodendrocytes and neurons (Yang and 
Strittmatter, 2007).  Alternative splicing of the Nogo gene results in three isoforms, Nogo-A, -B, 
and -C, all of which are membrane-associated proteins that contain a common carboxy-terminal 
region but differ in their amino-terminal portions (Dodd et al., 2005).  Included within the 
common carboxy-terminal region is an inhibitory 66 amino acid hydrophilic loop, Nogo-66, 
which is extracellular and located between two hydrophobic transmembrane-spanning regions 
(GrandPre et al., 2000).  Another inhibitory activity, NogoΔ20, is located in the amino-terminal 
region and specific for the Nogo-A isoform.  Both Nogo-66 and NogoΔ20 have been shown to 
inhibit neurite outgrowth and induce growth cone collapse in vitro (Oertle et al., 2003).  
NogoΔ20-induced growth cone collapse is mediated through Nogo-A signaling endosomes, 
which result from Pincher-dependent endocytosis.  These signalosomes can act within growth 
cones and can also be transported from neurites to cell bodies of DRG neurons (Joset et al., 
2010).   
 While all Nogo isoforms are expressed in the developing and adult mammalian nervous 
system, the expression pattern of Nogo-A is of particular interest.  Nogo-A is expressed by 
several types of neurons, as well as oligodendrocytes and their processes.  Consistent with a role 
of Nogo-A as a myelin-associated inhibitor of axon regeneration, its expression is detected at 
areas of oligodendrocyte-axon contact, as well as in the inner and outer loops of the myelin 
sheath (Huber et al., 2002; Wang et al., 2002c).  Following spinal cord transection, an increase of 
Nogo-A is seen around the injury site, which does not return to baseline levels until 1 month 




glia of the PNS.  Consistent with the idea that Nogo-A contributes to the regenerative failure of 
adult CNS neurons in higher vertebrates, inhibitory domains of mammalian Nogo-A are either 
missing or mutated in lower vertebrates.  The Nogo-66 loop is present in zebrafish but does not 
inhibit neurite outgrowth in vitro (Abdesselem et al., 2009; Schweigreiter, 2008). 
 Regeneration studies in spinal cord-injured Nogo mutants have been inconclusive and 
remain a matter of debate.  Following dorsal column lesion of adult mice that lack all three Nogo 
gene splice forms (Nogo-A/-B/-C-/- mice), no detectable enhancement of CST axon regeneration 
is seen beyond the lesion site (Lee et al., 2009b; Zheng et al., 2003).  In an independent study, 
extensive sprouting of corticospinal axons rostral to the spinal cord transection site and recovery 
of motor function in young adult Nogo-A/-B-/- mice was reported (Kim et al., 2003).  A mild 
anatomical regeneration phenotype was reported for Nogo-A-/- mice by the group of Martin 
Schwab.  A confounding effect of Nogo-A-/- mice is the strong upregulation of Nogo-B in the 
CNS (Simonen et al., 2003).  Due to differences in the gene targeting strategy to functionally 
ablate Nogo, mouse genetic backgrounds, lesion models, and axon tracing techniques employed, 
a direct comparison of these apparently conflicting results cannot be made (Cafferty et al., 2007; 
Dimou et al., 2006; Steward et al., 2007). 
 
Oligodendrocyte myelin glycoprotein 
 A third inhibitor of growth associated with CNS myelin is OMgp, a member of the 
leucine-rich repeat (LRR) family of proteins (Kottis et al., 2002; Wang et al., 2002b).  The 
ectodomain of OMgp is composed of eight canonical LRRs followed by a serine/threonine-rich 
region and a glycosylphosphatidylinositol (GPI) anchor for membrane attachment (Mikol and 




oligodendrocytes; however, it is also expressed in a wide range of neuronal populations, 
including hippocampal pyramidal cells, Purkinje cells of the cerebellum, and brainstem 
motoneurons (Habib et al., 1998; Huang et al., 2005; Lee et al., 2009a; Mikol and Stefansson, 
1988).  As a myelin inhibitor, OMgp is able to induce growth cone collapse and restrict neurite 
outgrowth in a number of primary neuronal cell types in vitro (Kottis et al., 2002; Wang et al., 
2002b).  In vivo, regeneration studies of spinal cord-injured OMgp-/- mice show minimal 
anatomical growth or functional improvements (Ji et al., 2008). 
 Collectively, individual germline ablation of Nogo, MAG, or OMgp has failed to 
demonstrate long-distance regeneration of severed CST axons, the most important spinal tract for 
motor function.  As discussed above, the presence of multiple growth-inhibitory proteins in the 
injured adult CNS indicates that some degree of functional redundancy exists.  To test this idea, 
mice were generated that are deficient in Nogo, OMgp, and MAG combined.  Two independent 
studies with spinal cord-injured Nogo/OMgp/MAG-/- mice were recently carried out.  In one 
study, it was reported that the combined loss of OMgp and MAG does not lead to enhanced 
sprouting of CST axons following dorsal hemisection.  Nogo-A/-B-/- mice show enhanced 
sprouting of CST axons across the midline, and sprouting is further enhanced in                   
Nogo-A/-B/OMgp/MAG-/- mice.  Based on these observations it was suggested that Nogo-A/-B is 
a major inhibitor of axonal growth and that loss of OMgp and MAG has a synergistic effect on 
axonal sprouting when simultaneously ablated with Nogo-A/-B (Cafferty et al., 2010).  In 
addition to the enhanced collateral sprouting from uninjured CST fibers, Cafferty et al. observed 
regenerative CST and raphespinal fiber growth past the injury site in Nogo-A/-B-/- mice, which 
was further enhanced in Nogo-A/-B/OMgp/MAG-/- mice.  Improved locomotor recovery was also 




 In an independent study by Lee et al., Nogo-A/-B/-C/OMgp/MAG-/- mice failed to show 
enhanced CST sprouting or longitudinal axon growth of CST and raphespinal fibers past the 
injury site (Lee et al., 2010a).  Interestingly, raphespinal axon sprouting was enhanced with 
OMgp-/- or MAG-/- mice but not with Nogo-A/-B/-C-/- mice.  There was no further enhancement of 
axonal sprouting with Nogo-A/-B/-C/OMgp/MAG-/- mice, and behavioral outcomes were not 
improved (Lee et al., 2010a).  Possible explanations for the discrepancies between the two 
studies include differences in how the mutant mice were generated and the injury models 
employed to assess CNS axon regeneration and sprouting.  However, both studies indicate that 
the combined ablation of three major inhibitors of growth may not be sufficient to achieve 
substantial regenerative growth.  There are several reasons that may account for the limited 
regeneration observed in Nogo/OMgp/MAG-/- mice: (1) canonical axon guidance molecules are 
still present in these mice and may be sufficient to block CNS axon regeneration; (2) inhibitors 
associated with the glial scar may be sufficient to prevent long-distance axonal growth; (3) 
trophic factors are absent; and (4) intrinsic growth programs need to be activated.  Finally, it is 
important to point out that germline ablation of Nogo, MAG, and OMgp may lead to activation 
of compensatory mechanisms in the nervous system of mutant mice, masking potential positive 
effects on axonal growth or behavioral outcomes following SCI. 
 
Other myelin-associated inhibitors                                                                             
 In addition to the prototypic myelin-associated inhibitors Nogo, MAG and OMgp, axon 
guidance molecules expressed in the mature CNS or upregulated following CNS injury have 
been implicated in axon growth inhibition.  For example, the semaphorin family of both secreted 




chemoattractant roles in developmental axon pathfinding, fasciculation, and branching (Dent et 
al., 2004; Luo et al., 1993; Taniguchi et al., 1997; Tran et al., 2007).  However, several 
semaphorin proteins are present in the mature CNS and have roles in limiting neuronal growth 
(Cohen et al., 2003; Pasterkamp and Verhaagen, 2006).  The transmembrane semaphorin 
Sema4D is selectively expressed by oligodendrocytes and CNS myelin in the postnatal mouse 
brain.  Furthermore, a strong upregulation of Sema4D expression is seen 1 week following spinal 
cord lesion in adult mice, specifically in oligodendrocytes at the periphery of the lesion (Moreau-
Fauvarque et al., 2003).  In addition, the GPI-anchored semaphorin Sema7A is expressed by 
oligodendrocytes in the spinal cord white matter of the postnatal rat (Pasterkamp et al., 2007).  
Recent evidence has also implicated Sema6A and one of its receptors, PlexinA2, in limiting 
axonal growth following a unilateral pyramidotomy injury model (Shim et al., 2012). 
 Another guidance cue that has been shown to function as a myelin-associated inhibitor of 
axon regeneration is netrin-1 (Low et al., 2008).  During nervous system development, netrin-1 
functions as a long-range chemotropic guidance molecule that either attracts or repels axons 
depending on surface expression of the netrin receptors DCC, UNC5, or DSCAM (Kennedy et 
al., 1994; Moore et al., 2007; Serafini et al., 1994).  As with members of the semaphorin family, 
netrin-1 is expressed in the adult CNS, particularly by neurons and oligodendrocytes in the spinal 
cord (Manitt et al., 2001).  Furthermore, netrin-1 is enriched in periaxonal myelin and associates 
with the extracellular matrix.  Following adult rat SCI, netrin-1 is expressed by neurons and 
oligodendrocytes immediately adjacent to the lesion (Manitt et al., 2006).  In vitro, neutralization 
of netrin-1 with soluble UNC5 receptor leads to enhanced neurite outgrowth of embryonic spinal 




containing netrin-1-secreting fibroblasts is significantly reduced compared to axonal growth into 
control grafts (Low et al., 2008). 
 A third family of axon guidance molecules implicated in limiting CNS axon regeneration 
is the ephrins.  Ephrins are membrane-bound proteins that participate in both forward and reverse 
signaling through Eph receptor tyrosine kinases to influence developmental axon guidance, 
fasciculation, and cell migration (O’Leary and Wilkinson, 1999; Wilkinson, 2001).  Expression 
of several ephrins and Eph receptors continues beyond development in rats and humans (Liebl et 
al., 2003; Sobel, 2005), many of which are upregulated following SCI, optic nerve injury, brain 
injury, or CNS disease (Bundesen et al., 2003; Goldshmit et al., 2004; Knoll et al., 2001; 
Moreno-Flores and Wandosell, 1999; Sobel, 2005; Wang et al., 2003; Willson et al., 2002).  In 
particular, ephrinB3, which is expressed in postnatal myelinating oligodendrocytes, inhibits 
growth of EphA4-expressing cortical neurons in vitro.  In addition, EphA4 activation is 
eliminated and outgrowth inhibition is significantly reduced when cortical neurons are plated on 
myelin from ephrinB3-/- mice compared to control myelin (Benson et al., 2005).  In spinal cord-
injured rats, infusion of an EphA4 peptide antagonist enhances CST sprouting and promotes 
functional recovery; however, axon regeneration across the lesion site is not seen (Fabes et al., 
2007).  More recent studies have demonstrated substantial axon regeneration and behavioral 
improvements in a hemisection model of SCI using prolonged administration of EphA4 blockers 
(Goldshmit et al., 2011), as well as significant axon regeneration following optic nerve crush 
injury in ephrinB3-/- mice (Duffy et al., 2012).  Collectively, these studies suggest that canonical 





 More recently, the lipid sulfatide was shown to be a novel myelin-associated inhibitor of 
growth (Winzeler et al., 2011).  Purified sulfatide from brain is sufficient to inhibit outgrowth of 
primary neurons, an effect that requires both the sulfate group and fatty acid moiety.  Loss of 
sulfatide function significantly reduces the inhibitory effects of crude CNS myelin in vitro; 
however, mice lacking sulfatide do not show enhanced RGC axon regeneration following optic 
nerve crush injury in vivo.  This is not altogether unexpected, given the presence of several other 
inhibitory molecules at the CNS injury site.  Interestingly, an in vivo role for sulfatides in RGC 
axon regeneration is uncovered when RGC intrinsic growth programs are activated by 
intravitreal injection of the yeast cell wall extract Zymosan.  Either injection of Zymosan or lens 
injury has been shown to stimulate an inflammatory response (Yin et al., 2003), with the 
subsequent release of RGC growth-promoting factors, including oncomodulin (Yin et al., 2009), 
ciliary neurotrophic factor (CNTF), and leukemia inhibitory factor (LIF) (Leibinger et al., 2009).  
This response alone is sufficient to enhance regeneration of RGC axons following crush injury to 
the optic nerve.  Intravitreal injection of Zymosan in the absence of sulfatides results in 
significantly more axon regeneration than Zymosan alone, suggesting that there are additive 
effects when extrinsic inhibitory and intrinsic growth-promoting pathways are manipulated 
(Winzeler et al., 2011). 
 
1.3.2 Receptor Complexes for the Prototypic Myelin-Associated Inhibitors 
 
Nogo-66 receptor 1 
 While the growth-inhibitory nature of adult mammalian CNS myelin is well established 




regeneration, comparatively little is known about the mechanisms by which myelin inhibitors 
signal growth inhibition to neurons.  To monitor growth inhibition by Nogo, MAG, and OMgp in 
vitro, and to test the role of potential receptor candidates, two different experimental paradigms 
are used: (1) chronic presentation of substrate-bound inhibitor to measure neurite extension and 
(2) acute application of soluble inhibitor to assay collapse of neuronal growth cones at the 
leading tip of neuritis.  The potent action of Nogo, MAG, and OMgp in neuronal inhibition 
assays suggests the existence of high-affinity cell surface receptors that recognize and bind these 
inhibitors to activate intracellular signaling cascades that ultimately destabilize the neuronal 
cytoskeleton.   
 Shortly after the identification of Nogo, a high-affinity binding partner for one of its 
inhibitory domains (Nogo-66) was discovered and named the Nogo-66 receptor 1 (NgR1) 
(Fournier et al., 2001).  To demonstrate the functional significance of the newly identified 
NgR1/Nogo-66 interaction, a gain-of-function approach was used.  E7 DRG neurons do not 
express NgR1, and their growth cones do not collapse in the presence of acutely applied Nogo-
66.  Ectopic expression of NgR1 in these neurons was sufficient to induce growth cone collapse 
in the presence of Nogo-66 (Fournier et al., 2001).  These studies identified NgR1 as a functional 
receptor for Nogo-66-elicited growth cone collapse. 
 NgR1 is a GPI-anchored protein comprised of 8.5 canonical LRRs flanked by cysteine-
rich N- and C-terminal capping domains (LRRNT and LRRCT) (Fournier et al., 2001).  The 
LRRNT-LRR-LRRCT cluster of NgR1 is connected to the cell membrane via a ~100-amino acid 
stalk region and a GPI anchor.  NgR1 can be shed off the cell surface by metalloproteinases 
(Ferraro et al., 2011; Walmsley et al., 2004) and is abundantly expressed in different types of 




hippocampus, neocortex, and basolateral amygdala (Funahashi et al., 2008; Hunt et al., 2002; 
Josephson et al., 2002; Lee et al., 2008). 
 Shortly after the identification of NgR1 as a high affinity receptor for Nogo-66, it was 
found that NgR1 also binds to the myelin inhibitors MAG and OMgp (Domeniconi et al., 2002; 
Liu et al., 2002; Wang et al., 2002b).  These findings were quite surprising, given the lack of any 
apparent structural similarities among the three NgR1 ligands.  Consistent with the idea that 
NgR1 functions as a high-affinity receptor for Nogo-66, MAG, and OMgp, DRG neurons 
isolated from NgR1-/- mice are more resistant to inhibitor-induced growth cone collapse than age-
matched wild-type control neurons (Kim et al., 2004).  Unexpectedly, when assayed for neurite 
outgrowth inhibition on substrate-coated myelin or Nogo-66, DRG neurons and cerebellar 
granule neurons (CGNs) isolated from NgR1-/- mice are strongly inhibited and do not extend 
processes that are longer than those from wild-type littermate controls (Zheng et al., 2005).  
Thus, loss of NgR1 is not sufficient to overcome myelin or Nogo-66 inhibition when presented 
in substrate-bound form.  These seemingly disparate results (Kim et al., 2004; Zheng et al., 2005) 
were later reconciled by a study showing that NgR1 is dispensable for MAG- and OMgp-
mediated inhibition of neurite extension but is necessary for MAG- and OMgp-induced growth 
cone collapse (Chivatakarn et al., 2007).  These results provide evidence that the growth cone 
collapsing activities and substrate growth-inhibitory activities of inhibitory ligands can be 
dissociated.  Furthermore, based on these observations it was concluded that additional and 
NgR1-independent mechanisms must exist for Nogo-,MAG-, and OMgp-mediated inhibition of 
neurite outgrowth. 
 NgR1 is the founding member of a small gene family that also includes NgR2 and NgR3 




organization and are expressed in overlapping, yet distinct patterns in the juvenile and adult 
CNS.  NgR2 strongly associates with MAG but unlike NgR1, it does not support binding of 
Nogo-66 or OMgp.  Ectopic expression of NgR2 in neonatal DRG neurons is sufficient to confer 
inhibitory responses to MAG (Venkatesh et al., 2005).  Loss of NgR2 alone is not sufficient to 
attenuate MAG-elicited neurite outgrowth inhibition.  The combined loss of NgR1 and NgR2 
results in a significant yet incomplete attenuation of MAG inhibition in vitro (Worter et al., 
2009). 
 In vivo, transection injury to the dorsal spinal cord of NgR1-/- mice failed to demonstrate 
improved longitudinal growth of CST axons beyond the lesion site (Kim et al., 2004; Zheng et 
al., 2005).  However, in a separate injury model involving unilateral pyramidotomy, collateral 
sprouting of uninjured CST axons into the denervated cervical gray matter was enhanced and 
associated with improved recovery of fine motor skills in the forelimb compared to wild-type 
controls (Cafferty and Strittmatter, 2006).  Furthermore, some degree of regeneration of 
raphespinal and rubrospinal axons following dorsal hemisection of the spinal cord was seen in 
NgR1-/- mice.  In particular, a significant increase in weightbearing postures was reported, most 
likely mediated in part by raphespinal tract recovery (Kim et al., 2004).  In an optic nerve injury 
model, however, transduction of RGCs with a viral vector that mediates expression of a 
dominant-negative form of NgR1 (NgRDN) had no effect on axon regeneration.  However, when 
combined with lens injury to activate cell intrinsic growth programs in RGCs, NgRDN 






 As NgR1 is a GPI-anchored protein, it is predicted to interact with one or several 
membrane-spanning co-receptors to allow signal transduction across the neuronal plasma 
membrane following inhibitor binding.  It has been proposed that neurite outgrowth inhibition by 
Nogo-66, MAG, and OMgp is mediated by a multi-component receptor complex, which includes 
NgR1, the transmembrane LRR protein Lingo-1, and a member of the tumor necrosis factor 
(TNF) receptor superfamily, either p75NTR or TROY (Mi et al., 2004; Park et al., 2005; Shao et 
al., 2005; Wang et al., 2002a; Yamashita et al., 2002).  In vitro, Lingo-1 is an essential functional 
component of the NgR1/p75NTR complex, and Lingo-1 has been shown to associate with both 
molecules in vivo (Llorens et al., 2008; Mi et al., 2004).  Furthermore, treatment of rats with a 
Lingo-1 antagonist (Lingo-1-Fc), which inhibits the binding of Lingo-1 to NgR1, significantly 
improves functional recovery and promotes axonal sprouting following dorsal or lateral 
hemisection of the spinal cord (Ji et al., 2006). 
 Interestingly, neuronal expression of p75NTR and TROY is quite restricted in the mature 
nervous system and absent from several neuronal cell types strongly inhibited by myelin 
(Barrette et al., 2007; Park et al., 2005; Roux and Barker, 2002).  Furthermore, the importance of 
p75NTR for neurite outgrowth inhibition is neuronal cell type dependent.  In DRG neurons, loss of 
p75NTR results in longer process outgrowth on substrate-bound CNS myelin or membrane-bound 
MAG.  Myelin or MAG inhibition of CGNs, on the other hand, does not depend on p75NTR 
(Venkatesh et al., 2007; Zheng et al., 2005).  p75NTR specifically interacts with NgR1 and is 
required for the inhibitory activity of the myelin inhibitors in select neuronal cell types (Park et 
al., 2005; Wang et al., 2002a; Yamashita et al., 2002).  It has been shown that binding of MAG 
to certain neuronal cell types induces α- and then γ-secretase proteolytic cleavage of p75NTR in a 




domain of p75NTR, which is necessary for RhoA activation and, in turn, initiates the downstream 
steps that inhibit axonal growth (Domeniconi et al., 2005).  In p75NTR-/- mice, however, no 
significant improvement in the regeneration of corticospinal tract axons was observed following 
a dorsal column lesion to the spinal cord (Song et al., 2004; Zheng et al., 2005). 
 
Paired immunoglobulin-like receptor B 
 Paired immunoglobulin-like receptor B (PirB) is a member of the leukocyte 
immunoglobulin receptor (LIR) subfamily with known regulatory functions in innate and 
adaptive immune responses.  PirB is a negative regulator of immune cell activation and a 
receptor for major histocompatibility complex (MHC) class I molecules (Takai, 2005).  
Importantly, PirB is not only expressed by cells of the immune system but is also detected in the 
CNS.  Initial studies revealed expression of PirB in the neocortex, CGNs, and to a lesser extent 
in pyramidal neurons of the hippocampus (Syken et al., 2006).  As discussed below, neural PirB 
has been implicated in limiting nervous system plasticity in the healthy CNS (Syken et al., 2006). 
 More recently, PirB was identified as a novel, high-affinity receptor for myelin inhibitors 
(Atwal et al., 2008).  In vitro, PirB acts as a growth-inhibitory receptor for Nogo-66, MAG, and 
OMgp.  Primary neurons isolated from PirB-/- mice, or wild-type neurons cultured in the 
presence of a PirB function-blocking antibody, extend significantly longer neurites when plated 
on substrate-bound crude CNS myelin or individual inhibitors compared to wild-type neurons or 
neurons treated with a control antibody (Atwal et al., 2008).  This finding stands in contrast to 
NgR1 loss of function, which is not sufficient to attenuate longitudinal neurite outgrowth 
inhibition on substrate-bound CNS myelin or individual myelin inhibitors (Chivatakarn et al., 




antibody grow longer neurites on CNS myelin substrate than wild-type neurons treated with a 
PirB function-blocking antibody.  This suggests that NgR1 and PirB collaborate in signaling 
myelin inhibition of neurite outgrowth (Atwal et al., 2008).  As is the case for NgR1, loss of PirB 
renders growth cones of DRG neurons resistant to Nogo-66-elicited growth cone collapse.  
Collectively, these in vitro studies show that PirB and NgR1 are both mediators of the acute 
growth cone collapsing activity of myelin inhibitors, while PirB (but not NgR1) is also required 
for neurite outgrowth inhibition on substrate-bound myelin inhibitors. 
 Recent in vivo studies have shown that genetic deletion of PirB does not result in 
enhanced RGC regeneration following optic nerve crush injury (Fujita et al., 2011).  Following 
traumatic brain injury to the sensorimotor cortex in PirB-/- mice, no axonal sprouting in the 
corticospinal or corticorubral tracts, or functional recovery in various motor tests, is noted 
(Omoto et al., 2010).  In a dorsal hemisection model of SCI, PirB-/- mice show no enhanced CST 
regeneration or sprouting, and no improvement in hindlimb motor function (Nakamura et al., 
2011). 
 
Gangliosides and β1-integrin in MAG-mediated inhibition 
 In addition to its interactions with NgR1, NgR2, and PirB, MAG associates in a sialic 
acid-dependent manner with complex brain gangliosides, including GD1a and GT1b (Collins et 
al., 1997; Yang et al., 1996).  The functional significance of the MAG/ganglioside interaction for 
neurite outgrowth inhibition was originally assayed by comparing neurite length of CGNs 
deficient for GalNAcT, an enzyme in the biosynthetic pathway for gangliosides, to wild-type 
CGNs.  GalNAcT-deficient CGNs show enhanced neurite outgrowth in the presence of 




neurons and RGCs, gangliosides are largely dispensable for MAG inhibition (Mehta et al., 2007; 
Venkatesh et al., 2007).  More recently, β1-integrin has also been reported to interact with MAG 
through a direct association with the MAG RGD motif.  β1-integrin mediates MAG-induced 
growth cone turning responses in both hippocampal and cerebellar neurons, independent of 
NgRs (Goh et al., 2008).   
 MAG employs different mechanisms to inhibit neurite outgrowth of various cell types in 
vitro.  Loss of complex gangliosides or enzymatic removal of terminal sialic acids is sufficient to 
antagonize MAG inhibition of CGNs.  However, neither removal of terminal sialic acids nor 
genetic ablation of NgR1 is sufficient to attenuate MAG inhibition of RGCs cultured on cell 
lines expressing MAG.  The combined loss of terminal sialic acids and NgR1 in RGCs, however, 
leads to a significant decrease in MAG inhibition (Venkatesh et al., 2007).  Similarly, combined 
pharmacological blockade of ganglioside biosynthesis and NgR1 antagonism leads to 
significantly more neuronal growth of DRG neurons cultured on substrate-adsorbed MAG than 
either treatment alone (Mehta et al., 2007).  Taken together, these studies strongly argue for the 
existence of cell type-specific mechanisms for MAG inhibition.  Furthermore, there appears to 
be a significant degree of redundancy among different MAG receptor systems (Mehta et al., 
2007; Venkatesh et al., 2007).  If myelin-associated inhibitors employ cell type-specific 
mechanisms to block regenerative axonal growth in vivo, this observation may have important 
implications for the development of treatment strategies aimed at overcoming myelin inhibition. 
 
1.3.3 Intracellular Signaling Pathways for Neurite Outgrowth Inhibition 
 




 In order to exert their inhibitory effects, myelin inhibitor/receptor complexes have to 
trigger specific signaling cascades that regulate neuronal actin and microtubule dynamics. Our 
understanding of the mechanisms by which this is accomplished, including the molecules and 
signaling pathways involved, is still incomplete; however, some key components have been 
identified (Figure 1.2).  Several studies show that the activation of RhoA, a member of the Rho 
family of small GTPases, is necessary for the inhibitory activity of several growth-inhibitory 
cues, including MAG, Nogo-66, and OMgp (McKerracher and Higuchi, 2006; Schmandke and 
Strittmatter, 2007).  RhoA protein can be inactivated by ADP ribosylation via C3 transferase of 
Clostridium botulinum.  Inactivation of RhoA with C3 promotes neurite outgrowth on CNS 
myelin substrate in vitro (Dergham et al., 2002; Lehmann et al., 1999).  The combination of C3 
treatment and lens injury, which activates the intrinsic growth state of RGCs, enhances 
regeneration of optic nerve axons following crush injury (Fischer et al., 2004b).  Blocking of the 
RhoA downstream effector Rho-kinase (ROCK) with Y-27632, a pharmacological inhibitor of 
ROCK1 and ROCK2, prevents myelin-induced growth cone collapse and neurite outgrowth 
inhibition (Borisoff et al., 2003; Fournier et al., 2003).  Furthermore, SCI in ROCK2-/- mice leads 
to enhanced growth of raphespinal and corticospinal axons into the lesion site (Duffy et al., 
2009). 
 If RhoA and ROCK are critical signaling intermediates for myelin-mediated inhibition, 
what downstream effectors do they regulate?  Recently, it has been shown that the 
phosphorylation status of cofilin, which controls actin dynamics through the depolymerization of 
F-actin, is regulated by Nogo-66 (Hsieh et al., 2006).  The switch between the active 
(dephosphorylated) and inactive (phosphorylated) state of cofilin is controlled in part by the LIM 




ROCK-dependent manner (Hsieh et al., 2006).  In addition to regulating actin dynamics, myelin-
associated inhibitors also regulate the assembly of microtubules.  The collapsin response 
mediator protein-2 (CRMP-2), which promotes microtubule assembly during axon growth, is 
inactivated, and microtubule levels are downregulated, in postnatal rat cerebellar neurons upon 
treatment with MAG.  Furthermore, expression of dominant negative CRMP-2 mimics the effect 
of MAG in vitro (Mimura et al., 2006).  Myelin inhibitors have also been shown to regulate the 
cytoskeleton through CRMP-4b, as Nogo-66 increases the association between CRMP-4b and 
RhoA.  Furthermore, siRNA knockdown of CRMP-4, or the use of a competitive peptide 
inhibitor that interferes with the CRMP4b/RhoA complex, promotes neurite outgrowth on myelin 
(Alabed et al., 2007).  More recently, the mechanism by which Nogo regulates the 
CRMP4b/RhoA association has been shown to include GSK-3β.  Nogo induces the 
phosphorylation and inactivation of GSK-3β, which leads to the dephosphorylation of CRMP-4b 
and the subsequent increase in CRMP-4b/RhoA complex formation (Alabed et al., 2010).  In 
support of this relationship, GSK-3β has also been shown to phosphorylate and inactivate the 
CRMP-4b-related molecule, CRMP-2 (Yoshimura et al., 2005). 
 
Crosstalk between myelin inhibitor and neurotrophin pathways 
 Members of the neurotrophin family of growth factors and their downstream signaling 
pathways have been shown to attenuate the action of myelin inhibitors in vitro and in vivo.  Local 
infusion of neurotrophins increases regenerative sprouting of corticospinal and rubrospinal tract 
fibers following transection to the adult rat spinal cord (Kobayashi et al., 1997; Lu and 
Tuszynski, 2008; Schnell et al., 1994).  In particular, NT-3, and to a lesser extent nerve growth 




derived neurotrophic factor (BDNF) enhances rubrospinal tract axon regeneration (Kobayashi et 
al., 1997; Schnell et al., 1994).  Of particular interest is the “priming effect” of neurotrophins 
toward neurons.  Pretreatment of sensory or cerebellar neurons with neurotrophins renders these 
cells non-responsive to the inhibitory action of myelin in vitro (Cai et al., 1999).  BDNF priming 
for 24 hours overrides MAG inhibition by triggering signaling cascades that lead to elevated 
levels of intracellular cyclic adenosine monophosphate (cAMP), a signaling intermediate 
previously shown to profoundly alter neuronal responses to inhibitory guidance cues in 
developing neurons (Song et al., 1997).  It has been proposed that binding of neurotrophins to 
tropomyosin receptor kinase (Trk) receptors leads to activation of the extracellular signal-
regulated kinases (Erk1/2), which inhibit phosphodiesterase 4 (PDE4), an enzyme responsible 
for cAMP hydrolysis, thereby leading to elevated cAMP-PKA signaling (Gao et al., 2003; 
Hannila and Filbin, 2008).  Consistent with this model, a dominant negative form of Erk blocks 
the ability of BDNF to overcome MAG inhibition of CGNs (Gao et al., 2003).  Collectively, 
these studies show that pretreatment of primary neurons with neurotrophins leads to a lasting 
switch in their growth behavior that renders them resistant to myelin inhibitors. 
 As mentioned above, there is an age-dependent switch from MAG growth promotion to 
growth inhibition for several neuronal cell types.  This switch coincides with a decrease in 
endogenous cAMP levels (Cai et al., 2001).  Studies have shown that elevation of cAMP levels 
in older retinal ganglion neurons attenuates CNS myelin- and MAG-mediated inhibition of 
neurite outgrowth and that, in vivo, the ability of neonatal spinal axons to regenerate following 
injury is dependent on the cAMP downstream effector, PKA (Cai et al., 2001).  The elevation of 
cAMP activates the transcription factor, cAMP-response element-binding protein (CREB), 




regeneration in vivo (Gao et al., 2004).  Activation of CREB leads to increased expression of a 
variety of genes, including arginase I and interleukin-6 (IL-6), both of which produce proteins 
that can overcome the inhibitory effects of myelin (Cai et al., 2002; Cao et al., 2006; Gao et al., 
2004).  These proteins are potential therapeutic targets following CNS injury, as are 
calcium/calmodulin-dependent kinase IV (CaMKIV) and spermidine, which also feed into this 
cAMP-dependent pathway (Deng et al., 2009; Spencer et al., 2008).  Recently, a transcriptional 
inducer of arginase I, daidzein, was identified as a small molecular compound that promotes 




 Conditional deletion of the phosphatase and tensin homolog (PTEN) gene in adult mouse 
RGCs results in robust and long-distance axon regeneration following crush injury to the optic 
nerve (Park et al., 2008).  PTEN is a negative regulator of PI3K, and deletion of PTEN results in 
enhanced PI3K activation.  Of the many pathways downstream of PI3K, the AKT-mTOR 
cascade is of particular interest, as it was found that long-distance axon regeneration in PTEN-
deficient RGCs is largely blocked in the presence of rapamycin, a potent inhibitor of the 
mammalian target of rapamycin (mTOR) (Park et al., 2008).  This suggests that increased 
activation of the AKT-mTOR pathway is necessary to promote axon regeneration in PTEN-
deficient RGCs in vivo.  Consistent with this idea, overexpression of AKT, an activator of mTOR 
signaling, in axotomized motoneurons enhances axon regeneration in vivo at 2-4 weeks post-
nerve transection (Namikawa et al., 2000).  As is the case for PTEN deletion, conditional 




robust regeneration of RGC axons following optic nerve crush injury (Park et al., 2008).  Thus, 
in adult mice, increased activation of the mTOR complex promotes regeneration of RGC axons.  
More recently, deletion of PTEN has been shown to promote robust regeneration of adult CST 
axons, as well as compensatory sprouting of uninjured CST axons, following spinal cord lesion.  
Furthermore, evidence was provided that regenerating CST axons are able to form new synapses 
caudal to the lesion site (Liu et al., 2010).  The mTOR kinase is a well-known regulator of cell 
growth and size and has been studied for some time in the CNS because of its regulatory role in 
synaptic plasticity and local translation of synaptic mRNA (Costa-Mattioli et al., 2009; Guertin 
and Sabatini, 2007).  In the regenerating CNS, PI3K-AKT-mTOR is now emerging as a key 
regulator of a “dormant” neuron intrinsic growth program.  When increased activation of the 
PI3K pathway is combined with other manipulations, including elevation of cAMP levels and 
intravitreal Zymosan injection (discussed above), RGC axons show even greater long-distance 
regeneration through the entire optic nerve and beyond the optic chiasm following crush injury 
(Kurimoto et al., 2010).  These combination approaches are quickly becoming some of the most 
promising regenerative strategies following CNS injury. 
 While a growing number of studies have demonstrated that mTOR signaling plays an 
important role in axonal regeneration, injury-induced growth signals are still needed to initiate 
axonal regeneration.  Many of these injury-induced signals, including IL-6, CNTF, LIF, and 
cardiotrophin-1, activate the Janus kinase (JAK)/signal transducer and activator of the 
transcription (STAT) pathway.  Recently, it was shown that deletion of the suppressor of 
cytokine signaling 3 (SOCS3) in RGCs enhances regeneration of injured axons in the optic nerve 
(Smith et al., 2009).  SOCS3 is a known negative regulator of the JAK/STAT pathway.  




upregulation of inflammatory mediators, including IL-6 (Dominguez et al., 2010).  Interestingly, 
a recent study has suggested that while mTOR is involved in maintaining RGCs in an active 
regenerative state, it does not seem to be critical for the initial transformation of RGCs into this 
regenerative state upon release of injury-induced signals (Leibinger et al., 2012).  This might 
explain why the combined deletion of PTEN and SOCS3 results in significantly more 
regeneration following optic nerve crush injury than deletion of either gene alone (Sun et al., 
2011). 
 In the future, it will be of great interest to determine how mTOR is regulated in injured 
CNS neurons. What are the upstream ligand-receptor systems that negatively regulate mTOR 
signaling in neurons and what are the protein products subjected to mTOR-regulated translation?  
Of interest are recent reports showing that inhibitory guidance cues, including ephrins (Nie et al., 
2010) and semaphorins (Oinuma et al., 2010), inhibit neurite outgrowth by negative regulation of 
the PI3K-AKT-mTOR pathway.  Furthermore, Nogo and OMgp negatively regulate 
neurotrophin-induced mTOR signaling in primary cortical neurons (Raiker et al., 2010).  This 
suggests that several classes of growth-inhibitory molecules impinge on the negative regulation 
of the mTOR pathway.  In further support of this, a recent study has shown that association of 
myelin inhibitors with PirB causes PirB to interact with Trk receptors and recruit Src homology 
2-containing protein tyrosine phosphatase (SHP)-1 and SHP-2 to this complex.  SHP-1/2 is then 
able to inactivate Trk receptors by tyrosine dephosphorylation, leading to neurite outgrowth 
inhibition (Fujita et al., 2011).  As Trk receptors activate proteins such as PI3K and AKT, this 
provides more evidence that myelin inhibitors negatively regulate the mTOR pathway and, more 





1.3.4 The Glial Scar and Its Inhibitory Components 
 
Reactive astrogliosis and inflammatory cell activation 
 In addition to the myelin-derived CNS inhibitors, a major source of growth-inhibitory 
cues is the glial scar.  Within days following CNS injury, a glial scar is formed at the injury site, 
composed of reactive astrocytes, infiltrating meningeal cells, macrophages, and microglia.  
Reactive astrocytes are the major cellular component of the scar.  Astrocytes become activated 
and proliferate as a response to CNS injury, upregulating the expression of numerous proteins, 
including glial fibrillary acidic protein (GFAP), vimentin, fibronectin, laminin, and inhibitory 
CSPGs (Busch and Silver, 2007; Nash et al., 2009).  The inflammatory response to the damaged 
tissue also activates microglia and oligodendrocyte precursor cells (OPCs), and recruits 
macrophages to the lesion site.  Like reactive astrocytes, microglia and OPCs continue to 
proliferate and eventually cover the entire lesion site.  Activated as a self-protection mechanism, 
the formation of the glial scar is meant to facilitate wound healing by sealing the injury site, 
helping to rebuild the blood-brain barrier (BBB), and preventing secondary degeneration of 
surrounding healthy tissue from the excitotoxic environment and inflammatory attack induced by 
the damaged tissue (Rolls et al., 2009).  It has been shown that targeted elimination of reactive 
astrocytes after injury causes failure of BBB repair, profound tissue loss, and more severe 
deficits of motor function (Faulkner et al., 2004).  However, the glial scar is a double-edged 
sword.  While it prevents further damage to the CNS parenchyma, it also forms a chemical 






Chondroitin sulfate proteoglycans 
 The major inhibitors associated with the glial scar are CSPGs.  CSPGs belong to a 
diverse family of membrane-bound and extracellular matrix glycoproteins composed of a protein 
core covalently linked to specific types of glycosaminoglycan (GAG) side chains.  CSPGs are 
widely expressed throughout the brain and spinal cord.  During early development, CSPGs 
function as repulsive molecules to guide migrating neural crest cells.  CSPGs also assist with 
axonal pathfinding in the visual system and of sensory neurons at the dorsal root entry zone 
(Becker and Becker, 2002; Kubota et al., 1999; Pindzola et al., 1993; Snow et al., 1990a).  
CSPGs are highly expressed in perineuronal nets (PNNs) of various neuronal populations to 
restrict growth and plasticity in the adult brain (Kwok et al., 2008).  Neural CSPGs with known 
inhibitory activities include members of the lectican family (aggrecan, brevican, neurocan, and 
versican), phosphacan, and NG2 (Fidler et al., 1999; Pizzorusso et al., 2002).  It is well 
established that CSPGs can induce growth cone collapse and strongly inhibit neurite outgrowth 
of various types of neurons in vitro (Braunewell et al., 1995; Dou and Levine, 1994; McKeon et 
al., 1991; Ughrin et al., 2003; Yamada et al., 1997).   
 Following injury, the levels of many CSPGs are dramatically upregulated in the glial scar 
(Jones et al., 2003; McKeon et al., 1995).  Aggrecan, neurocan, and phosphacan are abundantly 
expressed by reactive astrocytes, whereas NG2 is primarily produced by macrophages and 
hypertrophic OPCs (Dawson et al., 2000; Jones et al., 2002).  However, the inhibitory effect of 
some CSPGs, such as NG2, largely depends on the cellular context.  A recent study has shown 
that certain cells in the glial scar can actually provide a permissive substrate to stabilize the 
degenerating sensory axons that are under macrophage attack (Busch et al., 2010).  Although this 




and fibronectin, these cells also express NG2 (Busch et al., 2010).  Thus, NG2 is expressed on 
both the macrophages that attack axons and the cells that stabilize them.  This indicates that the 
inhibitory effect of NG2 can be balanced by other growth-promoting molecules.  In support of 
this, substrate-bound NG2 has been shown to lose its inhibitory effect on DRG neurons when co-
coated with L1, another growth-promoting molecule (Dou and Levine, 1994). 
 It is well established that the inhibitory activity of CSPGs is primarily mediated by their 
GAG chains, as this inhibitory action is largely abrogated by treatment with chondroitinase ABC 
(Ch’aseABC), a bacterial enzyme that selectively digests CS-GAG chains.  However, some 
inhibitory activity is thought to be associated with the protein core.  NG2, for example, inhibits 
neurite outgrowth of cultured cerebellar and DRG neurons in the absence of GAG chains 
(Ughrin et al., 2003).  In vitro studies have shown that when treated with Ch’aseABC, several 
neuronal populations grow longer neurites on either CSPG-coated substrate or injured CNS 
tissue sections (McKeon et al., 1995; Sango et al., 2003; Zuo et al., 1998).  In vivo, 
administration of Ch’aseABC directly into the injury site leads to an enhancement of axon 
regeneration for severed CST fibers and central fibers of sensory neurons in the spinal cord 
(Bradbury et al., 2002) (Figure 1.3b).  Axons from several other neuronal populations, including 
nigrostriatal (Moon et al., 2001), reticulospinal (Garcia-Alias et al., 2011), and serotonergic 
(Barritt et al., 2006; Fouad et al., 2005; Garcia-Alias et al., 2009; Tom et al., 2009) respond to 
Ch’aseABC treatment as well.  Based on these observations, Ch’aseABC treatments are now 
being developed as a therapeutic strategy to promote axon regeneration following SCI. 
 Although the inhibitory function of CSPGs was established more than 2 decades ago, the 
underlying mechanisms of how CSPGs exert their growth-inhibitory action toward neurons 




receptor protein tyrosine phosphatase sigma (RPTPσ), a member of the leukocyte antigen-related 
(LAR) subfamily, as the first neuronal receptor for the inhibitory action of aggrecan and 
neurocan (Shen et al., 2010).  The extracellular domain of RPTPσ is composed of three Ig-like 
repeats and eight fibronectin type III (FNIII)-like repeats.  RPTPσ binds to CSPGs directly, and 
the interaction site of RPTPσ with CS-GAG chains has been mapped to the first Ig-like domain 
of RPTPσ.  Furthermore, this interaction is sensitive to Ch’aseABC treatment (Shen et al., 2010).  
Interestingly, two other LAR family members, LAR and RPTPδ, also share the same GAG-
binding motif within the Ig-like repeats, suggesting some degree of functional redundancy 
among LAR family members in signaling CSPG inhibitory responses (Duan and Giger, 2010).  
Indeed, a recent study has confirmed LAR as a functional receptor for versican and neurocan, 
with the first Ig-like domain of LAR being important for binding (Fisher et al., 2011).  Similar to 
Ch’aseABC treatment, functional ablation of Ptprs, the gene encoding RPTPσ, promotes neurite 
outgrowth in the presence of CSPGs in vitro and enhances axonal regeneration into CSPG-rich 
scar tissue following SCI in vivo (Fry et al., 2009; Shen et al., 2010) (Figure 1.3b).  Enhanced 
axon regeneration following injury has been reported previously in RPTPσ-/- mice.  In the adult 
PNS, loss of RPTPσ enhances axonal regrowth in the sciatic and facial nerves following injury 
(McLean et al., 2002; Thompson et al., 2003), whereas in the CNS, loss of RPTPσ promotes 
axon regeneration in the injured optic nerve (Sapieha et al., 2005).  In addition, the use of LAR-
targeting peptides in mice with spinal cord transection injuries promotes significant growth of 
descending serotonergic fibers, as well as locomotor functional recovery (Fisher et al., 2011).   
 The identification of RPTPσ as a receptor for inhibitory CSPGs provides a mechanistic 
basis for these previously reported regeneration phenotypes in RPTPσ-/- mice (McLean et al., 




downstream signaling pathways of LAR family members that are triggered upon binding of 
CSPGs.  Considerable progress has been made in defining the downstream signaling 
mechanisms of LAR family members.  Some of the known pathways link LAR proteins to the 
neuronal cytoskeleton and thus are poised to mediate CSPG inhibitory responses.  The 
cytoplasmic portion of LAR family members contains a conserved tandem pair of phosphatase 
domains.  Only the membrane proximal phosphatase domain (D1) is catalytically active, whereas 
the membrane distal domain (D2) associates with guanine nucleotide exchange factors, as well as 
the tyrosine kinase Abl and its substrates Ena, β-catenin, and liprin-σ (Stryker and Johnson, 
2007).  Future studies will need to address how LAR family signaling is linked to molecules 
already implicated in CSPG inhibition, such as RhoA (Monnier et al., 2003) and PKC isoforms 
(Sivasankaran et al., 2004).  The CSPG/LAR interaction has already been suggested to inactivate 
AKT and activate the RhoA pathway (Fisher et al., 2011). 
 
Associated inhibitors in the glial scar 
 In addition to CSPGs, several axon guidance molecules with known inhibitory function 
are upregulated in the glial scar.  These include members of canonical axon guidance molecules 
belonging to the ephrin and semaphorin gene families (Bolsover et al., 2008).  Following CNS 
injury, increased expression of secreted semaphorins and their receptors has been reported (De 
Winter et al., 2002; Pasterkamp et al., 1999).  The role of secreted semaphorins in limiting 
axonal regeneration following SCI remains a matter of debate.  While pharmacological inhibition 
of Sema3A was found to enhance regenerative growth of serotonergic fibers (Kaneko et al., 




semaphorins, does not lead to enhanced regeneration of serotonergic neurons following spinal 
cord transection injury (Lee et al., 2010b). 
 
1.4 The Physiological Function of CNS Regeneration Inhibitors and Their Receptors   
 
1.4.1 The Prototypic Myelin Inhibitors in Nervous System Development and Maintenance 
 While most attention has focused on the role of Nogo, MAG, and OMgp during CNS 
regeneration, comparatively little is known about the physiological function of these proteins in 
the healthy CNS.  Nogo-A, for example, is expressed in developing and mature oligodendrocytes 
(Huber et al., 2002; Wang et al., 2002c).  Functional ablation of the Nogo-A gene results in a 
transient delay of oligodendrocyte differentiation and myelin sheath formation in the developing 
optic nerve and cerebellum (Pernet et al., 2008).  Additionally, Nogo-A has a role in controlling 
myelinogenic potential in the developing CNS, as genetic deletion of Nogo-A results in a spatial 
expansion of myelin in vivo.  Consistent with this result, remyelination following lysolecithin 
injection into the adult mouse spinal cord is accelerated in Nogo-A-/- mice (Chong et al., 2012).  
In the CNS, Nogo-A expression is not restricted to oligodendrocytes - Nogo-A is abundantly 
expressed by different types of developing and mature neurons.  Somewhat paradoxically,  
Nogo-A expression is highest in neurons known best for their high degree of structural plasticity, 
including principal neurons in the hippocampus and neocortex (Huber et al., 2002).  In the 
developing cortex, loss of Nogo-A/-B/-C accelerates radial cortical migration and leads to 
delayed tangential migration of GABAergic cortical interneurons from the ganglionic eminence 
in vivo.  In vitro, Nogo-A/-B/-C-deficient cortical neurons have increased neurite branching and 




2007).  Furthermore, in the PNS, genetic deletion of Nogo-A leads to increased fasciculation and 
reduced branching of peripheral nerves as they innervate fore- and hindlimbs at embryonic 
stages (Petrinovic et al., 2010). 
 The physiological role for MAG in the uninjured mammalian nervous system has been 
studied in some detail.  While MAG has been shown to mediate axon-oligodendrocyte adhesion 
in vitro, analysis of MAG-/- mice revealed that MAG is not necessary for CNS or PNS axon 
myelination in vivo (Li et al., 1994; Montag et al., 1994; Quarles, 2007).  However, as MAG-/- 
mice age, they exhibit a peripheral neuropathy characterized by degeneration of myelinated 
axons, decreased axonal caliber, reduced phosphorylation of the neurofilament proteins NFH and 
NFM, and reduction of neurofilament spacing (Yin et al., 1998).  It is known that 
phosphorylation of neurofilaments increases axonal caliber, and it has been shown that MAG 
increases phosphorylation of neurofilaments as well as their associated kinases, ERK1/2 and 
cdk5 (Dashiell et al., 2002).  In the CNS, focal swellings and spheroids, as well as decreases in 
axonal diameter and neurofilament spacing, have been noted in older MAG-/- mice.  The genetic 
background of these mice seems to influence the severity of the phenotype (Loers et al., 2004; 
Pan et al., 2005).  Other abnormalities in the absence of MAG have been reported, including an 
irregular distribution of sodium channels at the nodes of Ranvier, dystrophic oligodendrocytes, 
the formation of redundant myelin, and doubly myelinated axons (Bartsch, 1996; Marcus et al., 
2002; Weiss et al., 2000).  These subtle phenotypes suggest that MAG influences axonal 
maintenance, which is further supported by the fact that MAG promotes axon stability and 
resistance to degeneration and excitotoxicity in the presence of stresses such as vincristine, 





1.4.2 CNS Regeneration Inhibitors and Receptors in Synaptic Plasticity 
 As discussed above, acute perturbation of myelin inhibition has been shown to promote a 
limited degree of sprouting and axonal regeneration past the injury site following SCI.  It is 
believed that the observed anatomical fiber growth is the cellular basis for improved behavioral 
outcomes in experimentally-treated animals.  Lowering the growth-inhibitory barrier of myelin 
most likely leads to enhanced neuronal plasticity at multiple spinal and supraspinal levels, 
including growth of severed axons, compensatory sprouting of uninjured fibers, and more subtle 
structural rearrangements of neuronal networks directly or indirectly affected by the injury.  
Because adaptive responses to CNS injury occur at multiple levels, it is difficult to pinpoint the 
cellular basis of improved behavioral outcomes in spinal cord-injured animals.  In the healthy 
mature CNS, myelin inhibitors and their receptors have been shown to limit structural neuronal 
plasticity (McGee et al., 2005; Syken et al., 2006).  In the developing visual system, experience-
dependent refinement of neuronal connectivity is most robust during the “critical period” (CP), a 
limited time window during which changes in visual input lead to robust adaptive plasticity in 
the binocular zone of the visual cortex.  After the critical period, adaptive responses to changes 
in visual input are more restricted.  In Nogo-A/-B-/- mice and mice deficient in NgR1 and PirB, 
the CP is prolonged into adulthood (McGee et al., 2005; Syken et al., 2006).  Remarkably, 
another class of well-known inhibitors of axonal regeneration, the CSPGs, also limits 
experience-dependent plasticity in the visual cortex.  CSPGs accumulate in PNNs at the end of 
the CP, and enzymatic degradation of CS-GAG chains is sufficient to reopen the CP in the adult 
visual cortex (Pizzorusso et al., 2002) (Figure 1.3a).  Together, these findings strongly suggest 





 In addition to extracellular growth-inhibitory cues, cessation of experience-dependent 
plasticity is regulated by the maturation of inhibitory GABAergic circuits (Hensch et al., 1998).  
Recent evidence suggests that NgR1 not only participates in the regulation of structural neuronal 
plasticity but also plays an important role in activity-dependent synaptic plasticity (Lee et al., 
2008; Raiker et al., 2010).  In NgR1-/- mice, long-term potentiation (LTP) of synaptic 
transmission is enhanced in the presence of the neurotrophic factor FGF2 (Lee et al., 2008), and 
conversely, Nogo-66 and OMgp suppress LTP in an NgR1-dependent manner (Raiker et al., 
2010).  In acute hippocampal slices, loss of NgR1 impairs long-term depression (LTD) of 
synaptic transmission (Lee et al., 2008).  Because NgR1 expression itself is regulated by activity 
(Josephson et al., 2003) and has been shown to regulate the shape of dendritic spines (Lee et al., 
2008), NgR1 is well suited to link electrical activity to structural changes in mature CNS 
neurons.  In addition, NogoA was recently shown to regulate activity-dependent synaptic 
strength (Delekate et al., 2011).  Based on these observations, it appears likely that antagonism 
of growth inhibitors in the injured CNS not only facilitates structural neuronal plasticity but also 
simultaneously lowers the inhibitory tonus in neuronal networks.  This is further supported by 
the growing evidence that myelin-associated inhibitors/CSPGs and their receptors have a critical 
role in negatively regulating synapse formation in the developing CNS (Horn et al., 2012; Pyka 
et al., 2011; Wills et al., 2012).  Taken together, this suggests that the mechanisms that limit 
neuronal growth following CNS injury are similar to the mechanisms that negatively regulate 
synapse formation and plasticity during development. 
 




 Basic science discoveries continue to identify targets that may lead to the development of 
new treatment strategies for SCI repair.  Because some key mechanisms that block spontaneous 
repair of severed CNS axons have already been discovered and characterized in some detail, a 
number of new compounds and treatment strategies are currently being developed for or have 
already entered clinical trials.  Treatment strategies for SCI aimed at reestablishing neuronal 
connectivity fall broadly into three categories: (1) neutralization of extracellular growth-
inhibitory cues by blocking one or several inhibitors of growth; (2) local production or infusion 
of growth-promoting molecules, cells, or substrates that favor neuronal growth and survival; or 
(3) activation of “dormant” cell intrinsic growth programs in adult CNS neurons to promote 
axonal growth and sprouting.  Evidence from experiments in spinal cord-injured rodents suggests 
that some of these strategies may need to be combined in order to maximize anatomical and 
behavioral outcomes (Bunge 2008; Kadoya et al., 2009; Karimi-Abdolrezaee et al., 2010). 
 Due to the growth-inhibitory nature of injured adult mammalian CNS tissue, approaches 
to lower the inhibitory barrier for regenerating axons remain an area of great interest (Tables 1.2, 
1.3, 1.4).  These include a monoclonal antibody directed against the N-terminal portion of  
Nogo-A (Zorner and Schwab, 2010) and a soluble form of NgR1 (NgR(310)-Fc) (Harvey et al., 
2009; MacDermid et al., 2004; Peng et al., 2009; Wang et al., 2006).  As anti-Nogo-A and 
NgR(310)-Fc target different inhibitory epitopes present in CNS myelin, they may have additive 
effects in vivo.  A phase I clinical trial involving anti-Nogo-A treatment of subjects with acute 
SCI has been conducted successfully and is expected to enter phase II (Zorner and Schwab, 
2010). 
 Targeting of glycoproteins, including CSPGs and sialoglycans, has been met with some 




CST axons past the lesion site and also leads to improved functional outcomes (Bradbury et al., 
2002).  Furthermore, delivery of Taxol, a clinically approved anti-cancer drug that stabilizes 
microtubules, promotes serotonergic axonal regeneration and functional locomotor recovery 
following a dorsal hemisection SCI (Hellal et al., 2011).  Taxol-mediated microtubule 
stabilization hinders the nuclear translocation of Smad2/3, a key signaling component for CSPG 
release following injury.  Taxol treatment of the optic nerve also reduces CSPG expression and 
promotes regeneration of injured RGC axons (Sengottuvel et al., 2011).  Recently, it was found 
that local infusion of Vibrio cholerae neuramindase promotes repair following contusion injury 
to the spinal cord in rats (Mountney et al., 2010).  Furthermore, increasing extracellular signals 
that promote neuronal growth and sprouting has been successful.  Local infusion of neurotrophic 
factors (Blesch and Tuszynski, 2009) or implantation of specific cell types (Bunge and Pearse, 
2003; Davies et al., 2008; Radtke et al., 2008) into the injured rodent spinal cord promotes 
axonal growth of different types of spinal projection neurons.  A recent study showed impressive 
long-distance axonal outgrowth, synapse formation, and behavioral/electrophysiological 
recovery following grafting of neural stem cells (along with a growth factor cocktail) into 
transected spinal cords in rodents.  Of clinical relevance is the fact that the grafting was 
performed one or two weeks post-injury and that human neural stem cell grafts were also 
effective in injured rodent spinal cords (Lu et al., 2012). 
 In addition to extracellular molecules, intracellular signaling molecules implicated in 
neuronal growth inhibition are potential targets for therapeutic intervention.  The RhoA-ROCK 
cascade has been extensively studied and shown to be a convergence point for multiple 
inhibitory signaling pathways.  Pharmacological inhibition of both RhoA and ROCK with 




inhibition of RhoA by C3 transferase promotes axon regeneration in both the crushed optic nerve 
and hemisected CST (Dergham et al., 2002; Fournier et al., 2003; Lehmann et al., 1999).  
Moreover, Rho activation was found to mediate apoptotic cell death induced by SCI in a p75NTR-
dependent manner (Dubreuil et al., 2003).  Therefore, C3 may not only promote regeneration of 
severed axons but also prevent further neuronal cell death following injury.  A modified version 
of C3 with improved membrane permeability, BA-210, has been commercialized under the name 
Cethrin and is currently being tested in clinical trials (Fehlings et al., 2011).  The recent 
identification of the PI3K-AKT-mTOR signaling pathway as a key regulatory mechanism of 
neuronal growth in mature neurons (Namikawa et al., 2000; Park et al., 2008; Smith et al., 2009) 
suggests that additional small molecular compounds can be developed to promote robust axonal 
growth. 
 Collectively, there is considerable optimism in the field of nervous system regeneration 
that robust fiber growth following CNS injury can be accomplished.  It remains, however, 
somewhat less clear to what extent regenerating CNS axons are able to reach pre-injury targets 
and form functionally meaningful synaptic connections.  Direct evidence that long-distance axon 
regeneration in spinal cord-injured animals contributes to the observed functional improvements 
is sparse.  In one study it was shown that newly grown sensory axons are capable of reaching 
pre-injury targets and forming new synapses but fail to propagate electrical impulses (Alto et al., 
2009).  One possible explanation for this lack of efficient propagation of action potentials may be 
incomplete myelination.  If new axons can be grown and connectivity can be reestablished, these 
axons will need to be myelinated in order to rapidly and faithfully conduct complex electrical 
impulses.  As many human spinal cord injuries are anatomically incomplete and maintain tissue 




already existing fibers may be easier to accomplish than regrowing new axons.  For patients with 
complete (or nearly complete) transection of ascending and descending spinal axons, long-
distance axon regeneration will be necessary to improve behavioral outcomes following SCI. 
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Figure 1.1: The major ligands and receptor complexes involved in CNS neurite outgrowth 
inhibition.  The best characterized outgrowth inhibitors include the prototypic myelin-associated 
inhibitors (MAG, Nogo-A, and OMgp), CSPGs, and members of the semaphorin, ephrin, and 
netrin families of axon guidance molecules.  MAG (Siglec4a) is a sialic acid-binding lectin 
containing five Ig-like domains, a transmembrane domain, and a cytoplasmic portion.  Nogo-A 
(RTN4a) is comprised of two distinct inhibitory domains: Nogo-66 and NogoΔ20.  NogoΔ20 can 
be detected extracellularly but is also thought to have a cytoplasmic orientation (dotted line).  
OMgp is a member of the LRR protein family and is linked via a GPI anchor to the cell surface.  
MAG, Nogo-A, and OMgp have little structural similarity but share two common axonal 
receptors: NgR1 and PirB.  In some neuronal cell types, NgR1 is thought to form a receptor 
complex with Lingo-1 and a TNF receptor superfamily member (either p75NTR or TROY).  In 
addition, NgR2 acts as a receptor for MAG but not Nogo-A or OMgp.  MAG also forms a 
complex with the gangliosides GT1b and GD1a, and participates in a functional interaction with 
integrins.  CSPGs, a group of glycoproteins composed of a core protein linked to GAG side 
chains, interact with RPTPσ and LAR (not shown) to signal neuronal growth inhibition.  Both 
secreted semaphorins and membrane-bound semaphorins, which are glycoproteins containing an 
amino-terminal semaphorin (sema) domain and a plexin-semaphorin-integrin (PSI) domain, have 
been implicated in growth inhibition.  Plexins are the most prominent semaphorin receptors, 
while most class 3 semaphorins require neuropilins as obligatory co-receptors.  GPI-anchored 
ephrinAs and transmembrane ephrinBs also act as inhibitors through bidirectional signaling with 
their Eph receptor tyrosine kinase counterparts.  Secreted netrin-1 acts as a myelin-associated 

























Figure 1.2: The major intracellular signaling pathways involved in CNS neurite outgrowth 
inhibition.  While our understanding of the signaling pathways that mediate neurite outgrowth 
inhibition is limited, a few major pathways have thus far been implicated.  Activation of the 
Rho/ROCK pathway is necessary for the inhibitory activity of MAG, Nogo-A, and OMgp, and 
provides a link to the actin cytoskeleton through the control of cofilin phosphorylation.  
Currently, the only direct link between myelin inhibitor-receptor complexes and RhoA involves 
the release of RhoA and its subsequent activation following binding of prototypic myelin 
inhibitors to p75NTR.  The sequential cleavage of p75NTR by α- and γ-secretases is necessary for 
RhoA activation.  Myelin inhibitors can also regulate the cytoskeleton through the inactivation of 
CRMP-2 to influence microtubule dynamics or the inactivation of GSK-3β (and 
dephosphorylation of CRMP-4b) to influence actin dynamics.  Additionally, there is crosstalk 
between myelin inhibitor and neurotrophin pathways, as priming with neurotrophins can block 
outgrowth inhibition through the activation of Erk and subsequent inhibition of PDE4.  This 
leads to elevated levels of intracellular cAMP, activation of PKA, and initiation of CREB-
induced transcription in the nucleus, all of which have been shown to be necessary for release 
from inhibition.  More recently, the PI3K-AKT-mTOR pathway has been implicated in 
outgrowth inhibition.  mTOR complex activation promotes axon regeneration, supported by 
studies that show enhanced regeneration when proteins that negatively influence mTOR activity 






Figure 1.3: The physiological role of CSPGs in ocular dominance (OD) plasticity and their 
pathological role in axon regeneration inhibition following spinal cord injury (SCI).  (a) 
Schematic of the mammalian visual system, showing the visual pathway of the left eye in brown 
and of the right eye in orange through the lateral geniculate nuclei (LGN) to the primary visual 
cortex (V1 and V2).  The binocular zone (BZ) receives input from both eyes.  Monocular 
deprivation (MD)-induced OD plasticity is extremely limited after the critical period (-
ChaseABC).  Local infusion of ChaseABC near the BZ of the rat visual cortex is sufficient to 
reactivate OD plasticity after the closure of the critical period (+ChaseABC).  This indicates that 
CSPGs in perineuronal nets (PNNs) restrict experience-dependent neuronal plasticity in 
adulthood.  Enzymatic degradation of CS-GAG chains removes non-permissive substrates 
surrounding synapses and presumably facilitates rearrangement and formation of new synapses 
in favor of the nondeprived eye.  v.c = visual cortex.  (b) Injury to the spinal cord results in 
axonal damage and formation of a glial scar at the injury site.  Injury to the dorsal column severs 




ganglion (DRG) neurons.  The glial scar is composed of reactive astrocytes, microglia, 
macrophages, and meningeal fibroblasts, and forms a boundary for regenerating axons.  CSPGs 
are highly upregulated in the glial scar and exert the major inhibitory effect.  In wild-type mice 
with no treatment, regenerating axons stall at the border of scar tissue and show dystrophic end 
bulbs at their leading tips (-ChaseABC/Ptprs+/+).  Treatment with ChaseABC after SCI leads to 
various improvements of CST axon regeneration, including enhanced regeneration across the 
lesion site and increased axonal sprouting before and after the lesion site (+ChaseABC).  
Similarly, genetic deletion of the CSPG receptor, RPTPσ, allows severed axons to grow deeper 




Table 1.1: The key factors that influence axonal regeneration following injury to the adult 






Table 1.2: Summary of key studies that demonstrate axon regeneration or sprouting upon 
targeting of major inhibitory ligands in the injured mammalian CNS.  Abbreviations: CRST 
(coeruleospinal tract axons), CST (corticospinal tract axons), DC (ascending dorsal column 





                                                                                                                                                    
                                                                                                                                                                                         
                                                                                                        
Table 1.3: Summary of key studies that demonstrate axon regeneration or sprouting upon 
targeting of major inhibitory receptors in the injured mammalian CNS.  Abbreviations: 





















Table 1.4: Summary of key studies that demonstrate a lack of substantial axon 
regeneration upon targeting of major inhibitory ligands or receptors in the injured 
mammalian CNS.  Abbreviations: CRT (corticorubral tract axons), CST (corticospinal tract 
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NgR1 and NgR3 are Receptors for Chondroitin Sulfate Proteoglycans 
 
2.1 Abstract 
 In the adult mammalian central nervous system (CNS), chondroitin sulfate proteoglycans 
(CSPGs) and myelin-associated inhibitors (MAIs) stabilize neuronal structure and restrict 
compensatory sprouting following injury.  The Nogo receptor family members NgR1 and NgR2 
bind to MAIs and have been implicated in neuronal inhibition.  Here we show that NgR1 and 
NgR3 bind with high affinity to the sugar moiety of CSPGs and participate in CSPG inhibition in 
cultured neurons.  Nogo receptor triple mutants (NgR123-/-), but not single mutants, show 
enhanced axonal regeneration following retro-orbital optic nerve crush injury.  The combined 
loss of NgR1 and NgR3 (NgR13-/-), but not NgR1 and NgR2 (NgR12-/-), is sufficient to mimic 
the NgR123-/- regeneration phenotype.  Regeneration in NgR13-/- mice is further enhanced by 
simultaneous ablation of RPTPσ, a known CSPG receptor.  Collectively, these results identify 
NgR1 and NgR3 as novel CSPG receptors, demonstrate functional redundancy among CSPG 
receptors, and provide unexpected evidence for shared mechanisms of MAI and CSPG 






 In the adult mammalian CNS, structural neuronal plasticity is restricted by a number of 
extrinsic (environmental) and cell-intrinsic growth-inhibitory mechanisms (Liu et al., 2006; Park 
et al., 2008).  While such mechanisms are believed to be important for stabilization of intricate 
networks of neuronal connectivity in CNS health, they also limit adaptive neuronal growth and 
sprouting following brain or spinal cord injury (SCI).  Spontaneous repair following severe CNS 
injury is incomplete and commonly associated with permanent neurological deficits.  Thus, a 
detailed understanding of the mechanisms that block neuronal growth and repair is of great 
interest, both biologically and clinically.  
 A large number of CNS inhibitory cues have been identified (Liu et al., 2006; Silver and 
Miller, 2004; Winzeler et al., 2011).  In experimental animal models of SCI, acute blockage of 
MAIs (Bregman et al., 1995; Li et al., 2004) or enzymatic degradation of CSPGs with 
chondroitinase ABC (Ch’aseABC) (Bradbury et al., 2002; Garcia-Alias et al., 2009; Massey et 
al., 2006) promotes neuronal sprouting and correlates with improved behavioral outcomes.  The 
best characterized MAIs are the reticulon family member Nogo, myelin-associated glycoprotein 
(MAG), and oligodendrocyte myelin glycoprotein (OMgp) (Liu et al., 2006).  Three isoforms of 
Nogo have been identified, all of which contain a 66 amino acid loop (Nogo66) that signals 
neuronal inhibition.  Mechanistic studies identified the Nogo66 receptor-1 (NgR1) and paired 
immunoglobulin (Ig)-like receptor B (PirB) as functional receptors for MAIs (Atwal et al., 2008; 
Fournier et al., 2001).  NgR1 is comprised of 8.5 leucine-rich repeats (LRRs), flanked by N-
terminal (NT-) and C-terminal (CT-) LRR capping domains.  The NT-LRR-CT cluster of NgR1 
is fused to a ~ 100 amino acid residue stalk region and connected to the plasma membrane by a 
glycosylphosphatidylinositol (GPI) anchor (Fournier et al., 2001).   NgR1 and its close relative 




bind selectively to NgR1 (Liu et al., 2006), while MAG associates with NgR1 and NgR2 
(Venkatesh et al., 2005).  The related molecule NgR3 is poorly characterized, and thus far no 
functional NgR3 ligand(s) have been identified.  In vitro, loss of NgR1 renders neurons more 
resistant to Nogo66-, MAG-, and OMgp-induced growth cone collapse but not to longitudinal 
neurite outgrowth inhibition on substrate-bound inhibitors (Chivatakarn et al., 2007; Kim et al., 
2004; Zheng et al., 2005).  MAIs activate RhoA, RockII, and conventional isoforms of protein 
kinase C (PKC) to destabilize the neuronal cytoskeleton (Schweigreiter et al., 2004; 
Sivasankaran et al., 2004).  Similar to NgR1, PirB supports binding of Nogo66, MAG, and 
OMgp.  In culture, functional ablation of PirB promotes neurite outgrowth on substrate-bound 
MAIs and crude CNS myelin.  Interestingly, the combined perturbation of PirB and NgR1 
signaling leads to a further release of neurite outgrowth inhibition on crude CNS myelin but not 
on recombinant Nogo66 or MAG (Atwal et al., 2008). 
 CSPGs are a diverse class of extracellular matrix molecules that influence axonal growth 
and guidance of developing neurons (Kantor et al., 2004).  Following injury to the adult CNS, 
CSPG expression is upregulated and abundant in reactive astrocytes associated with glial scar 
tissue (McKeon et al., 1995; Rhodes and Fawcett, 2004; Silver and Miller, 2004).  CSPGs are 
comprised of a protein core with covalently attached glycosaminoglycan (GAG) side chains.  
GAG chains are large, unbranched polymers composed of ~20-200 repeating disaccharide units.  
Chondroitin sulfate (CS)-GAGs contain alternating units of N-acetyl-galactosamine and 
glucuronic acid.  Most commonly, the hydroxyl groups at position 4 (CS-A) or position 6 (CS-C) 
of N-acetyl-galactosamine are sulfated. In CS-B, iduronic acid replaces glucuronic acid in the CS 
disaccharide unit.  In CS-D and CS-E, two sulfate groups per disaccharide unit are present.  




important for neuronal growth inhibition (Bradbury et al., 2002; Garcia-Alias et al., 2009; Houle 
et al., 2006; Pizzorusso et al., 2002).  
 Similar to MAIs, CSPG-mediated inhibition depends on activation of RhoA and 
conventional PKCs (Powell et al., 2001; Schweigreiter et al., 2004; Sivasankaran et al., 2004).  
Mechanistic studies recently identified the receptor protein tyrosine phosphatase sigma (RPTPσ) 
as a high-affinity receptor for CSPGs (Shen et al., 2009).  RPTPσ is a member of the leukocyte 
common antigen-related protein (LAR) family that also includes LAR and RPTPδ.  RPTPσ binds 
to CS-GAG chains and the structurally related heparan sulfate (HS)-GAG chains via its first Ig-
like domain (Aricescu et al., 2002; Shen et al., 2009).  The association of RPTPσ with CS- and 
HS-GAGs critically depends on the presence of an evolutionarily conserved cluster of basic 
amino acid residues.  Functional ablation of RPTPσ enhances neurite outgrowth in the presence 
of CSPGs in vitro, and, following CNS injury, promotes growth of sensory afferents (Shen et al., 
2009), corticospinal tract axons (Fry et al., 2010), and retinal ganglion cell axons (Sapieha et al., 
2005).  The incomplete release of CSPG inhibition in RPTPσ-deficient neurons suggests the 
existence of additional mechanisms of CSPG inhibition.  Here we report on the identification of 
the Nogo receptor family members NgR1 and NgR3 as novel CSPG receptors. 
 
2.3 Results 
Nogo receptors participate in Nogo-, MAG-, and OMgp-independent inhibition  
 To determine the role of Nogo receptor (NgR) family members in CNS myelin inhibition, 
we generated NgR1-/-; NgR2-/-; NgR3-/- triple null mice (NgR123-/-) (Figure 2.1).  NgR123-/- mice 
are born at Mendelian ratios, viable into adulthood, fertile, and indistinguishable from wild-type 




postnatal day 7 (P7) cerebellar granule neurons (CGNs), but not dorsal root ganglion (DRG) 
neurons, of NgR123-/- mice show a significant (P< 0.001, one-way ANOVA, Tukey’s post hoc), 
yet incomplete release of growth inhibition (Figures 2.2, 2.3).  Compared to CGNs isolated from 
WT, NgR1-/-, NgR12-/-, or NgR3-/- mice, CGNs from NgR123-/- mutants grow significantly longer 
neurites on myelin.  Remarkably, in two different types of neurons, CGNs and DRG neurons, the 
combined loss of NgR1 and NgR2 does not result in enhanced neurite growth on crude CNS 
myelin (Figures 2.2, 2.3).  Because only NgR1 and NgR3, but not NgR2, are expressed in P7 
CGNs (Venkatesh et al., 2005; Zheng et al., 2005), this suggests that NgR3 participates in myelin 
inhibition.  This is somewhat surprising, as NgR3 does not associate with recombinant Nogo, 
MAG or OMgp (Venkatesh et al., 2005).   
 To directly test whether NgR3 participates in neurite outgrowth inhibition of 
endogenously expressed Nogo, MAG, or OMgp, experiments were repeated with CNS myelin 
isolated from NogoABC-/-; MAG-/-; OMgp-/- triple mutant mice (NMO-/-) (Lee et al., 2010).  
Consistent with previous reports (Cafferty et al., 2010; Lee et al., 2010), NMO-/- myelin is less 
inhibitory than WT myelin (Figures 2.2, 2.3).  Importantly, on NMO-/- myelin, CGNs from 
NgR123-/- mice continue to extend longer neurites (P< 0.001, one-way ANOVA, Tukey’s post 
hoc) than CGNs from WT, NgR1-/-, NgR12-/-, or NgR3-/- mice (Figure 2.2).  This observation 
indicates that NgR3 participates in Nogo-, MAG- and OMgp-independent growth inhibition.  
Because loss of NgR1 or NgR3 alone is not sufficient to promote growth on myelin, this 
suggests some degree of functional redundancy among these two receptors.  
 




 To identify candidate NgR3 ligand(s), we generated alkaline phosphatase (AP)-tagged 
receptor fusion proteins and assayed binding to rat brain tissue sections.  Prior to the onset of 
CNS myelination, NgR1 and NgR3, but not NgR2, bind strongly to numerous fiber tracts in the 
brain and spinal cord (Figures 2.4a, 2.5).  After myelination, a more uniform binding pattern is 
observed with a much less pronounced labeling of fiber tracts (data not shown).  Importantly, 
brain sections of NMO-/- and NgR123-/- triple mutants, p75NTR-/- single mutants, and mice lacking 
select gangliosides show no substantial reduction in soluble receptor binding (Figure 2.6).  In 
COS-7 cells, components of the NgR1 holoreceptor complex, including p75NTR, TROY, and 
Lingo-1 (Yamashita et al., 2005), fail to support NgR3 binding (Figure 2.7).  This suggests that 
binding of NgR3 to brain is not mediated by previously identified components of the NgR1 
complex.  Receptor deletion studies further revealed that the LRRs are not required for binding, 
and identified two discontinuous and evolutionarily conserved sequence motifs, in both NgR1 
and NgR3, that are necessary for binding to brain (Figures 2.4b-e, 2.8).  Motif 1 is located in the 
CT capping domain and overlaps with the FRG motif, which was previously shown to participate 
in sialic acid-dependent binding of the ganglioside GT1b to NgR1 (Williams et al., 2008).   
Motif 2, separated from motif 1 by approximately 130 amino acid residues, is located near the 
juxtamembrane region of the NgR1 and NgR3 stalk domain.  Motif 2 in NgR1 and NgR3 is 
comprised of a highly conserved cluster of basic amino acid residues, deletion of which 
completely abolishes binding to brain (Figures 2.4b-e, 2.8).  Furthermore, a soluble form of 
NgR1 in which the basic residues of motif 2 are replaced by seven alanines [NgR1(7ala)-Fc] no 
longer binds to brain tissue (Figure 2.4d). 
 To assess whether the association of NgR1 and NgR3 with neural tissue is the result of a 




Remarkably, binding was largely resistant to either treatment (Figure 2.6), suggesting a possible 
interaction with neural glycan(s).  Pretreatment of brain tissue sections with various glycosidases 
revealed sensitivity to heparinase and Ch’aseABC.  Moreover, in the presence of heparin, 
binding was completely abolished (Figures 2.6, 2.9a).  Together, these studies suggest that 
NgR1 and NgR3 associate with neural glycosaminoglycans. 
 
NgR1 and NgR3 complex with select CS-GAGs 
 To examine the specificity of the GAG association, AP-NgR1 and AP-NgR3 fusion 
proteins were preincubated with various types of CS-GAGs.  Strikingly, CS-B, CS-D and CS-E, 
but not CS-A or CS-C, effectively compete with brain sections for binding to soluble NgR1 and 
NgR3 (Figure 2.9b).  To test whether NgR1 and NgR3 bind to purified GAGs directly, we 
developed a sandwich ELISA, in which biotinylated GAGs were adsorbed to streptavidin-coated 
microtiter plates and then incubated with soluble AP-tagged NgRs (Figure 2.10a).  Consistent 
with binding experiments to rat brain tissue, NgR1 and NgR3 bind robustly to heparin and 
purified CS-GAGs, indicating that these receptors bind GAGs directly (Figures 2.9c, 2.10b).  
NgR1 and NgR3 bind with high specificity and selectivity to different types of monosulfated and 
disulfated GAGs.  Strong binding was observed to monosulfated CS-B, and disulfated CS-D and 
CS-E.  The dissociation constants for these interactions are in the low nanomolar range (Figures 
2.9c, 2.10b).  No interactions with CS-A or CS-C were detected.  This argues against a 
nonspecific interaction with negatively-charged compounds and underscores the selectivity of 
the NgR1- and NgR3-GAG associations.   
 Notably, the first three Ig-like domains of RPTPσ [RPTPσ(1-3)] show very similar GAG-




NgR1 for binding to CS-E, indicating that these two receptors complex with, at least in part, 
overlapping CS-GAG epitopes (Figure 2.10c).  Functional studies with primary neurons show 
that soluble RPTPσ(1-3)-Fc and NgR1-Fc block the growth-inhibitory activity of CSPGs toward 
P7 CGNs in vitro.  The neutralizing effects of NgR1-Fc critically depend on the presence of the 
GAG-binding motif 2, as soluble NgR1(7ala)-Fc fails to block CSPG inhibition (Figure 2.9d).     
 
The CSPG and MAI binding sites on NgR1 are distinct and dissociable 
 To further characterize the relation of CSPG and MAI binding sites on NgR1, we 
generated a chimeric receptor construct in which the GAG-binding portion of NgR1 (amino acid 
residues 278-445) was replaced by the corresponding, non-GAG-binding sequence of NgR2 
(amino acid residues 281-420).  Nogo66, MAG, and OMgp bind strongly to this chimeric 
NgR1/NgR2 receptor, indicating that the GAG-binding sequences of NgR1 are not necessary for 
MAI binding (Figure 2.11a).  A soluble form of this same chimeric receptor fails to bind to rat 
brain tissue sections or to GAGs directly (Figure 2.10d-e).  This suggests that MAIs and CSPGs 
bind to distinct and dissociable sites on NgR1 (Figure 2.11b).  Moreover, the presence of CS-B, 
CS-D, or CS-E does not substantially influence binding of AP-Nogo66 to NgR1 (Figure 2.11c).   
 
Neuronal Nogo receptors participate in CSPG inhibition 
 To determine whether loss of NgRs leads to disinhibition of neurite growth on substrate-
bound CSPGs, CGNs from NgR single and compound mutants were analyzed (Figure 2.12).  
Loss of NgR1 or NgR3 alone, or the combined loss of NgR1 and NgR2 (NgR12-/-), is not 
sufficient to attenuate CSPG inhibition.  Loss of all three NgRs (NgR123-/-), however, results in 




inhibition.  Furthermore, release of inhibition for CGNs isolated from NgR123-/- and RPTPσ-/- 
pups is comparable (Figure 2.12).   
 Dose-response experiments show that when challenged with high concentrations of 
CSPGs, NgR123-/- and RPTPσ-/- neurons are strongly inhibited and lose their growth advantage 
over WT neurons (Figure 2.13a).  This suggests that these receptor systems share some degree 
of functional redundancy.  At high doses of CSPGs, loss of NgRs may be compensated by 
RPTPσ and vice versa.  NgRs are not abundantly expressed in P7 DRG neurons (Zheng et al., 
2005) and NgR123-/- DRG neurons are not disinhibited on CSPG substrate.  In a parallel 
experiment with DRG neurons from RPTPσ-/- mice, neurite length is increased on CSPGs 
(Figure 2.13b).  Collectively, these studies show that NgR1 and NgR3 bind CS-GAGs directly 
and participate in CSPG-mediated neurite outgrowth inhibition in a neuronal cell type-specific 
manner. 
 
NgR1 and NgR3 associate in a ligand-dependent manner 
 NgRs are GPI-anchored proteins and therefore depend on interactions with 
transmembrane receptor components to signal growth inhibition across the neuronal plasma 
membrane.  To assess whether NgR1 and NgR3 employ shared signaling mechanisms, we 
assayed binding of NgR3-Fc to the previously identified NgR1 receptor components p75NTR, 
TROY, and Lingo-1 in COS-7 cells. We observed no binding of soluble NgR3 to p75NTR, 
TROY, Lingo-1, or NgR1 (Figure 2.7).  There are conflicting results on whether NgR1 and 
NgR3 interact (Barton et al., 2003; Zhang et al., 2011).  We therefore revisited this issue and 
found that NgR1 and NgR3 are part of the same immune complex when co-expressed in 




presence of exogenously-applied CSPGs (Figure 2.7), suggesting that the two receptors may be 
part of the same receptor complex.  In this same assay, no association of NgR1 with NgR2 is 
observed, neither in the presence nor the absence of CSPGs.  Next we examined whether NgR1, 
NgR3, and p75NTR may be part of the same receptor complex.  In HEK293T cells co-transfected 
with NgR1, NgR3, and p75NTR, anti-NgR1 pull-down experiments revealed that the three 
receptors are present in the same immune complex if cells are treated with CSPGs (Figure 2.7).   
 To directly test whether p75NTR is important for CSPG-mediated neurite outgrowth 
inhibition, P7 CGNs from p75NTR-/- mice were plated on substrate-bound CSPGs.  Loss of p75NTR 
does not result in a substantial release of CSPG inhibition (Figure 2.7).  Together these data 
indicate that p75NTR, NgR1, and NgR3 do interact in the presence of CSPGs; however, p75NTR is 
not necessary for CSPG-mediated outgrowth inhibition.  Our studies confirm and expand on 
previous work showing that the versican isoform V2 mediates neurite outgrowth inhibition in 
CGNs and DRG neurons in a p75NTR-independent manner (Schweigreiter et al., 2004). 
 
CSPGs in the injured CNS support binding of NgR1 and NgR3 
 Similar to other CNS fiber tracts, severed retinal ganglion cell (RGC) axons in the rodent 
optic nerve fail to show spontaneous long-distance axonal regeneration.  Retro-orbital crush 
injury to the optic nerve results in a global upregulation of CSPGs along the nerve (Ohlsson et 
al., 2004).  Importantly, injured but not control optic nerve sections support enhanced binding of 
soluble NgR1-Fc and NgR3-Fc, and the GAG-binding motif 2 of NgR1 and NgR3 is necessary 
for this binding (Figure 2.14).  Moreover, binding of soluble receptors is largely abrogated by 




likely due to association with endogenous MAIs (Figure 2.14).  Together, these studies suggest 
that CSPGs are endogenous ligands for neuronal NgR1 and NgR3. 
 
Regeneration is enhanced in NgR123-/- and NgR13-/- mice 
 In the adult mouse retina, NgR1, NgR2, and NgR3 are all strongly expressed in RGCs 
(Figure 2.15a).  Retinal stratification (Figure 2.15b) and optic nerve myelination (Figure 2.15c) 
in NgR123-/- mice appear normal.  To assess RGC axon targeting to the superior colliculus, the 
suprachiasmatic nucleus, and the lateral geniculate nucleus, the right eye of adult WT and 
NgR123-/- mice was injected with Alexa 594-conjugated Cholera Toxin β (CTB-red) tracer, and 
the left eye with Alexa 488-conjugated Cholera Toxin β (CTB-green) tracer.  No defects in RGC 
axon central projections or target innervation were observed (Figure 2.15d-f).  Thus, germline 
ablation of all three NgRs does not appear to compromise retinal stratification, optic nerve 
myelination, or RGC axonal pathfinding.   
 To assess whether NgRs contribute to the regenerative failure of injured CNS axons, we 
performed retro-orbital optic nerve crush injury in Nogo receptor single and compound mutant 
mice.  Compared to injured wild-type controls, NgR123-/- mice show a modest but significant 
(P< 0.001, one-way ANOVA, Tukey’s post hoc) increase in RGC axon regeneration (Figure 
2.16).  At two weeks post-injury, more GAP-43-positive fibers are observed at 0.2-1.0mm distal 
to the injury site in NgR123-/- mice compared to WT mice.  Because NgR1 and NgR2 are known 
to associate with MAIs, the NgR123-/- regeneration phenotype may be a reflection of (i) 
decreased Nogo, MAG and OMgp inhibition, (ii) decreased CSPG inhibition, or (iii) a 
combination thereof.  To address this issue, we directly compared regeneration of NgR1-/-,  




NgR123-/- triple mutants.  Loss of NgR1, NgR2, or NgR3 alone, or the combined loss of NgR1 
and NgR2 (NgR12-/-), does not result in substantially enhanced RGC axon regeneration 
compared to WT mice (Figures 2.16, 2.17; Table 2.1).  However, NgR13-/- mice show a similar 
degree of axon regeneration as NgR123-/- mice.  This suggests a novel role for NgR3 in signaling 
neuronal growth inhibition.  When coupled with our neurite outgrowth studies in vitro, showing 
that NgR1 and NgR3 operate as functionally redundant CSPG receptors, this suggests that the 
optic nerve regeneration in NgR13-/- and NgR123-/- mice is at least in part a reflection of 
decreased CSPG inhibition.   
 As RPTPσ is expressed in adult RGCs (Sapieha et al., 2005), we examined whether the 
combined loss of NgR1 and NgR3 on an RPTPσ-/- background (NgR13/RPTPσ-/-) results in a 
further increase of regenerating axons.  Few regenerating axons were observed in RPTPσ-/- single 
mutants, with no significant difference compared to WT controls (P> 0.05).  Compared to 
NgR13-/- double mutants, NgR13/RPTPσ-/- triple mutants show a further increase in the number 
of regenerating axons (P< 0.001, one-way ANOVA, Tukey’s post hoc), suggesting a genetic 
interaction among these receptors (Figures 2.16, 2.17; Table 2.1).   
 
In growth-enabled RGCs, loss of all NgRs greatly enhances optic nerve axon regeneration   
 An advantage of optic nerve regeneration studies is that the growth potential of RGCs can 
be sensitized by intraocular (i.o.) injection of the yeast cell wall extract Zymosan, resulting in the 
release of RGC survival and growth-promoting factors, including oncomodulin (Yin et al., 
2009), ciliary neurotrophic factor (CNTF), and leukemia inhibitory factor (LIF) (Leibinger et al., 
2009).  WT mice that receive i.o. Zymosan show greatly enhanced regeneration of RGC axons, 




mice (Figure 2.16).  Importantly, NgR123-/- mice that receive i.o. Zymosan show significantly 
more (P< 0.05, one-way ANOVA, Tukey’s post hoc) regenerating axons than WT, NgR1-/-, 
NgR2-/-, NgR3-/-, or RPTPσ-/- single mutants, as well as NgR12-/- double mutants, subjected to i.o. 
Zymosan.  NgR13-/- and NgR123-/- mice with i.o. Zymosan show a similar regeneration 
phenotype.  At several distances from the injury site, NgR13/RPTPσ-/- triple mutants with i.o. 
Zymosan show a further increase in the number of regenerating axons compared to NgR123-/- 
mice with i.o. Zymosan (P< 0.05, one-way ANOVA, Tukey’s post hoc) (Figures 2.16, 2.17; 
Table 2.1). 
 In mice, optic nerve injury leads to the death of ~ 70% of RGCs by two weeks post-injury 
(Figure 2.18).  The enhanced regeneration observed in NgR123-/- mice is not a result of 
increased RGC survival, as similar numbers of injury-induced RGC death were observed in WT 
and NgR123-/- triple mutants.  Intraocular Zymosan administration partially protects RGCs from 
axotomy-induced cell death; however, the protective effect of Zymosan is similar in WT and 
NgR123-/- mice (Figure 2.18).  Consistent with the view that a decrease in RGC death is not 
sufficient to promote axonal regeneration, p53-deficient RGCs are more resistant to injury-
induced cell death but fail to show enhanced regeneration (Park et al., 2008).  To assess whether 
i.o. Zymosan influences expression of NgRs or RPTPσ in RGCs, we performed in situ 
hybridization at 3 and 7 days post-Zymosan injection, but did not observe any obvious changes 
(Figure 2.19).   
 
2.4 Discussion 
 The main finding of the present study is the identification of two novel CSPG receptors.  




and operate as functionally redundant CSPG receptors.  Loss of NgR family members 
individually is not sufficient to overcome CSPG inhibition; however, the combined loss of NgR1 
and NgR3 leads to a significant release of CSPG inhibition (P< 0.05).  In NgR123-/- triple 
mutants, severed RGC axons show enhanced regenerative growth.  Interestingly, NgR13-/-, but 
not NgR12-/- mutants, phenocopy the optic nerve regeneration phenotype of NgR123-/- mice.  A 
further enhancement of axon regeneration is observed in NgR13/RPTPσ triple mutants, revealing 
a genetic interaction among NgR family members and the previously identified CSPG receptor 
RPTPσ.  Collectively, our studies provide unexpected evidence for shared receptor mechanisms 
for “prototypic myelin inhibitors” and CSPGs, two major classes of growth-inhibitory molecules 
abundant in the adult mammalian CNS.   
 
NgR1 and NgR3 bind with high selectivity to specific CS-GAGs 
 CSPG inhibition depends on the presence of CS-GAG chains; we therefore explored the 
molecular basis of Nogo receptor-GAG interactions.  We identified two sequence motifs in each 
receptor, both of which are necessary for GAG binding.  Motif 1 is located in the LRR-CT 
capping domain and is identical to the GT1b binding motif identified in NgR1 (Williams et al., 
2008).  Motif 2 is located in the distal stalk region juxtaposed to the GPI anchor.   
 Remarkably, NgR1 and NgR3 show exquisite specificity toward select types of CS-
GAGs.  Binding to monosulfated CS-B, but not CS-A or CS-C, is very robust.  In addition, the 
disulfated GAGs CS-D and CS-E bind strongly to NgR1 and NgR3.  Identical binding 
preferences were observed for RPTPσ.  Competition of soluble NgR1 and RPTPσ(1-3) 
ectodomain for CS-E binding suggests that two very different protein modules complex with  at 




NgRs or RPTPσ is sufficient to attenuate inhibition of neurite outgrowth at low and intermediate, 
but not at high, doses of CSPGs.  A very recent study identified the receptor tyrosine 
phosphatase LAR as a CSPG receptor (Fisher et al., 2011).  Together, these findings reveal a 
significant degree of functional redundancy among CSPG receptor mechanisms and suggest that 
antagonism of multiple NgR and LAR family members will be required to fully overcome CSPG 
inhibition.    
 
Additive effects of manipulating extrinsic and intrinsic pathways   
 The relatively modest regeneration phenotype observed in NgR123-/- and NgR13/RPTPσ-/- 
mice at two weeks post-injury is consistent with previous studies showing that expression of a 
dominant negative form of NgR1 in RGCs (Fischer et al., 2004a) or blocking of RhoA with C3 
transferase (Fischer et al., 2004b) is not sufficient to promote substantial regeneration of severed 
optic nerve axons.  In a similar vein, removal of one or several MAIs results in inconsistent and 
often poor regeneration in spinal cord-injured mice (Cafferty et al., 2010; Lee et al., 2010).  
Collectively, mouse genetic studies suggest that germline ablation of multiple growth-inhibitory 
ligands or receptors is not sufficient to promote robust and long-distance regeneration in 
different fiber tracts of the injured adult CNS.   
 A significant impact of environmental inhibitory signals on limiting axon regeneration 
was revealed, however, when genetic manipulations were combined with activation of RGC 
intrinsic growth programs.  On an NgR13-/-, NgR123-/-, or NgR13/RPTPσ-/- background, i.o. 
Zymosan injection results in significantly enhanced axonal growth distal to the injury site 
compared to WT, NgR12-/-, or RPTPσ-/- mutant mice with i.o. Zymosan.  While the additive 




growth programs have been reported (Fischer et al., 2004a; Fujita et al., 2011; Kadoya et al., 
2009), our data show that in growth-enabled RGCs, members of the NgR family and LAR family 
collaborate to negatively impact the number and length of regenerating axons following CNS 
injury. 
 
NgR3 participates in neuronal growth inhibition 
 Enhanced axon regeneration observed in the optic nerve of NgR123-/- mice is mimicked 
by NgR13-/-, but not NgR12-/-, mutants.  This suggests that on an NgR1-/- background, NgR3, but 
not NgR2, contributes to the regenerative failure of severed RGC axons.  As NgR3 does not 
directly associate with Nogo, MAG, or OMgp, but supports CSPG binding and participates in 
CSPG inhibition in vitro, our findings suggest that NgR3-CSPG-mediated growth inhibition 
contributes to the regenerative failure of CNS axons in vivo.   
 While CSPGs are the first ligands identified for NgR3, they also bind to NgR1, further 
underscoring the high promiscuity of NgR1.  CSPGs are found in crude CNS myelin 
preparations (Niederost et al., 1999; Schweigreiter et al., 2004) and present in the CNS myelin 
used for this study (data not shown).  Similar to the enhanced neurite outgrowth of NgR123-/- 
neurons on CNS myelin (Figure 2.2), the enhanced growth of neurons functionally depleted of 
NgR1 and PirB (Atwal et al., 2008) may be, at least in part, a reflection of decreased MAI and 
CSPG inhibition.   
 
Implications for experience-dependent neural plasticity 
 While it has been known for some time that MAIs and CSPGs share similar downstream 




MAI and CSPG signaling cascades converge to regulate neuronal cytoskeletal dynamics has not 
yet been determined.  Here we identify NgR1 and NgR3 as novel and functionally redundant 
CSPG receptors.  We provide evidence that Nogo, MAG, OMgp, and CSPGs share receptor 
components and perhaps signal through related receptor complexes to block neuronal plasticity, 
sprouting, and axonal regeneration.  In support of this idea, the myelin inhibitor Nogo-A shares 
structural and sequential similarities with neurocan, an inhibitory CSPG implicated in blocking 
neuronal regeneration (Shypitsyna et al., 2010), suggesting a common origin for two seemingly 
unrelated  inhibitors of growth.  The newly discovered connection between CSPGs and NgRs is 
not only relevant for neuronal repair, but may also provide a mechanistic explanation for why 
two seemingly unrelated manipulations, such as Ch’aseABC infusion into the mature visual 
cortex and germline ablation of NgR1 or Nogo, result in enhanced ocular dominance plasticity 
following monocular deprivation (McGee et al., 2005; Pizzorusso et al., 2002).  Mounting 
evidence suggests that mechanisms that limit neuronal growth and plasticity following CNS 
injury and disease resemble those that negatively regulate neuronal growth and synaptic structure 
under physiological conditions (Lee et al., 2008; Zagrebelsky et al., 2010).   
 The identification of NgRs as shared receptors for MAIs and CSPGs provides new 
insights into how a diverse group of inhibitory cues regulates neuronal structure and function 
under physiological conditions and following injury.  We propose that Nogo receptors are part of 
a multicomponent receptor system that serves as a signaling platform to initiate pathways that 
limit neuronal growth and increase structural stability of synapses.  When combined with recent 
findings that NgR1and its ligands Nogo and OMgp influence synaptic transmission (Raiker et 
al., 2010), experience-dependent network refinement (McGee et al., 2005), and spatial memory 




repair, and shed light on a vital part of the neuronal machinery that limits growth and plasticity in 
CNS health and disease.  
 
2.5 Future Directions 
Identification of specific CSPG ligands that bind and signal via NgRs 
 While we have found that NgR1 and NgR3 bind with high affinity to select types of GAG 
side chains, the identity of specific CSPG ligands (protein cores) has not yet been determined.  
Following CNS injury, a number of CSPG ligands are dramatically upregulated by reactive 
astrocytes, including aggrecan, neurocan, and phosphacan (Jones et al., 2003; McKeon et al., 
1995).  These astrocytes are made “reactive” by the release of soluble serum factors and 
microglia-derived molecules at the injury site, including various interleukins and cytokines 
(Pekny and Nilsson, 2005; Silver and Miller, 2004; Sofroniew, 2009).  One of these molecules, 
TGFβ1, has been shown to make astrocytes “reactive” in vitro, based on increased glial fibrillary 
acidic protein (GFAP) expression and CSPG production (Wang et al., 2008; Yu et al., 2012).  
Indeed, cultures of mouse cortical astrocytes that have been treated with TGFβ1 for 7 days are 
“reactive” (Figure 2.20a) and show robust binding to NgR1-Fc, NgR2-Fc, and RPTPσ(Ig1-3)-
Fc, but not to AP-Fc or NgR2-Fc (Figure 2.20b).  Importantly, this binding is dependent on the 
GAG-binding motif 2 of NgR1 and NgR3 and is abolished with Ch’aseABC treatment, 
suggesting an interaction with astrocyte-derived CSPGs.   
 To identify the CSPG binding partners of NgR1 and NgR3, reactive astrocyte-
conditioned medium (ACM) was concentrated and tumbled with affinity-purified NgR1-Fc, 
NgR2-Fc, NgR3-Fc, and RPTPσ(Ig1-3)-Fc (bound to Protein G Plus/Protein A-Agarose beads).  





GAG chains, leaving only the CSPG protein cores.  Successful enzyme treatment was shown by 
western blotting with an antibody (anti-chondroitin sulfate, “stub”) selectively reacting with the 
CS-GAG stub epitopes generated following enzymatic digestion.  Following Ch’aseABC 
treatment of the NgR1, NgR3, and RPTPσ(Ig1-3)-Fc (but not NgR2) conditions, several bands 
are noted in the 100-250 kilodalton range (Figure 2.20c).  These bands are of similar sizes 
between all three conditions, suggesting that NgR1, NgR3, and RPTPσ interact with the same 
CSPG protein cores.  As expected, no bands are recognized by the “stub” antibody without 
Ch’aseABC treatment (Figure 2.20c).  Importantly, all Fc fusion proteins were 
immunoprecipitated at comparable levels (data not shown).   
 To identify specific CSPG protein cores present in the precipitates, samples were 
subjected to SDS-PAGE, stained with Coomassie Blue to identify protein bands, and 
proteolytically digested prior to liquid chromatography-tandem mass spectrometry (LC-MS/MS).  
Coomassie Blue staining revealed distinct bands (in the 100-250 kilodalton range) present in the 
NgR1, but not NgR2, conditions (Figure 2.20d); however, LC-MS/MS analysis revealed no 
presence of proteoglycans (Table 2.2).  As expected, NgR, Fc, and Ch’aseABC components 
were identified by LC-MS/MS (data not shown), as well as proteins known to be expressed by 
reactive astrocytes (vimentin, 14-3-3) (Satoh et al., 2004; Schiffer et al., 1986).  Surprisingly, all 
identified proteins were present in both the NgR1 and NgR2 conditions (Table 2.2).  A number 
of factors likely contributed to the failure of this approach, including the relatively low amount 
of input material (astrocyte-conditioned medium) and the fact that proteoglycans are among the 
most difficult proteins to analyze due to their extensive glycosylation and structural complexity 




 As an alternative approach to proteomics, precipitates will be subjected to western 
blotting, using antibodies raised against likely candidate CSPG protein cores (aggrecan, 
neurocan, phosphacan, etc.).  Functional neurite outgrowth inhibition assays will then be used to 
determine if neurons lacking NgR1 and/or NgR3 show enhanced growth on these protein cores.  
Preliminary evidence suggests that NgR123-/- CGNs do not grow longer neurites on either 
substrate-bound aggrecan or neurocan, compared to control CGNs (P> 0.05) (Figure 2.20e-f), 
despite the fact that RPTPσ interacts with these CSPG ligands and RPTPσ-/- neurons are less 
inhibited on neurocan substrate (Shen et al., 2009).  As RPTPσ also interacts with heparan 
sulfate proteoglycans (HSPGs) to signal neuronal growth promotion (Coles et al., 2011), and 
NgR1 and NgR3 bind tissue in a heparinase-sensitive manner (Figures 2.6, 2.9), future studies 
will also address the molecular identity of HSPG ligands for NgRs and the functional 
consequence of these interactions.  
 
Development of blocking peptides that inhibit CSPG-receptor interactions 
 While CNS regeneration studies in genetically engineered mice are a powerful tool for 
target validation, genetic approaches cannot be readily translated to more clinically-relevant 
settings.  Thus, future studies will include the design of polypeptides that block interactions of 
CSPGs with their high-affinity receptors.  As we have identified two short peptide motifs in 
NgR1 (motif 1: residues 278-281, motif 2: residues 414-426) and NgR3 (motif 1: residues 273-
276, motif 2: residues 403-415) that are sufficient to mediate binding to neural CSPGs (Figures 
2.4, 2.8), standard PCR cloning can be used to generate truncated polypeptides of NgR1 (278-
426) and NgR3 (273-415), which can be tested by ELISA for their ability to compete with NgR1 




be used as a negative control.  In addition, smaller peptides consisting of only motif 1 or motif 2 
can be generated and tested for their ability to block CSPG binding to NgRs.  It would also be 
interesting to know whether the spacing between motif 1 and motif 2 can be reduced without 
compromising CS-GAG binding.  If these peptides successfully block CSPG-receptor 
interactions, future studies can address their ability to override CSPG inhibition of primary 
neurons in vitro and to promote axonal regeneration following crush injury to the optic nerve in 
vivo.  
 
Long-term regeneration studies with an emphasis on functional recovery 
 While the optic nerve injury model is becoming more widely accepted as an appropriate 
system for the study of anatomical regeneration in rodents (Fischer et al., 2004a; Fujita et al., 
2011; Park et al., 2008), only one research group has demonstrated functional recovery in this 
model (de Lima et al., 2012).  In this study, combined genetic and pharmacological 
manipulations allowed for RGC fiber regeneration through the optic nerve and into target areas 
of the brain, with a partial restoration of the optomotor response, depth perception, and circadian 
photoentrainment (de Lima et al., 2012).  As an alternative and more sensitive readout for 
functional recovery of RGC fibers, we have developed an electrophysiological approach, in 
which compound action potential (CAP) propagation is measured in acutely isolated optic nerves 
to determine if regenerating fibers are electrically active.  CAP recordings from uninjured, adult 
optic nerves reveal a large peak with multiple components (Figure 2.21a), likely representing 
the fast and slow myelinated fibers of the optic nerve (average peak amplitude: 5mV, average 
conduction velocity: 4m/s).  This peak almost completely disappears at 2 weeks post-crush injury 




correlating with the lack of RGC fiber regeneration in the injured mammalian CNS.  Despite the 
significant amount of anatomical regeneration seen in both wild-type animals with Zymosan 
administration and NgR123-/- animals with Zymosan administration (Figure 2.16), CAP 
recordings at several timepoints following injury reveal no substantial improvements in peak 
amplitude or conduction velocity in either of these conditions (Figure 2.21b; Table 2.3).  This 
could represent either technical limitations in the recording strategy or the fact that these 
regenerating fibers are not electrically active.  Thus, future experiments will need to be 
performed to distinguish between these two possibilities.  
 As shown in Figure 2.16 (and discussed above), we have discovered additive effects on 
RGC fiber regeneration when extrinsic factors are genetically deleted (NgRs) and intrinsic 
pathways are activated (Zymosan injection).  Recent evidence has suggested that manipulation of 
another intrinsic signaling pathway, the mTOR pathway, can also promote axon regeneration 
following CNS injury.  Genetic deletion of PTEN, which results in enhanced PI3K and mTOR 
activation, greatly enhances regeneration of both RGC fibers following optic nerve crush injury 
and corticospinal tract axons following spinal cord injury (Liu et al., 2010; Park et al., 2008).  
Indeed, intraocular injection of adeno-associated virus 2, which is expressing GFP and 
PTENshRNA (AAV2-GFP-PTENshRNA), results in substantial transduction of RGCs (Figure 
2.21c).  Furthermore, phospho-S6 (pS6) levels are greatly increased in RGCs upon transduction 
with AAV2-GFP-PTENshRNA compared to a scrambled shRNA control (AAV2-GFP-
scrambled) (Figure 2.21d), suggesting that mTOR levels are thus increased.  In addition, 
substantial RGC fiber growth is seen distal to the injury site, two weeks following optic nerve 
crush injury (and four weeks following AAV2-GFP-PTENshRNA injection) (Figure 2.21d).  




genetic deletion of NgRs, as well as how far these regenerating fibers can travel at several weeks 
and months post-injury.  If significant fiber growth is seen into target regions of the brain, the 
possibility of remyelination, synaptogenesis, and functional recovery will be explored.  Improved 
imaging techniques will also be utilized, including tetrahydrofuran-based chemical clearing of 
the brain and optic nerve (Figure 2.21e-f), which renders fixed and unsectioned tissue 
transparent for high-resolution ultramicroscopy and 3D reconstruction (Erturk et al., 2011; Luo 
et al., 2013 ).  With this method, axonal trajectories can be unequivocally traced and regenerating 
axons can be evaluated as a whole unit, rather than in separate 2D fragments. 
 
2.6 Methods 
 Transgenic mice: All animal handling and surgical procedures were performed in 
compliance with local and national animal care guidelines and approved by the University of 
Michigan Committee on Use and Care of Animals (UCUCA).  NogoABC-/-;MAG-/-;OMgp-/-, 
RPTPσ-/-, NgR1-/-, NgR2-/-, and p75NTR-/- mice have been described (Lee et al., 2010; Shen et al., 
2009; Zheng et al., 2005).  NgR3-/- germline mutants were generated by Lexicon Genetics and 
kindly provided by M. Greenberg (Harvard Medical School).  NgR1 and NgR2 conditional 
mutants have been described elsewhere (Williams et al., 2008).  NgR3 conditional knockout 
mice were generated by flanking exon2 with loxP sites (Figure 2.1).  To generate germline 
deletion mutants, conditional knockouts were crossed with protamine-cre transgenic mice and 
then intercrossed with each other, or onto an RPTPσ-/- background, to generate double and triple 
mutants.  
 To confirm that NgR123-/- mice are null for NgR1, NgR2, and NgR3, brain extracts of 




membranes were isolated, lysed in RIPA buffer (Sigma) containing protease inhibitor cocktail 
(Sigma), and affinity precipitated with agarose-Concanavalin A beads (Vector Laboratories) 
overnight at 4°C.  Bound glycoproteins were subjected to SDS-PAGE, blotted onto 
nitrocellulose membranes (Thermo Fisher Scientific), and probed with polyclonal anti-NgR1, 
anti-NgR2, anti-NgR3 or anti-β-actin (Sigma).  
 
 Neurite outgrowth assays: To assay myelin inhibition, 96-well plates were coated with 
poly-D-lysine hydrobromide (50μg/ml; Sigma) overnight, rinsed in water, air dried, and then 
incubated with a 5μl spot of BSA (40μg/ml) or CNS myelin (40μg/ml) prepared from wild-type 
or NogoABC-/-;MAG-/-;OMgp-/- (NMO-/-) mice (Lee et al., 2010).  Proteins were adsorbed to poly-
D-lysine for 3 hours at 37°C.  Wells were then rinsed and incubated with laminin (10μg/ml; 
Sigma) for 1 hour at 37°C.  P7 mouse cerebellum was dissected, trypsinized, gently triturated, 
and CGNs were purified in a discontinuous Percoll gradient before resuspension in Neurobasal 
medium (Invitrogen) with B-27® supplement (Invitrogen), glutamine, glucose, and 
penicillin/streptomycin, as described previously (Venkatesh et al., 2005).  P7 mouse DRG 
neurons were dissected, incubated in 0.05% trypsin and 0.1% collagenase, and triturated before 
resuspension in Neurobasal medium with B-27® supplement, glutamine, penicillin/streptomycin, 
and 15ng/ml nerve growth factor.  CGNs and DRG neurons were then plated at 8,000 cells/well, 
and cultured for 24 hours before fixation with 4% paraformaldehyde, blocking in 1% horse 
serum and 0.1% Triton X-100 in PBS, and staining with anti-class III β-tubulin (TuJ1; Promega).  
To visualize the spotted myelin, wells were also stained with anti-myelin basic protein (Sigma).  




Images were taken using an inverted microscope (IX71; Olympus) attached to a digital camera 
(DP72; Olympus). 
 To assay CSPG inhibition, 5μl spots (1, 2, 10, 100μg/ml) of either a mixture of large, 
extracellular chondroitin sulfate proteoglycans isolated from embryonic chicken brain 
(Millipore), aggrecan (Sigma), neurocan (Millipore) or BSA were adsorbed on 96-well plates for 
3 hours at 37°C before coating with poly-D-lysine hydrobromide and laminin.  After 24 hours in 
culture, neurite length of CGNs or DRG neurons was determined as described above.  To 
visualize the spotted CSPGs, wells were also stained with anti-chondroitin sulfate (CS56; 
Sigma).  For some experiments, receptor fusion proteins (10μg/ml) or the ROCK inhibitor Y-
27632 (10μM) were added to the wells at the time of CGN plating.   
 
 Construction of fusion proteins: AP- and Fc-tagged fusion proteins were constructed by 
standard PCR cloning using the Tth-DNA polymerase (Applied Biosystems).  Constructs for AP-
Fc, AP-NgR1(∆GPI), AP-NgR2(∆GPI), AP-NgR3(∆GPI), AP-Nogo66, AP-OMgp, AP-
Sema3A, AP-Sema3F, and MAG-Fc have been described previously (Kantor et al., 2004; 
Venkatesh et al., 2005).  Additional constructs included AP-NgR1NT-LRR-CT(Ala24-Val311), AP-
NgR2NT-LRR-CT(Ser30-Thr314), AP-NgR3NT-LRR-CT(Ser22-Pro307), AP-NgR1CT+stalk (Val263-Glu445), 
AP-NgR2CT+stalk (Ala264-Ser397), AP-NgR3CT+stalk (Asp258-Val413), AP-NgR1stalk(Ala310-Glu445), 
AP-NgR1CT(Phe278-Cys336), AP-NgR1∆15CT+stalk(Phe278-Glu445), AP-NgR3 ∆15CT+stalk(Phe273-
Val413), AP-NgR1∆17CT+stalk(Gly280-Glu445), and AP-NgR1(CT+stalk)∆m2(Phe278-Gly412).  Soluble Fc 
fusion proteins contain a PAM-myc signal sequence and a C-terminal Fc region of human IgG1.  
Constructs were assembled in the expression vector pcDNA3.0 as described (Venkatesh et al., 




414-429 RRRPGCSRKNRTRSHC of NgR1 were replaced by AAAPGCSAATSTASHC - the 
location of an internal Spe1 restriction site introduced for PCR construction is underlined), 
NgR2-Fc(Cys31-Gly399), NgR3-Fc(Pro25-Val420), NgR3Δm2-Fc(Pro25-Met397), NgR1(Cys27-
Lys277)/NgR2(Val281-Gly399)-Fc, and RPTPσ(Ig1-3)-Fc(Glu30-Val315). 
 
 Binding assays: COS-7 cells grown in 24-well plates were transiently transfected 
(Lipofectamine® 2000) with plasmid DNA encoding p75NTR, TROY, Lingo-1, L-MAG,  NgR1, 
NgR3, NgR1(7ala), chimeric NgR1(Cys27-Lys277)/NgR2(Val281-Leu420), or GFP.  Ligand-
receptor binding studies were carried out and developed as described previously (Venkatesh et 
al., 2005).  For some COS-7 cell binding assays, CS-GAGs, at a concentration of 1mg/ml, were 
added to the wells at the time of ligand incubation.  Binding studies with astrocytes were 
performed in a similar fashion, using P1 mouse cortical astrocytes.  Briefly, mouse cerebral 
cortex from 4 pups was dissected (including removal of the meninges and hippocampus), 
trypsinized, triturated, and plated in a T75 tissue culture flask in DMEM (Invitrogen) with 10% 
fetal bovine serum and penicillin/streptomycin (Yu et al., 2012).  Once confluent, the flasks were 
placed on a platform shaker (200rpm, 37ºC) for 24 hours to remove neurons, microglia, and 
oligodendrocyte progenitor cells (Yu et al., 2012).  The culture medium was immediately 
replaced and the astrocytes were harvested onto 24-well plates.  Once confluent, astrocytes were 
switched to DMEM (without serum) for 24 hours, followed by addition of 1μg/ml TGFβ1 (R&D 
Systems) for 7 days before binding studies were carried out.  Some wells were incubated with 
chondroitinase ABC (Calbiolchem; 1unit/ml in Tris-acetate buffer - pH 8.0 - with 0.02% BSA) 




stained with anti-chondroitin sulfate (CS56; Sigma) and anti-GFAP (Millipore) to confirm 
astrocyte reactivity. 
 To monitor binding of soluble Nogo receptors to brain tissue sections in situ, binding 
studies with embryonic (E18) and neonatal (P1-P3) rat or mouse brains were carried out as 
described previously (Kantor et al., 2004; Venkatesh et al., 2005).  Additional binding studies 
included longitudinal optic nerve sections of adult mice.  To assess whether the association of 
AP-NgR1CT+stalk or AP-NgR3CT+stalk to brain tissue sections is mediated by protein-protein 
interactions, brain sections were preincubated at 75ºC for 3 hours or treated with trypsin (10 
units for 30 minutes at 37°C) prior to incubation with AP-fusion proteins.  To explore whether 
glycoconjugates participate in binding of soluble Nogo receptors to brain tissue, sections were 
enzymatically treated with glycosidases according to manufacturer’s instructions prior to adding 
the AP-fusion proteins.  Enzymes included N-acetylglucosaminidase, Vibrio cholerae 
neuraminidase, heparinase III (Flavobacterium heparinium), chondroitinase ABC (all from 
Calbiochem), glycopeptidase F (New England Biolabs), and endoneuraminidase-N (kindly 
provided by U. Rutishauser, Sloan-Kettering Institute).  Some injured optic nerve sections were 
incubated with chondroitinase ABC (1unit/ml) for 3 hours at 37°C prior to addition of receptor 
fusion proteins.  To assay whether specific types of GAG side chains block binding of soluble 
NgRs to brain tissue, competition binding experiments were carried out in the presence of 
heparin or different types of CS-GAG chains (50μg/ml; Seikagaku Glycobiology).  
 To determine whether NgRs or RPTPσ bind directly to GAG chains, enzyme-linked 
immunosorbent assays (ELISAs) were performed as described previously (Briani et al., 1998).  
Briefly, GAG chains were biotinylated with EDC and EZ-Link Sulfo-NHS-LC-LC-Biotin 




with streptavidin (5µg/ml; Invitrogen).  Plates were blocked (5% BSA), rinsed with HBS, and 
incubated with various amounts of fusion proteins (diluted with 5% BSA) for 2 hours at 22˚C.  
Following five washes with HBS, bound AP activity was monitored with a BluePhos Microwell 
Substrate Kit (KPL).  For competitive binding experiments, immobilized GAG chains were 
preincubated with various amounts of RPTPσ(Ig1-3)-Fc for 16 hours at 4˚C, and then incubated 
with AP-NgR1 (1nM) for 2 hours at 22˚C.  Bound AP activity was measured as described above.  
 
 Immunoprecipitation/proteomics analysis: HEK293T cells (in 10cm culture dishes) 
were transfected with various combinations of p75NTR, NgR1, NgR1-myc, NgR2-myc, and 
NgR3-myc expression constructs.  After 48 hours, the cells were incubated in lysis buffer 
containing the following: 20mM Tris-HCl (pH 7.5), 150mM NaCl, 5mM EDTA, 1% NP-40, and 
protease inhibitor mixture.  For some assays, cells were incubated for 30 minutes with 100µg/ml 
of CSPG mixture prior to lysis.  Cell lysates were tumbled overnight at 4°C in the presence of 
either anti-p75NTR (Promega) or anti-NgR1, and precipitated with Protein G Plus/Protein A-
Agarose (Calbiochem) after incubation at 4°C for 2 hours.  Precipitated beads were rinsed three 
times with lysis buffer, and bound proteins were eluted with 2X SDS sample buffer.  Precipitates 
were analyzed by immunoblotting, using anti-NgR1, anti-p75NTR (Promega), anti-myc (Cell 
Signaling), or anti-β-actin.  
 For proteomics analysis, astrocyte-conditioned medium (ACM) from TGFβ1-treated 
cultures (see above) was collected and concentrated tenfold using centrifugal filter units 
(Millipore).  Concentrated ACM was tumbled overnight at 4°C in the presence of either affinity-
purified NgR1-Fc, NgR2-Fc, NgR3-Fc, or RPTPσ(Ig1-3)-Fc, and precipitated with Protein G 




times with DMEM, and some samples were then incubated with chondroitinase ABC (1unit/ml) 
for 3 hours at 37°C.  Bound proteins were eluted with 2X SDS sample buffer, and some 
precipitates were analyzed by immunoblotting, using anti-chondroitin sulfate “stub” (MAB2030, 
Millipore) or anti-human IgG, Fc (Millipore).  The remaining precipitates were submitted to the 
University of Michigan Proteomics and Peptide Synthesis Core (Henriette Remmer, Director).  
These samples were subjected to SDS-PAGE, Coomassie Blue staining, and in-gel digestion 
(reduction with dithiothreitol, alkylation with iodoacetamide, overnight incubation with trypsin 
at 37°C, peptide extraction).  The digests were analyzed using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) on a LTQ ion trap mass spectrometer (Thermo Fisher 
Scientific).  Briefly, digests were loaded and gradient elution was performed over a 10cm by 
75μm ID C18 column at 400nL/min.  A 30 minute gradient was employed.  The mass 
spectrometer was operated in data-dependent mode and the seven most abundant ions were 
selected for MS/MS.  Product ion data were searched against the NCBI and UniProt protein 
database using the Mascot and X! Tandem search engines.  Mascot output files were parsed into 
the Scaffold program for filtering to assess false discovery rates and allow only correct protein 
identifications.  
 
 Optic nerve surgery: Adult mice (6-8 weeks of age) of either sex were anesthetized with 
an intraperitoneal injection of Ketamine (100mg/kg; Fort Dodge Animal Health) and Xylazine 
(10mg/kg; Akorn, Inc.).  The optic nerve was exposed through an incision in the conjunctiva and 
compressed for 10 seconds with angle jeweler’s forceps (Dumont #5; Fine Science Tools) at 
approximately 1mm behind the eyeball.  Care was taken not to damage or rupture the ophthalmic 




Sigma) was injected manually using a Hamilton syringe with a 30 gauge removable needle.  
Following optic nerve surgery, the operated eye was rinsed with sterile PBS and ophthalmic 
ointment was applied (Butler AHS).  All surgeries were performed under aseptic conditions.  
Fourteen days after optic nerve injury, mice were given a lethal dose of anesthesia and perfused 
through the heart with PBS followed by ice-cold 4% paraformaldehyde (with the exception of 
mice used for electrophysiology studies).  For studies that included intraocular injection of 
adeno-associated virus 2 (AAV2), 2µl of AAV2-GFP-scrambled was injected into the left eye, 
while 2µl of AAV2-GFP-PTENshRNA was injected into the right eye, fourteen days prior to 
optic nerve injury.   
 
 Electrophysiology: Age-matched, background-matched mice (uninjured or 3-11 weeks 
post-optic nerve crush) were killed by CO2 inhalation.  Optic nerves from each animal were 
dissected and placed in oxygenated artificial CSF (ACSF).  ACSF contains the following: 
125mM NaCl, 1.25mM NaH2PO4, 25mM glucose, 25mM NaHCO3, 2.5mM CaCl2, 1.3mM 
MgCl2, and 2.5mM KCl (saturated with 95% O2/5% CO2).  Nerves were incubated in 
oxygenated ACSF for 45-60 minutes at room temperature and then transferred to a temperature-
controlled recording chamber held at 37 ± 0.4°C.  The retinal end of the nerve was drawn into 
the tip of a suction pipette electrode, and nerve at a distance of 1.7mm distal to the retinal end 
was drawn into the tip of a second suction pipette electrode.  One electrode was connected to a 
constant-current stimulus isolation unit (WPI) driven by AxonTM pClamp® 10.3 software, and 
the other to one input of a differential alternating current amplifier (custom-made).  The other 
amplifier input was connected to a pipette that was placed near the recording pipette but not in 




recordings.  Signals were filtered at 10 kHz, sampled at 50-100 kHz, and fed into the AxonTM 
Digidata 1440A - AxonTM pClamp® 10.3 data acquisition system.  For analysis, conduction 
velocity was taken as the length of the nerve divided by the time-to-peak.  
 
 Histochemical studies: In situ hybridization of mouse retina with cRNA probes specific 
for NgR1, NgR2, NgR3, and RPTPσ was carried out as described previously (Sapieha et al., 
2005; Venkatesh et al., 2005).  For immunohistochemical procedures, cryosections of adult 
retina were stained with anti-calbindin (Swant; 1:2500 dilution) or anti-calretinin (Swant; 1:2500 
dilution), and then counterstained with Hoechst 33342 (1:30000 dilution).  For retinal whole-
mount immunostaining, eyes were post-fixed in 4% paraformaldehyde overnight at 4°C, and 
retinal “cups” were dissected out and fixed in 4% paraformaldehyde for 30 minutes at 4°C.  
Retinas were washed with PBS, blocked in 10% goat serum and 0.2% Triton X-100 for 1 hour, 
incubated with primary antibodies (anti-GFP, Invitrogen; anti-phospho-S6, Cell Signaling) for 1-
2 days at 4°C, and washed with PBS.  Following incubation with the appropriate Alexa Fluor-
conjugated secondary antibodies (Invitrogen) overnight at 4°C and another round of washing 
with PBS, retinas were mounted onto slides for imaging.  To assess axon density and 
myelination, optic nerves were embedded in epon and stained with Toluidine Blue.  To assess 
retinal ganglion cell death at various time points following optic nerve injury, retinal sections 
were stained with anti-class III β-tubulin (TuJ1), and in some instances, with anti-active caspase-
3 (Promega).  
 For intraocular injections of anterograde tracer, 6-week-old mice received bilateral 
injections (2µl) of 1µg/µl Alexa 488- and Alexa 594-conjugated Cholera Toxin β (Invitrogen) in 




and their brains were dissected, post-fixed in 4% paraformaldehyde overnight, and cryoprotected 
in 30% sucrose overnight.  Brain tissue was embedded in OCT Tissue-Tek Medium (Sakura 
Finetek) and coronal sections (50μm thickness) were imaged.  
 To visualize regenerating axons in the injured optic nerve, eyes with optic nerves 
attached were dissected, post-fixed, and cryoprotected.  Optic nerves were embedded and 
longitudinal sections (14μm thickness) were stained with anti-GAP-43 and/or anti-GFP.  The 
appropriate Alexa Fluor-conjugated secondary antibodies (Invitrogen) were then used for 
fluorescent labeling.  Images were acquired using an inverted microscope (IX71; Olympus) 
attached to a digital camera (DP72; Olympus). 
 For chemical clearing of CNS tissue (Luo et al., 2013), adult mice were perfused 
transcardially, five days post-Cholera Toxin β injection.  The optic nerve and brain tissue were 
dissected and post-fixed in 4% paraformaldehyde overnight.  Samples underwent dehydration by 
incubation in increasing concentrations of tetrahydrofuran (THF; Sigma) solutions under 
constant rocking at room temperature (protected from light).  Optic nerves were incubated in 
50% THF (diluted in water), 80% THF, and 100% THF for 20 minutes each.  Dehydrated optic 
nerves were rendered clear by incubating in a ratio of 1:2 benzyl alcohol: benzyl benzoate 
(Sigma) for 30 minutes.  Brain tissue was incubated in 50% THF for 12 hours, 80% THF for 
12 hours, 100% THF for 2 × 12 hours, and BABB for 12 hours. 
 
 Statistical analysis: For quantification of neurite outgrowth, UTHSCSA ImageTool for 
Windows was used, and processes equal or longer to approximately one cell body diameter were 
measured.  For each condition, at least 150 neurites were quantified, and the mean and SEM of 




quantification of retinal ganglion cell death, the density of TuJ1-positive cells in the ganglion 
cell layer per field of view (at least 10 sections, 3 independent experiments per condition) was 
counted.  For quantification of activated caspase-3-positive retinal ganglion cells, the number of 
cells labeled for activated caspase-3 was calculated as a percentage of the total number of cells 
(TuJ1-positive) per field of view (at least 10 sections, 3 independent experiments per condition).  
Quantification of optic nerve binding assays and in situ hybridization (at least 20 sections, 4 
independent experiments per condition) was performed as previously described (Robak et al., 
2009), using Microsuite Five (Olympus) quantification software.  All data were analyzed using 
one-way analysis of variance followed by Tukey’s post hoc comparisons.  All statistics were 
performed using SigmaStat 3.0 for Windows (Systat Software).  
 To assess regenerative axonal growth, the number of GAP-43-positive axons at 
prespecified distances from the injury site was counted in at least three sections per nerve.  These 
numbers were converted into the number of regenerating axons per nerve at various distances as 
described previously (Fischer et al., 2004a).  All data were analyzed using one-way analysis of 
variance followed by Tukey’s post hoc comparisons.  All statistics were performed using 
GraphPad Prism 5.00 (GraphPad Software).  Our finding that loss of all three NgRs elicits 
significant retinal ganglion cell regeneration is based on two independently generated data sets 
produced by two independent surgeons (K.T.B. and Y. Koriyama).  Both data sets were analyzed 
separately and lead to the same conclusions (Table 2.1).  In addition, no significant differences 
(P> 0.05) in axon regeneration following injury (with or without intraocular Zymosan injection) 
were observed between mice on three different genetic backgrounds (129, C57BL/6, BALB/c) 
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Figure 2.1: Generation of Nogo receptor conditional knockout mice.  (a) Targeting strategy 
for the generation of NgR1, NgR2, and NgR3 conditional knockout mice. The mouse NgR1 and 
NgR3 genes are each comprised of 2 coding exons and the mouse NgR2 gene is comprised of 3 
coding exons. For all three genes, exon 2 was flanked by loxP sites (black triangles). Exons are 
shown in blue. The size of exons in base pairs (bp) and introns in kilobases (kb) is indicated. A 
neo/ura selection marker (orange) flanked by frt sites (green boxes) was inserted in each of the 
three gene loci. (b) NgR3 gene targeting strategy. (Top) Distribution of BamH1 and Xba1 




generation of NgR3 conditional knockout mice. (Bottom) Targeted locus in NgR3 conditional 
mutants. The position of the 5’ and 3’ outside probes used for Southern blot analysis (XbaI) of 
double selected embryonic stem cells is indicated. To generate germline deletion mutants, mice 
carrying conditional alleles were crossed with protamine-cre transgenic mice and then 
intercrossed to generate double and triple mutants. (c) PCR genotyping of DNA isolated from 
tail biopsies of WT and NgR123-/- mice. For all primer sets (NgR1, NgR2, NgR3), the null PCR 
product is larger than the WT PCR product. PCR primers for NgR1 conditional mice include: 5’-
GGTCTAGGGATGCATCTCAG-3’, 5’-ACATCTGAAGGCCTTCTGG-3’, and 5’-
GTGGTCTGTGTGGCTCCTGC-3’ (WT allele - 200bp, conditional allele - 300bp, null allele - 
320bp); PCR primers for NgR2 conditional mice include: 5’-
CAGTCTTGCAGCTGACTGTAGCTGAG-3’, 5’-GACCTGTGGGGAGAGCATAGTGAG-3’, 
and 5’-GTTTAACGGCTAGCCAGCCAACATC-3’ (WT allele - 333bp, conditional allele - 
425bp, null allele - 458bp); and PCR primers for NgR3 conditional mice include: 5’-
AGTGCTCTGAGATTGCTGGTTGC-3’,        5’-GGAAGGGTATCACGTCTCACTCGG-3’, 
and               5’-CAGAAAAGCAGGCTGGGAAGC-3’ (WT allele - 255bp, conditional allele - 
340bp, null allele - 370bp). (d) Western blot analysis of Concanavalin A affinity-purified 
proteins from adult brain lysates of WT and NgR123-/- mice, using polyclonal rabbit anti-NgR1, -
NgR2, and -NgR3 immune sera (normalized to β-actin), shows that triple mutants are null for 






























Figure 2.2: Loss of all three Nogo receptors results in enhanced growth on CNS myelin.  (a) 
P7 CGNs from WT, NgR1-/-, NgR12-/-, and NgR3-/- pups are strongly inhibited when plated on 
crude CNS myelin substrate (40μg/ml). In marked contrast, CGNs from NgR triple mutant 
(NgR123-/-) mice grow longer neurites on CNS myelin. On CNS myelin isolated from 
NogoABC;MAG;OMgp triple null (NMO-/-) mice (40μg/ml), CGNs from WT, NgR1-/-, NgR12-/-, 
and NgR3-/- pups show enhanced neurite outgrowth. A further release of inhibition is observed 
when NgR123-/- neurons are plated on NMO-/- CNS myelin. On a BSA control substrate, neurite 
length of all five genotypes is comparable. (b) Quantification of neurite length. At least 300 
neurites of TuJ1-labeled cells were counted per condition (n=9 independent experiments). Light 
gray bars (BSA); black bars (WT myelin); dark gray bars (NMO myelin). Results are presented 










Figure 2.3: Myelin inhibition of DRG neurons is mediated by Nogo receptor-independent 
mechanisms.  (a) P7 DRG neurons from WT, NgR1-/-, NgR12-/-, NgR3-/-, and NgR123-/- pups are 
strongly and equally inhibited when plated on crude CNS myelin substrate (40μg/ml). On CNS 
myelin isolated from NogoABC;MAG;OMgp triple null (NMO-/-) mice (40μg/ml), DRG neurons 
from all genotypes show enhanced  neurite outgrowth, with no significant difference between 
WT and NgR single or compound mutant neurons. On a BSA control substrate, neurite length of 
all five genotypes is comparable. (b) Quantification of neurite length. At least 300 neurites of 
TuJ1-labeled cells were counted per condition (n=7 independent experiments). Light gray bars 
(BSA); black bars (WT myelin); dark gray bars (NMO myelin). Results are presented as mean 
±SEMs (one-way ANOVA, Tukey’s post hoc), n.s.=not significant. Scale bar, 50μm. 







Figure 2.4: NgR1 and NgR3, but not NgR2, contain two discontinuous and evolutionarily 
conserved sequence motifs necessary for binding to brain tissue.  (a) Coronal sections of E18 
rat brain showing the binding pattern of AP-NgR1 and AP-NgR3. No binding is observed for 
AP-NgR2. (b-c) Binding of (b) NgR1-Fc and (c) NgR3-Fc to E18 brain sections is abolished 
upon deletion of a cluster of basic residues (motif 2) in the stalk region. (d) Schematic of 
receptor deletion constructs and their relative binding to E18 rat brain tissue compared to soluble 
NgR1 [NgR1(ΔGPI)]. Soluble NgR1 (red) and NgR3 (yellow), but not NgR2 (green), bind 
strongly to brain tissue sections. The LRRs of NgR1, previously shown to participate in myelin 
inhibitor binding, are dispensable for binding to neural tissue. Deletion of a cluster of basic 
amino acid residues in the C-terminal region of the NgR1 and NgR3 stalk (motif 2), or 
replacement of these residues with alanines [NgR1(7ala)], completely abolishes binding. (e) 
Sequence alignment of binding motifs 1 and 2 of NgR1 and NgR3. In the LRR-CT domain, 
residues F278 and R279 in NgR1 and residues F273 and R274 in NgR3 (motif 1) are important 
for GAG binding. Motif 2 is comprised of a cluster of basic amino acids, including residues 414-
426 in NgR1 and residues 403-415 in NgR3. The basic residues of motif 1 and motif 2 are 



















                                                                 
 
Figure 2.5: Soluble NgR1 and NgR3, but not NgR2, bind strongly and broadly to neural 
fiber systems.  Binding of soluble NgR1 (AP-NgR1), NgR2 (AP-NgR2), and NgR3 (AP-NgR3) 
to embryonic and neonatal rat brain and spinal cord tissue sections at E18-P1. (a-e) Binding of 
AP-NgR1 to brain tissue sections. a. and b. Coronal brain sections show strong binding of AP-
NgR1 to the corpus callosum, internal capsule, lateral olfactory tract, anterior commissure, and 
fimbria. c. The developing fiber layer in the inner retina and the optic nerve strongly support 
binding of AP-NgR1. d. In the cortical mantle, the marginal zone and axons in the intermediate 
zone are strongly labeled. e. Higher magnification view of the hippocampus. Robust labeling is 
associated with the alveus, fimbria, and the CA1 and CA3 dendritic fields. (f-i) AP-NgR1 and 
AP-NgR3, but not AP-NgR2, bind to E18 rat brain tissue sections. AP is shown as a negative 
control. (j-q) Binding of soluble fusion proteins to E18 spinal cord (j-m) and P1 spinal cord (n-
q) cross sections. AP-NgR1 and AP-NgR3 bind strongly and broadly to spinal fiber tracts at E18 
and P1. In contrast, AP-Sema3A binds weakly to spinal fibers at E18 and preferentially binds to 
the dorsal root entry zone and ventral motor roots at P1. AP-Sema3F binds strongly to the ventral 


















            
Figure 2.6: Proteoglycans participate in binding of soluble NgR1 and NgR3 to brain 
sections.  Binding of soluble AP-NgR1CT+stalk (5nM) or AP-NgR3CT+stalk (5nM) to brain tissue 




(c) p75NTR-/-(exonIII), p75NTR-/-(exonIV), NgR1-/-, GalNAcT-/- (GM2/GD2 synthase), and GD3S-/- (GD3 
synthase) mutants is indistinguishable from WT mice. This suggests that binding of AP-
NgR1CT+stalk and AP-NgR3CT+stalk to brain is mediated by novel, as of yet unidentified binding 
partners. To examine whether binding of AP-NgR1CT+stalk or AP-NgR3CT+stalk to brain is 
mediated by a protein-protein interaction, tissue sections were pretreated with heat or 
preincubated with trypsin. Neither treatment significantly reduced binding. This suggests that 
carbohydrate structures participate in Nogo receptor binding. To examine whether Nogo 
receptors associate with neural glycoconjugates, brain tissue sections were preincubated with 
glycopeptidase-F, N-acetylglucosaminidase, Vibrio cholerae neuraminidase (VCN), 
endoneuraminidase-N (Endo-N), heparinase III, or chondroitinase ABC. Digestion with 
heparinase III or chondroitinase ABC leads to a partial, yet substantial reduction in binding of 
AP-NgR1CT+stalk or AP-NgR3CT+stalk. The most pronounced reduction is observed in the presence 
of heparin (50µg/ml). In marked contrast, glycopeptidase-F, N-acetylglucosaminidase, VCN, or 
Endo-N incubation does not lead to a substantial reduction in fusion protein binding. Together, 
these results suggest that neural glycosaminoglycans (GAGs) participate in soluble NgR1 and 







                              
Figure 2.7: Ligand-dependent association of NgR1 and NgR3.  (a) In transfected COS-7 cells, 
the NgR1 co-receptors p75NTR, TROY, and Lingo-1 show binding to bath-applied, soluble 




immunoprecipitation (IP) experiments in HEK293T cells confirm that p75NTR interacts with 
NgR1 in cis, but not with NgR2 or NgR3. For IP experiments, HEK293T cells were co-
transfected with p75NTR and either NgR1-myc, NgR2-myc, or NgR3-myc. Cell lysates were 
immunoprecipitated with anti-p75NTR, and the immune complex was analyzed by anti-myc 
western blotting. (c) HEK293T cells were transfected with NgR1 and either NgR2-myc or 
NgR3-myc. Prior to lysis and IP with anti-NgR1, cells were incubated for 30 minutes with 
CSPGs. The precipitated immune complex was analyzed by anti-myc western blotting. A CSPG-
dependent association of NgR1 and NgR3, but not NgR1 and NgR2, was observed. (d) The 
ligand-dependent interaction of NgR1and NgR3 is not sensitive to co-expression of p75NTR. 
HEK293T cells were transfected with NgR1, NgR3-myc, and p75NTR; cell lysates were 
immunoprecipitated with anti-NgR1; and the immune complex was analyzed by anti-myc and 
anti-p75NTR western blotting, revealing the presence of p75NTR and NgR3. (e) In CGNs, p75NTR 
is not necessary for inhibition on substrate-bound CSPGs (10μg/ml). P7 CGNs from WT and 
p75NTR-/- pups are strongly and equally inhibited when plated on CSPGs. A partial release of 
inhibition was observed in the presence of the bath-applied ROCK inhibitor Y-27632 (10µM). 
On a BSA control substrate, neurite lengths of WT and p75NTR-/- CGNs are comparable, and 
increased in the presence of Y-27632. (f) Quantification of neurite length. At least 150 neurites 
of TuJ1-labeled cells were counted per condition (n=3 independent experiments). Light gray bars 
(WT); black bars (p75NTR-/-) dark gray bars (WT w/ Y-27632). Results are presented as mean 
±SEMs. ** P< 0.001 (one-way ANOVA, Tukey’s post hoc), n.s.= not significant. Scale bar: a, 
































































Figure 2.8: Molecular basis of the NgR1 and NgR3 interaction with embryonic brain tissue.  
To determine the molecular basis of the NgR1 and NgR3 interactions with rat brain tissue 
sections, AP- and Fc-tagged deletion mutants were generated and assessed for binding to E18 
brain. The binding sites for myelin inhibitors (Nogo66, MAG, and OMgp) have previously been 
mapped to the NgR1 LRR cluster, including amino acid residues 27-310. The LRR cluster is 
comprised of 8.5 LRRs flanked N- and C-terminally by LRR-NT and LRR-CT capping domains. 
The LRR clusters of NgR1 (AP-NgR1NT-LRR-CT) or NgR3 (AP-NgR3NT-LRR-CT) do not support 
binding to embryonic brain tissue sections. However, AP fusion proteins comprised of the LRR-
CT capping domain and the stalk domain of NgR1 (AP-NgR1CT+stalk) or NgR3 (AP-NgR3CT+stalk) 
are sufficient to mediate strong binding to brain tissue sections. The LRR-CT capping domain of 




via a proline- and serine/threonine-rich stalk region of approximately 100 amino acids. Neither 
the LRR-CT domain (AP-NgR1CT) nor the stalk region (AP-NgR1stalk) of NgR1 is sufficient for 
binding to brain. Deletion of the first 15 amino acid residues of the LRR-CT domains of NgR1 
and NgR3, resulting in constructs AP-NgR1Δ15CT+stalk and AP-NgR3Δ15CT+stalk, does not decrease 
binding to brain tissue. However, deletion of F278 and R279 of NgR1 (AP-NgR1Δ17CT+stalk) 
completely abolishes binding. This suggests that residues F278/R279 of NgR1 (motif 1) are 
necessary but not sufficient for binding.  Deletion of sequences from the C-terminal end of the 
stalk (AP-NgR1CT+stalkΔm2) identified a sequence motif, located juxtaposed to the GPI anchor of 
NgR1 [410TSGPRRRPGCSRKNRTRSHC429], that is necessary for binding (motif 2). Most 
notable in this region is a prevalence of basic amino acid residues. A similar cluster of basic 
amino acids is present near the C-terminus of the NgR3 stalk 
[399TARPKRKGKCARRTPIRAPS418] and is necessary for binding of AP-NgR3 to brain tissue 
sections. Of interest, no cluster of basic amino acids is found in the juxtamembrane region of 
NgR2, providing a molecular basis for the lack of binding to brain sections. Taken together, 
mutagenesis studies identified two discontinuous sequence motifs, one located in the LRR-CT 
capping domain (motif 1) and a second one located in the juxtamembrane stalk region (motif 2), 























Figure 2.9: NgR1 and NgR3 interact directly with specific GAGs.  (a) Binding of soluble AP-
NgR1 to P1 rat brain tissue sections is sensitive to heparinase (Hep’ase) and chondroitinase ABC 
(Ch’aseABC) treatment (1unit/ml). (b) Binding of soluble AP-NgR1 and AP-NgR3 to E18 rat 
brain tissue sections in the presence of PBS (vehicle control), 50μg/ml monosulfated CS-GAGs 
(CS-A, CS-B, or CS-C), or 50μg/ml disulfated CS-GAGs (CS-D or CS-E). Only CS-B, CS-D, 
and CS-E compete effectively with brain tissue sections for binding to NgR1 and NgR3. (c) 
ELISA binding studies revealed a direct association of soluble NgR1 and RPTPσ(1-3) with 
specific GAGs (insets show Scatchard plot analysis). The calculated Kds for CS-B, CS-D, CS-E, 
and heparin are 3.2, 1.3, 1.0, and 1.2nM (NgR1) and 1.4, 3.0, 0.1, and 0.1nM [RPTPσ(1-3)], 
respectively. (d) WT P7 mouse CGNs are strongly inhibited when plated on substrate-bound 
CSPGs. Long neurites are seen on a BSA control substrate. In the presence of NgR1-Fc or 
RPTPσ(1-3)-Fc, but not NgR1(7ala)-Fc or IgG1 control, CSPG inhibition is  abolished.  On a 
BSA substrate, soluble receptors do not influence neurite outgrowth. Quantification of neurite 
length is shown as a percentage of the IgG1-BSA control (100%). At least 300 neurites of TuJ1-
labeled cells were counted per condition (n=4 independent experiments). Gray bars (BSA); black 
bars (CSPGs). Results are presented as mean ±SEMs. ** P< 0.001 (one-way ANOVA, Tukey’s 








Figure 2.10: NgR1 and NgR3 show very similar GAG binding preferences.  (a) Schematic of 
the ELISA strategy used to test whether soluble NgRs and RPTPσ bind directly to immobilized 
GAGs. ELISA plates were precoated with streptavidin and incubated with biotinylated GAGs. 
Increasing concentrations of soluble receptor fusion proteins were added to the plates, the plates 
were rinsed, and bound AP activity was quantified. (b) Summary of ELISA data. NgR1 and 
NgR3 bind directly to CS-B, CS-D, CS-E, and heparin, but not to CS-A or CS-C. (c) Soluble 
RPTPσ(1-3) competes effectively with NgR1 for binding to CS-E. The binding of AP-NgR1 to 
CS-E decreases in the presence of increasing doses of RPTPσ(1-3)-Fc. (d) Replacement of both 
GAG-binding motifs of NgR1 with the corresponding sequences of NgR2 (NgR1C27-
K277/NgR2V281-G399-Fc) abolishes binding to P1 rat brain tissue sections. (e) Quantification of 
NgR1-Fc and NgR1C27-K277/NgR2V281-G399-Fc binding to CS-B, CS-E, and heparin by ELISA. 














Figure 2.11: Binding sites for MAIs and CSPGs on NgR1 are distinct and dissociable.  (a) 
In transiently transfected COS-7 cells, wild-type NgR1 and the GAG-binding-deficient mutant 
[NgR1(7ala)] show very similar binding of the MAIs AP-Nogo66, MAG-Fc, and AP-OMgp. The 
NgR1 fragment F278-E445 (AP-NgR1Δ15CT+stalk) is sufficient for high-affinity binding to neural 
GAGs. When residues 278-445 in NgR1 are replaced with the corresponding sequences of 
NgR2, resulting in construct NgR1C27-K277/NgR2V281-L420, binding of MAIs is not diminished 
compared to wild-type NgR1. Ligand binding to GFP-transfected COS-7 cells is shown as a 
negative control. (b) Schematic of NgR1, showing the regions necessary for binding of MAIs 
and GAGs. The GAG-binding motifs m1 and m2 of NgR1 are distinct and dissociable from the 
Nogo-, MAG-, and OMgp-binding sequences. (c) In the presence of bath-applied CS-B, CS-D, 
or CS-E GAGs (1mg/ml), binding of AP-Nogo66 to NgR1-expressing COS-7 cells is not altered. 







Figure 2.12: Nogo receptors mediate CSPG inhibition.  (a) In vitro, WT P7 CGNs are 
strongly inhibited when plated on substrate-bound CSPGs (10μg/ml). Studies with CGNs from 
NgR1-/-, NgR12-/-, and NgR3-/- mutants revealed no substantial release of CSPG inhibition. Loss 
of all three NgRs (NgR123-/-) or RPTPσ alone (RPTPσ-/-) leads to a significant, yet incomplete 
release of CSPG inhibition. On a control substrate (BSA), neurite length of all six genotypes is 
comparable. (b) Quantification of neurite length. Gray bars (BSA); black bars (CSPGs). At least 
300 neurites of TuJ1-labeled cells were counted per condition (n=8 independent experiments). 
Results are presented as mean ±SEMs. ** P< 0.001 (one-way ANOVA, Tukey’s post hoc), n.s.= 







































Figure 2.13: Evidence for Nogo receptor-independent mechanisms for CSPG inhibition.  
(a) CSPG dose-response effect on P7 CGN neurite outgrowth inhibition. When adsorbed to 
culture plates at 1μg/ml, CSPGs do not significantly inhibit neurite outgrowth. At 10μg/ml, 
neurite length is decreased in all genotypes; however, NgR123-/- and RPTPσ-/- neurites are 
significantly longer than WT, NgR1-/-, NgR12-/-, and NgR3-/- neurites. At 100μg/ml CSPG, 
NgR123-/- and RPTPσ-/- CGNs no longer show enhanced neurite growth compared to controls. 
Light gray bars (WT); black bars (NgR1-/-); purple bars (NgR12-/-); dark gray bars (NgR3-/-); blue 
bars (NgR123-/-); orange bars (RPTPσ-/-). At least 300 neurites were counted per condition (n=4 
independent experiments). Results are presented as mean ±SEMs. ** P< 0.001 (one-way 
ANOVA, Tukey’s post hoc), n.s.=not significant. (b) WT, NgR1-/-, and NgR123-/- P7 DRG 
neurons are strongly inhibited when plated on substrate-bound CSPGs (10μg/ml). RPTPσ-/- DRG 
neurons show a significant, yet incomplete release of CSPG inhibition. On a BSA control 
substrate, neurite length of all four genotypes is comparable. Gray bars (BSA); black bars 
(CSPGs). At least 300 neurites of TuJ1-labeled cells were counted per condition (n=4 
independent experiments). Results are presented as mean ±SEMs. ** P< 0.001 (one-way 





Figure 2.14: Binding of soluble NgR1-Fc and NgR3-Fc to optic nerve is enhanced by injury.  
(a) Longitudinal sections of uninjured and injured adult mouse optic nerve (7 days following 
retro-orbital nerve crush) were incubated with NgR1-Fc, NgR3-Fc, NgR1(7ala)-Fc, and 
NgR3Δm2-Fc. Soluble NgR1-Fc and NgR1(7ala)-Fc, but not NgR3-Fc or NgR3Δm2-Fc, bind 
weakly to uninjured optic nerve sections. Following injury, binding of NgR1-Fc and NgR3-Fc is 
strongly increased and depends on the presence of the proteoglycan-binding motif 2, as no 
increase was observed for NgR1(7ala)-Fc and NgR3∆m2-Fc . Treatment of injured optic nerve 
sections with 1unit/ml chondroitinase ABC (Ch’ase) strongly reduces NgR1-Fc and NgR3-Fc 
binding, suggesting that endogenous CSPGs participate in the binding of NgR1 and NgR3. (b) 
Quantification of binding to optic nerve sections. All binding is shown as a fold increase relative 
to AP-Fc. At least 20 sections were counted per condition (n=4 independent experiments). Light 
gray bars (Uninjured); black bars (Injured); dark gray bars (Injured + Ch’ase). Results are 
presented as mean ±SEMs. ** P< 0.001 (one-way ANOVA, Tukey’s post hoc), n.s.= not 

































Figure 2.15: Retinal stratification, optic nerve myelination, and RGC central projections 
appear normal in NgR123-/- mice.  (a) Sections of adult WT and Nogo receptor triple mutant 
(NgR123-/-) mouse retina were subjected to in situ hybridization with digoxigenin-labeled cRNA 
probes specific for NgR1, NgR2, and NgR3 transcripts. All three receptors are strongly 
expressed in the ganglion cell layer (arrow) and the inner nuclear layer, but are absent from the 
outer nuclear layer of the retina. No signal was detected on parallel-processed sections of 
NgR123-/- retina. (b) Hoechst 33342 nuclear staining, as well as anti-calbindin and anti-calretinin 
immunolabeling, of adult WT and NgR123-/- retina did not reveal any noticeable differences in 
retinal organization among the two genotypes. (c) Toluidine Blue labeling of epon-embedded 
adult WT and NgR123-/- optic nerve cross sections reveals a comparable number of axons and 
degree of myelinated fibers. (d-f) The fidelity of RGC central projections in six-week-old WT 
and NgR123-/- mice was assessed by anterograde fiber tracing.  Five days after injection of Alexa 
594-conjugated Cholera Toxin β into the right eye and Alexa 488-conjugated Cholera Toxin β 
into the left eye, mice were sacrificed, perfused, and brain sections analyzed by fluorescence 
microscopy. Right eye (red) and left eye (green) RGC projections to the (d) superior colliculus, 
(e) suprachiasmatic nucleus and (f) lateral geniculate nucleus in NgR123-/- mice are 





               
 
Figure 2.16: NgR123-/- and NgR13/RPTPσ-/- compound mutants show enhanced fiber 
regeneration following crush injury to the optic nerve.  2 weeks following injury, 
regenerating axons in optic nerve sections were visualized by anti-GAP-43 immunolabeling. The 
injury site is marked with an asterisk. (a) WT mice show very limited regenerative axonal 
growth following injury. (b) In NgR123-/- mice, many GAP-43-positive fibers grow beyond the 
lesion site. (c) In NgR13/RPTPσ-/- (NgR13/σ-/-) mice, a further increase of GAP-43-positive fiber 
growth is observed. (g) Quantification of the number of GAP-43-positive axons at 0.2 to 1.2mm 
distal to the lesion site. Light gray bars (WT, n=6); black bars (NgR1-/-, n=7); purple bars 
(RPTPσ-/-, n=5); dark gray bars (NgR123-/-, n=8); blue bars (NgR13/σ-/-, n=4). (d) Intraocular 
injection of Zymosan enhances regenerative axonal growth in WT mice. A further increase is 
observed in (e) NgR123-/- mice, which is further enhanced in (f) NgR13/σ-/-, mice. (h) 
Quantification of the number of GAP-43-positive axons at 0.2 to 1.6mm distal to the lesion site 
in Zymosan-injected mice. Light gray bars (WT + Zymosan, n=6); black bars (NgR1-/- + 
Zymosan, n=6); purple bars (RPTPσ-/- + Zymosan, n=4); dark gray bars (NgR123-/- + Zymosan, 
n=8); blue bars (NgR13/σ-/- + Zymosan, n=3). Results are presented as mean ±SEMs. ** P< 0.05 



















































Figure 2.17: In adult mice, the combined loss of NgR1 and NgR3, but not NgR1 and NgR2, 




crush injury.  (a-i) 2 weeks following optic nerve injury, regenerative axonal growth was 
assessed by anti-GAP-43 immunolabeling of longitudinal optic nerve sections. (a’-i’) To assess 
whether RGCs in a growth-activated state show an additive growth effect when combined with 
genetic ablation of Nogo receptors, a separate group of animals received an intraocular injection 
(i.o.) of Zymosan at the time of optic nerve injury. Anti-GAP-43 immunolabeling of injured 
optic nerve from (a) WT, (b) NgR1-/-, (c) NgR2-/-, (d) NgR3-/-, (e) RPTPσ-/-, and (f) NgR12-/- mice 
fails to identify significant regenerative growth of axons beyond the lesion site (asterisk). (g) 
NgR13-/- and (h) NgR123-/- mice show increased and comparable axonal regeneration, which is 
further enhanced in (i) NgR13/RPTPσ-/- (NgR13/σ-/-) triple mutant mice. Following i.o. Zymosan 
injection, (b’) NgR1-/-, (c’) NgR2-/-, (d’) NgR3-/-, (e’) RPTPσ-/-, and (f’) NgR12-/- mice do not 
show enhanced regeneration compared to (a’) WT mice with i.o. Zymosan. An additive effect of 
i.o. Zymosan with genetic manipulation was observed for (g’) NgR13-/- and (h’) NgR123-/- mice. 
(i’) Loss of NgR1, NgR3 and RPTPσ (NgR13/σ-/-) combined with i.o. Zymosan resulted in a 














































































Figure 2.18: Optic nerve injury-induced retinal ganglion cell death is similar in WT and 
NgR123-/- triple mutants.  (a) To assess cell loss in the RGC layer 14 days after nerve crush 




compared to uninjured retina.  Intraocular injection of Zymosan increased the density of TuJ1-
labeled cells in the RGC layer; however, this effect was independent of the Nogo receptor 
genotype. (b) Quantification of the density of TuJ1+ cells in the RGC layer per field of view as a 
percentage of the uninjured WT control. Cell counts were performed on at least 15 sections per 
condition (n=3 independent experiments). Gray bars (WT); black bars (NgR123-/-). Results are 
presented as mean ±SEMs (one-way ANOVA, Tukey’s post hoc), n.s.=not significant. (c) Time 
course of RGC death following optic nerve injury. Shown is the quantification of the density of 
TuJ1+ cells in the RGC layer per field of view (at 0, 3, 5, 7, 9, 14, and 19 days following injury) 
as a percentage of the uninjured retina. The majority of cell death occurs by 7 days post-optic 
nerve injury. Cell counts were performed on at least 10 sections per condition. Results are 
presented as mean ±SEMs. (d-e) Time course of caspase-3 activation following optic nerve 
injury. The number of RGCs labeled for activated caspase-3 is shown as a percentage of the total 
number of cells (TUJ1-positive) per field of view at each time point (0, 3, 5, 7, 9, 14, and 19 days 
following injury). The peak of activated caspase-3 labeling is seen between 3 and 5 days post-
injury. Cell counts were performed on at least 10 sections per condition. Results are presented as 























































           
Figure 2.19: Intraocular Zymosan injection does not affect the expression of Nogo 
receptors or RPTPσ in the retinal ganglion cell layer.  In situ hybridization on adult WT 
retina with digoxigenin-labeled cRNA probes specific for (a) NgR1, (b) NgR2, (c) NgR3, and            
(d) RPTPσ transcripts. Mice received either no Zymosan or intraocular Zymosan injection on 
day 0, followed by examination at 3 or 7 days post-injection. Zymosan injection does not result 
in any obvious changes in expression of NgRs or RPTPσ in the RGC layer or inner nuclear layer. 
For quantification of receptor expression in the RGC layer, all retinal sections were developed 
for the same amount of time. The expression of each receptor in the RGC layer is shown as a 
percentage of the “No Zymosan” control. At least 20 sections were assessed per condition (n=4 
independent experiments). Light gray bars (No Zymosan); black bars (Zymosan 3d); dark gray 
bars (Zymosan 7d). Results are presented as mean ±SEMs (one-way ANOVA, Tukey’s post 














               
 
Figure 2.20: NgR1 and NgR3, but not NgR2, interact with astrocyte-released CSPGs.  (a) 
P1 cortical astrocytes were cultured and treated with TGFβ1 (1μg/ml) for 7 days, prior to anti-




astrocyte cultures were incubated with AP-Fc, NgR1-Fc, NgR2-Fc, NgR3-Fc, RPTPσ(Ig1-3)-Fc, 
NgR1(7ala)-Fc, or NgR3Δm2-Fc. Soluble NgR1-Fc, NgR3-Fc, and RPTPσ(Ig1-3)-Fc, but not 
NgR1(7ala)-Fc or NgR3Δm2-Fc, bind strongly to reactive astrocytes, suggesting that this 
interaction depends on the presence of the proteoglycan-binding motif 2. Treatment of astrocytes 
with 1unit/ml Ch’aseABC abolishes binding, suggesting that CSPGs participate in the binding of 
NgR1, NgR3, and RPTPσ. (c) ACM from TGFβ1-treated cultures was tumbled with either 
affinity-purified NgR1-Fc, NgR2-Fc, NgR3-Fc, or RPTPσ(Ig1-3)-Fc. Some of the precipitated 
immune complex was then incubated with Ch’aseABC (1unit/ml), before analysis by 
immunoblotting, using anti-chondroitin sulfate “stub”. Following Ch’aseABC treatment of the 
NgR1, NgR3, and RPTPσ(Ig1-3)-Fc (but not NgR2) conditions, several bands are noted in the 
100-250 kilodalton range. No bands are recognized by the “stub” antibody without Ch’aseABC 
treatment. (d) Some Ch’aseABC-treated precipitates were subjected to SDS-PAGE and stained 
with Coomassie Blue to identify protein bands. Coomassie Blue staining revealed distinct bands 
(in the 100-250 kilodalton range; white arrows) present in the NgR1, but not NgR2, conditions. 
(e) In CGNs, NgRs are not necessary for inhibition on substrate-bound aggrecan or neurocan 
(10μg/ml). P7 CGNs from WT and NgR123-/- pups are strongly and equally inhibited when 
plated on either CSPG protein core. On a BSA control substrate, neurite lengths of WT and 
NgR123-/- CGNs are comparable. (f) Quantification of neurite length. At least 200 neurites of 
TuJ1-labeled cells were counted per condition (n=5 independent experiments). Gray bars (BSA); 
black bars (CSPG); blue bars (Aggrecan); red bars (Neurocan). Results are presented as mean 











Figure 2.21: Future strategies for assessment of long-distance axonal regeneration and 
functional recovery.  (a) Representative CAP recording from an adult mouse optic nerve, in 




represent the fast and slow myelinated fibers of the optic nerve. An uninjured, adult nerve has an 
average conduction velocity of 4m/s and average peak amplitude of 5mV. (b) A plot of the 
conduction velocities and peak amplitudes of optic nerves from WT and NgR123-/- animals with 
Zymosan administration, 3-11 weeks post-crush injury. With the exception of a few outliers that 
show marginal improvement, neither condition reveals any substantial functional recovery when 
compared to WT animals with crush injury. It should be noted that there is no correlation 
between the number of weeks passed before recording and the conduction velocity/peak 
amplitude. Blue triangles (WT + Zymosan, n=8 nerves); red squares (NgR123-/- + Zymosan, 
n=12 nerves). (c) Intraocular injection of AAV2-GFP-PTENshRNA results in efficient 
transduction of RGCs and their projections, as visualized by anti-GFP immunolabeling of the 
retina (top) and optic nerve (bottom). (d) pS6 levels are greatly increased in RGCs upon 
transduction with AAV2-GFP-PTENshRNA compared to the AAV2-GFP-scrambled control, as 
determined by anti-pS6 immunolabeling of the retina (top). Additionally, intraocular injection of 
AAV2-GFP-PTENshRNA results in substantial RGC fiber growth distal to the injury site in the 
optic nerve, 2 weeks following crush injury (bottom). The injury site is marked with an asterisk. 
(e) Representative images of the brain (top) and optic nerve (bottom), following THF-based 
chemical clearing. Uncleared tissues are also shown for comparison. (f) Five days after injection 
of Alexa 488-conjugated Cholera Toxin β into the left eye and Alexa 594-conjugated Cholera 
Toxin β into the right eye, mice were sacrificed, perfused, and optic nerves were chemically 
cleared. Strong levels of fluorescence are seen in both cleared optic nerves, without the need for 
























































Figure 2.22: The genetic background of wild-type mice does not significantly influence 
RGC axon regeneration.  (a) Quantification of the number of GAP-43-positive axons at 0.2 to 
0.6mm distal to the lesion site in 129 (light gray bars, n=6), C57BL/6 (black bars, n= 6), and 
BALB/c (dark gray bars, n= 4) wild-type mice 2 weeks following optic nerve injury revealed no 
significant differences. (b) Quantification of the number of GAP-43-positive axons at 0.2 to 
1.6mm distal to the lesion site following intraocular Zymosan injection in 129 (light gray bars, 
n=6), C57BL/6 (black bars, n=7), and BALB/c (dark gray bars, n=3) wild-type mice, 2 weeks 
following optic nerve injury. No significant differences at any distance were observed. Results 




























































Table 2.1: Summary of optic nerve regeneration studies.  (a) 2 weeks following injury, 
regeneration in NgR123-/-, NgR13-/-, and NgR13/RPTPσ-/- compound mutant mice is significantly 
increased compared to WT mice at 0.2 and 0.4mm distal to the injury site. Compared to WT 
mice, regeneration in NgR1-/-, NgR2-/-, NgR3-/-, NgR12-/-, or RPTPσ-/- at 0.2 and 0.4mm is not 
significantly enhanced. *** P< 0.001 (one-way ANOVA, Tukey’s post hoc), n.s.= not 
significant. (b) Following intraorbital Zymosan injection, regeneration in NgR123-/-, NgR13-/-, 
and NgR13/RPTPσ-/- compound mutant mice is significantly enhanced compared to WT mice at 
0.2 and 0.8mm distal to the injury site. There is no significant difference in axon regeneration 
between WT mice and NgR1-/-, NgR2-/-, NgR3-/-, NgR12-/-, or RPTPσ-/- mutant mice. *** P< 
0.001, ** P< 0.01 (one-way ANOVA, Tukey’s post hoc), n.s.= not significant. (c) 2 weeks 
following injury, regeneration in NgR123-/- mice is significantly increased compared to WT, 
NgR1-/-, NgR2-/-, NgR3-/-, NgR12-/-, and RPTPσ-/- mice, and decreased compared to 
NgR13/RPTPσ-/- mice, at 0.2 and 0.4mm distal to the injury site. There is no significant 
difference in the regeneration phenotype of NgR123-/- and NgR13-/- compound mutants. *** P< 
0.001, ** P< 0.01 (one-way ANOVA, Tukey’s post hoc), n.s.= not significant. (d) Following 
intraocular Zymosan injection, axon regeneration in NgR123-/- mice is significantly increased 
compared to WT, NgR1-/-, NgR2-/-, NgR3-/-, NgR12-/-, and RPTPσ-/- mice at 0.2 and 0.8mm distal 
to the injury site. There is no significant difference in axon regeneration between NgR123-/- and 
NgR13-/- or NgR13/RPTPσ-/- mutant mice (with intraocular Zymosan injection) at these distances. 
At distances 0.4, 0.6, 1.0, 1.2, and 1.4mm beyond the injury site, axon regeneration in 
NgR13/RPTPσ-/- mice is significantly greater than in NgR123-/- mice (with intraocular Zymosan 
injection). *** P< 0.001, ** P< 0.01, * P< 0.05 (one-way ANOVA, Tukey’s post hoc), n.s.= not 
significant. (e) For an unbiased assessment of the optic nerve regeneration phenotype in Nogo 
receptor single and compound mutants, two independent data sets were generated by two 
independent surgeons: K. Baldwin (University of Michigan) and Y. Koriyama (visiting scientist 
from Kanazawa University). Both surgeons were originally trained in the laboratory of L. 
Benowitz. A total of 84 mice (K.B. - 51 mice, Y.K. - 33 mice) were operated on, and each 
surgeon performed crush injury on the following genotypes: WT, NgR1-/-, and NgR123-/- mice. 
Only optic nerves from mice that showed no bleeding, infection, degeneration, or other 
complications of the operated eye were included for quantification of regenerating axons. The 
two data sets were then compared and analyzed for any significant differences between them, 
comparing the total number of GAP-43-positive axons for each genotype at two prespecified 
distances (0.4mm, 1.0mm) beyond the lesion site (unpaired t test). While there is some variation 
in the number of regenerating fibers, the principal findings of the two independently generated 
data sets are very comparable: WT mice (129 background or C57BL/6 background) show 
minimal regeneration of GAP-43-positive retinal ganglion cell axons. Regeneration in NgR1-/- 
mice is not enhanced compared to WT mice. Both data sets show a modest but significant 
increase in regenerating axons in NgR123-/- mice (P< 0.001, K.B; P< 0.05, Y.K.). WT mice that 
received Zymosan show greatly enhanced axon regeneration compared to WT mice that did not 
receive Zymosan. Notably, regeneration in Zymosan-treated WT mice is significantly enhanced 
compared to NgR123-/- mice without Zymosan (P< 0.001 for both data sets). Importantly, both 
data sets show significantly enhanced fiber growth at 0.2-1.4mm beyond the injury site in 
NgR123-/- mice with Zymosan compared to WT mice with Zymosan (P< 0.05 at 1.0, 1.2, and 
1.4mm; P< 0.01 at 0.8mm; P< 0.001 at 0.2, 0.4, and 0.6mm - K.B.; P< 0.05 at 0.4 and 0.6mm; 
























Table 2.2: Summary of identified proteins from LC-MS/MS.  LC-MS/MS analysis from 
NgR1-Fc/ACM/Ch’aseABC and NgR2-Fc/ACM/Ch’aseABC samples. All mouse proteins 
identified by LC-MS/MS were found in both groups (and at comparable levels). Additionally, 
NgR (rat), Fc (human), and Ch’aseABC (bacteria) components were identified by LC-MS/MS 
























Table 2.3: Summary of optic nerve conduction recordings.  Peak amplitudes (μV) and 
conduction velocities (m/s) of optic nerves from WT and NgR123-/- adult mice with Zymosan 
administration, 3-11 weeks post-crush injury. For reference purposes, uninjured optic nerves 
have an average peak amplitude of 5mV and average conduction velocity of 4m/s. Injured optic 
nerves have an average peak amplitude of 15μV and average conduction velocity of 0.5m/s. 
Neither experimental condition reveals any substantial functional recovery when compared to 
WT animals with crush injury. It should be noted that there is no correlation between the number 





Aricescu AR, McKinnell IW, Halfter W, Stoker AW (2002) Heparan sulfate proteoglycans are 
ligands for receptor protein tyrosine phosphatase sigma. Mol Cell Biol 22:1881-1892. 
Atwal JK, Pinkston-Gosse J, Syken J, Stawicki S, Wu Y, Shatz C, Tessier-Lavigne M (2008) 
PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science 
322:967-970. 
Barton WA, Liu BP, Tzvetkova D, Jeffrey PD, Fournier AE, Sah D, Cate R, Strittmatter SM, 
Nikolov DB (2003) Structure and axon outgrowth inhibitor binding of the Nogo-66 
receptor and related proteins. EMBO J 22:3291-3302. 
Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB 
(2002) Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 
416:636-640. 
Bregman BS, Kunkel-Bagden E, Schnell L, Dai HN, Gao D, Schwab ME (1995) Recovery from 
spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 378:498-
501. 
Briani C, Berger JS, Latov N (1998) Antibodies to chondroitin sulfate C: a new detection assay 
and correlations with neurological diseases. J Neuroimmunol 84:117-121. 
Cafferty WB, Duffy P, Huebner E, Strittmatter SM (2010) MAG and OMgp synergize with 
Nogo-A to restrict axonal growth and neurological recovery after spinal cord trauma. J 
Neurosci 30:6825-6837. 
Chivatakarn O, Kaneko S, He Z, Tessier-Lavigne M, Giger RJ (2007) The Nogo-66 receptor 
NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-
inhibitory actions of myelin inhibitors. J Neurosci 27:7117-7124. 
Coles CH, Shen Y, Tenney AP, Siebold C, Sutton GC, Lu W, Gallagher JT, Jones EY, Flanagan 
 JG, Aricescu AR (2011) Proteoglycan-specific molecular switch for RPTPσ clustering 
 and neuronal extension. Science 332:484-488.         
de Lima S, Koriyama Y, Kurimoto T, Oliveira JT, Yin Y, Li Y, Gilbert HY, Fagiolini M, 
 Martinez AM, Benowitz L (2012). Full-length axon regeneration in the adult mouse optic 
 nerve and partial recovery of simple visual behaviors. Proc Natl Acad Sci U S A 
 109:9149-9154. 
Erturk A, Mauch CP, Hellal F, Forstner F, Keck T, Becker K, Jahrling N, Steffens H, Richter M, 
 Hubener M, Kramer E, Kirchhoff F, Dodt HU, Bradke F (2011) Three-dimensional 
 imaging of the unsectioned adult spinal cord to assess axon regeneration and glial 
 responses after injury. Nat Med 18:166-171.  
Fischer D, He Z, Benowitz LI (2004a) Counteracting the Nogo receptor enhances optic nerve 
 regeneration if retinal ganglion cells are in an active growth state. J Neurosci 24:1646-
 1651.                        
Fischer D, Petkova V, Thanos S, Benowitz LI (2004b) Switching mature retinal ganglion cells to 
 a robust growth state in vivo: gene expression and synergy with RhoA inactivation. J 
 Neurosci 24:8726-8740. 
Fisher D, Xing B, Dill J, Li H, Hoang HH, Zhao Z, Yang XL, Bachoo R, Cannon  S, Longo FM, 
 Sheng M, Silver J, Li S (2011) Leukocyte common antigen-related phosphatase is a 
 functional receptor for chondroitin sulfate proteoglycan axon growth inhibitors. J 




Fournier AE, GrandPre T, Strittmatter SM (2001) Identification of a receptor mediating Nogo-66 
 inhibition of axonal regeneration. Nature 409:341-346. 
Fry EJ, Chagnon MJ, Lopez-Vales R, Tremblay ML, David S (2009) Corticospinal tract 
regeneration after spinal cord injury in receptor protein tyrosine phosphatase sigma 
deficient mice. Glia 58:423-433. 
Fujita Y, Endo S, Takai T, Yamashita T (2011) Myelin suppresses axon regeneration by PIR-
B/SHP-mediated inhibition of Trk activity. EMBO J 30:1389-1401. 
Garcia-Alias G, Barkhuysen S, Buckle M, Fawcett JW (2009) Chondroitinase ABC treatment 
 opens a window of opportunity for task-specific rehabilitation. Nat Neurosci 12:1145-
 1151. 
Harvey DJ (2005) Proteomic analysis of glycosylation: structural determination of N- and O-
 linked glycans by mass spectrometry. Expert Rev Proteomics 2:87-101. 
Houle JD, Tom VJ, Mayes D, Wagoner G, Phillips N, Silver J (2006) Combining an autologous 
peripheral nervous system "bridge" and matrix modification by chondroitinase allows 
robust, functional regeneration beyond a hemisection lesion of the adult rat spinal cord. J 
Neurosci 26:7405-7415. 
Jones LL, Margolis RU, Tuszynski MH (2003) The chondroitin sulfate proteoglycans neurocan, 
brevican, phosphacan, and versican are differentially regulated following spinal cord 
injury. Exp Neurol 182:399-411. 
Kadoya K, Tsukada S, Lu P, Coppola G, Geschwind D, Filbin MT, Blesch A, Tuszynski MH 
(2009) Combined intrinsic and extrinsic neuronal mechanisms facilitate bridging axonal 
regeneration one year after spinal cord injury. Neuron 64:165-172. 
Kantor DB, Chivatakarn O, Peer KL, Oster SF, Inatani M, Hansen MJ, Flanagan JG, Yamaguchi 
Y, Sretavan DW, Giger RJ, Kolodkin AL (2004) Semaphorin 5A is a bifunctional axon 
guidance cue regulated by heparan and chondroitin sulfate proteoglycans. Neuron 
44:961-975. 
Karlen A, Karlsson TE, Mattsson A, Lundstromer K, Codeluppi S, Pham TM, Backman CM, 
Ogren SO, Aberg E, Hoffman AF, Sherling MA, Lupica CR, Hoffer BJ, Spenger C, 
Josephson A, Brene S, Olson L (2009) Nogo receptor 1 regulates formation of lasting 
memories. Proc Natl Acad Sci U S A 106:20476-20481. 
Kim JE, Liu BP, Park JH, Strittmatter SM (2004) Nogo-66 receptor prevents raphespinal and 
rubrospinal axon regeneration and limits functional recovery from spinal cord injury. 
Neuron 44:439-451. 
Lee H, Raiker SJ, Venkatesh K, Geary R, Robak LA, Zhang Y, Yeh HH, Shrager  P, Giger RJ 
 (2008) Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine 
 morphology and activity-dependent synaptic strength. J Neurosci 28:2753-2765.                                                               
Lee JK, Geoffroy CG, Chan AF, Tolentino KE, Crawford MJ, Leal MA, Kang B,  Zheng B 
(2010) Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-
deficient mice. Neuron 66:663-670.      
Leibinger M, Muller A, Andreadaki A, Hauk TG, Kirsch M, Fischer D (2009) Neuroprotective 
 and axon growth-promoting effects following inflammatory stimulation on mature retinal 
 ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory 
 factor. J Neurosci 29:14334-14341. 
Li S, Liu BP, Budel S, Li M, Ji B, Walus L, Li W, Jirik A, Rabacchi S, Choi E, Worley D, Sah 
DW, Pepinsky B, Lee D, Relton J, Strittmatter SM (2004) Blockade of Nogo-66, myelin-




receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci 
24:10511-10520. 
Liu BP, Cafferty WB, Budel SO, Strittmatter SM (2006) Extracellular regulators of axonal 
growth in the adult central nervous system. Philos Trans R Soc Lond B Biol Sci 
361:1593-1610. 
Liu K, Lu Y, Lee JK, Samara R, Willenberg R, Sears-Kraxberger I, Tedeschi A, Park KK, Jin D, 
Cai B, Xu B, Connolly L, Steward O, Zheng B, He Z (2010) PTEN deletion enhances the 
regenerative ability of adult corticospinal neurons. Nat Neurosci. 13:1075-1081. 
Luo X, Salgueiro Y, Beckerman SR, Lemmon VP, Tsoulfas P, Park KK (2013) Three-
 dimensional evaluation of retinal ganglion cell axon regeneration and pathfinding in 
 whole mouse tissue after injury. Exp Neurol S0014-4886:00084-00088. 
Massey JM, Hubscher CH, Wagoner MR, Decker JA, Amps J, Silver J, Onifer SM (2006) 
Chondroitinase ABC digestion of the perineuronal net promotes functional collateral 
sprouting in the cuneate nucleus after cervical spinal cord injury. J Neurosci 26:4406-
4414. 
McGee AW, Yang Y, Fischer QS, Daw NW, Strittmatter SM (2005) Experience-driven plasticity 
of visual cortex limited by myelin and Nogo receptor. Science 309:2222-2226. 
McKeon RJ, Hoke A, Silver J (1995) Injury-induced proteoglycans inhibit the potential for 
laminin-mediated axon growth on astrocytic scars. Exp Neurol 136:32-43. 
Niederost BP, Zimmermann DR., Schwab ME, Bandtlow CE (1999) Bovine CNS myelin 
contains neurite growth-inhibitory activity associated with chondroitin sulfate 
proteoglycans. J Neurosci 19:8979-8989. 
Ohlsson M, Mattsson P, Svensson M (2004) A temporal study of axonal degeneration and glial 
scar formation following a standardized crush injury of the optic nerve in the adult rat. 
Restor Neurol Neurosci 22:1-10. 
Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B, Xu B, Connolly L, Kramvis I, Sahin M, He Z 
(2008) Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR 
pathway. Science 322:963-966. 
Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia 50:427-434. 
Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L (2002) Reactivation of 
ocular dominance plasticity in the adult visual cortex. Science 298:1248-1251. 
Powell EM, Mercado ML, Calle-Patino Y, Geller HM (2001) Protein kinase C mediates neurite 
guidance at an astrocyte boundary. Glia 33:288-297. 
Raiker SJ, Lee H, Baldwin KT, Duan Y, Shrager P, Giger RJ (2010) Oligodendrocyte-myelin 
glycoprotein and Nogo negatively regulate activity-dependent synaptic plasticity. J 
Neurosci 30:12432-12445. 
Rhodes KE, Fawcett JW (2004) Chondroitin sulphate proteoglycans: preventing plasticity or 
protecting the CNS? J Anat 204:33-48. 
Robak LA, Venkatesh K, Lee H, Raiker SJ, Duan Y, Lee-Osbourne J, Hofer T, Mage RG, Rader 
C, Giger RJ (2009) Molecular basis of the interactions of the Nogo-66 receptor and its 
homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a 
novel antagonist of CNS myelin inhibition. J Neurosci 29:5768-5783. 
Sapieha PS, Duplan L, Uetani N, Joly S, Tremblay ML, Kennedy TE, Di Polo A (2005) Receptor 
protein tyrosine phosphatase sigma inhibits axon regrowth in the adult injured CNS. Mol 




Satoh J, Yamamura T, Arima K (2004) The 14-3-3 protein epsilon isoform expressed in reactive 
 astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial 
 fibrillary acidic protein in cultured human astrocytes. Am J Pathol 165:577-592. 
Schiffer D, Giordana MT, Migheli A, Giaccone G, Pezzotta S, Mauro A (1986) Glial fibrillary 
 acidic protein and vimentin in the experimental glial reaction of the rat brain. Brain Res 
 374:110-118. 
Schweigreiter R, Walmsley AR, Niederost B, Zimmermann DR, Oertle T, Casademunt E, 
Frentzel S, Dechant G, Mir A, Bandtlow CE (2004) Versican V2 and the central 
inhibitory domain of Nogo-A inhibit neurite growth via p75NTR/NgR-independent 
pathways that converge at RhoA. Mol Cell Neurosci 27:163-174. 
Shen Y, Tenney AP, Busch SA, Horn KP, Cuascut FX, Liu K, He Z, Silver J, Flanagan JG 
(2009) PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural 
regeneration. Science 326:592-596. 
Shypitsyna A, Malaga-Trillo E, Reuter A, Stuermer CA (2010) Origin of Nogo-A by domain 
shuffling in an early jawed vertebrate. Mol Biol Evol 28:1363-1370. 
Silver J, Miller JH (2004) Regeneration beyond the glial scar. Nat Rev Neurosci 5:146-156. 
Sivasankaran R, Pei J, Wang KC, Zhang YP, Shields CB, Xu XM, He Z (2004) PKC mediates 
inhibitory effects of myelin and chondroitin sulfate proteoglycans on axonal regeneration. 
Nat Neurosci 7:261-268. 
Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar formation. 
 Trends Neurosci 32:638-647. 
Venkatesh K, Chivatakarn O, Lee H, Joshi PS, Kantor DB, Newman BA, Mage R, Rader C, 
Giger RJ (2005) The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor 
selective for myelin-associated glycoprotein. J Neurosci 25:808-822. 
Wang H, Katagiri Y, McCann TE, Unsworth E, Goldsmith P, Yu ZX, Tan F, Santiago L, Mills 
 EM, Wang Y, Symes AJ, Geller HM (2008) Chondroitin-4-sulfation negatively regulates 
 axonal guidance and growth. J Cell Sci 121:3083-3091. 
Williams G, Wood A, Williams EJ, Gao Y, Mercado ML, Katz A, Joseph-McCarthy D, Bates B, 
Ling HP, Aulabaugh A, Zaccardi J, Xie Y, Pangalos MN, Walsh FS, Doherty P (2008) 
Ganglioside inhibition of neurite outgrowth requires Nogo receptor function: 
identification of interaction sites and development of novel antagonists. J Biol Chem 
283:16641-16652. 
Winzeler AM, Mandemakers WJ, Sun MZ, Stafford M, Phillips CT, Barres BA (2011) The lipid 
sulfatide is a novel myelin-associated inhibitor of CNS axon outgrowth. J Neurosci 
31:6481-6492. 
Yamashita T, Fujitani M, Yamagishi S, Hata K, Mimura F (2005). Multiple signals regulate axon 
regeneration through the Nogo receptor complex. Mol Neurobiol 32:105-111. 
Yin Y, Cui Q, Gilbert HY, Yang Y, Yang Z, Berlinicke C, Li Z, Zaverucha-do-Valle C, He H, 
 Petkova V, Zack DJ, Benowitz LI (2009) Oncomodulin links inflammation to optic nerve 
 regeneration. Proc Natl Acad Sci U S A 106:19587-19592. 
Yu P, Wang H, Katagiri Y, Geller HM (2012) An in vitro model of reactive astrogliosis and its 
 effect on neuronal growth. Methods Mol Biol 814:327-340.          
Zagrebelsky M, Schweigreiter R, Bandtlow CE, Schwab ME, Korte M (2010) Nogo-A stabilizes 
 the architecture of hippocampal neurons. J Neurosci 30:13220-13234.                
Zhang L, Kuang X, Zhang J (2011) Nogo receptor 3, a paralog of Nogo-66 receptor 1 (NgR1), 




Zheng B, Atwal J, Ho C, Case L, He XL, Garcia KC, Steward O, Tessier-Lavigne M (2005) 
 Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or 

































 In the injured adult mammalian central nervous system (CNS), neuronal regeneration is 
inhibited by myelin-associated inhibitory proteins (MAIs), including myelin-associated 
glycoprotein (MAG), Nogo, and oligodendrocyte myelin glycoprotein (OMgp).  Binding of 
MAIs to neuronal cell surface receptors leads to activation of RhoA, growth cone collapse, and 
neurite outgrowth inhibition.  Herein, we identify the low-density lipoprotein receptor-related 
protein 1 (LRP1) as a high-affinity, endocytic receptor for MAG.  Unlike previously identified 
MAG receptors, MAG binds to LRP1 directly and independently of terminal sialic acids.  In 
primary neurons, functional inactivation of LRP1 is sufficient to significantly reverse both 
MAG- and myelin-mediated inhibition of neurite outgrowth.  Mechanistic studies show that 
LRP1 and p75NTR associate in a MAG-dependent manner and that MAG-mediated activation of 
RhoA involves both of these receptors.  Furthermore, purified LRP1 and derivatives that retain 
ligand-binding activity counteract the effects of MAG and myelin.  Collectively, our studies 






 Neuronal regeneration in the injured adult mammalian CNS is limited.  The inhibitory 
nature of adult CNS myelin and glial scar tissue contribute to the regenerative failure of severed 
axons (Busch and Silver, 2007; Fawcett, 2009; Schwab et al., 1993).  Several MAIs have been 
identified, including MAG, Nogo, and OMgp (Filbin, 2003; Schwab, 2010; Yiu and He, 2006).  
Nogo-A, the largest splice form of the Nogo/reticulon 4 gene, is comprised of at least two 
distinct growth-inhibitory regions: amino-Nogo and Nogo66 (Schwab, 2010).  MAG is a sialic 
acid-recognizing, Ig-family lectin (Tang et al., 1997; Vinson et al., 2001; Vyas et al., 2002).  
Deletion of the lectin activity in MAG disrupts binding to gangliosides and to the Nogo receptor 
family members NgR1 and NgR2, yet does not abolish growth inhibition (Cao et al., 2007; 
Robak et al., 2009). 
NgR1 is the ligand-binding portion of a tripartite receptor complex that includes Lingo-1 
and p75NTR or TROY (Yiu and He, 2006).  This receptor complex participates in growth cone 
collapse in response to MAG, Nogo66 and OMgp (Kim et al., 2004).  Similar to NgR1, paired 
Ig-like receptor B (PirB) binds to Nogo66, MAG and OMgp.  Loss of PirB, but not NgR1, leads 
to a significant, yet incomplete release of neurite outgrowth inhibition in response to substrate-
bound inhibitors (Atwal et al., 2008; Chivatakarn et al., 2007; Zheng et al., 2005).  Myelin 
inhibition can be released by pretreatment of neurons with BDNF or by blocking activation of 
RhoA (Cai et al., 1999; Schmandke and Strittmatter, 2007).  In the presence of Nogo and MAG, 
association of p75NTR with the Rho-GDP dissociation inhibitor (Rho-GDI) is enhanced and this 
leads to the release and subsequent activation of RhoA (Yamashita and Tohyama, 2003).  Loss 
of p75NTR in sensory neurons, but not in cerebellar neurons, attenuates MAG and myelin 
inhibition in vitro, suggesting the existence of neuronal cell type-specific signaling mechanisms 




LRP1 is a type 1 transmembrane receptor that binds over forty structurally and 
functionally distinct ligands, mediating their endocytosis and delivery to lysosomes (Strickland 
et al., 2002).  LRP1 also functions in phagocytosis of large particles, including degenerated 
myelin (Gaultier et al., 2009; Lillis et al., 2008).  Neurons in both the CNS and PNS express 
LRP1 (Bu et al., 1994; Campana et al., 2006; Wolf et al., 1992), which is partially localized to 
neuronal growth cones, both in intracellular vesicles and at the cell surface (Steuble et al., 2010). 
LRP1 regulates cell signaling in conjunction with co-receptors or by regulating the 
plasma membrane abundance of other receptors, including uPAR, TNFR1, PDGFR, Trk 
receptors, and Frizzled-1 (Boucher et al., 2003; Gaultier et al., 2008; Shi et al., 2009; Webb et 
al., 2001; Zilberberg et al., 2004).  Given the diversity of LRP1 co-receptors, it is reasonable to 
hypothesize that the activity of LRP1 in cell signaling may be ligand- and cell type-specific.  In 
neurons and neuron-like cell lines, binding of tissue-type plasminogen activator (tPA) or α2-
macroglobulin (α2M) to LRP1 activates ERK and AKT to promote neurite outgrowth 
(Fuentealba et al., 2009; Hayashi et al., 2007; Mantuano et al., 2008; Qiu et al., 2004; Shi et al., 
2009).  This response requires Trk receptor transactivation downstream of phosphorylated c-Src 
(Shi et al., 2009). 
Previous work demonstrating myelin phagocytosis by LRP1 (Gaultier et al., 2009) 
prompted us to examine the role of LRP1 in the mechanism by which MAIs inhibit axonal 
regeneration.  In this study, we demonstrate that LRP1 is a high-affinity, endocytic MAG 
receptor, which is important for RhoA activation and inhibition of neurite outgrowth by MAG.   
 
3.3 Results 




 Full-length LRP1 is a 600-kDa, two-chain transmembrane receptor (Franchini and 
Montagnana, 2011).  Two of the four clusters of complement-like repeats (CII and CIV) in the 
extracellular α-chain of LRP1 are responsible for most of the ligand-binding activity of this 
receptor (Willnow et al., 1994).  To screen for proteins in CNS myelin that bind to LRP1, we 
expressed CII and CIV as separate Fc fusion proteins (Figure 3.1a).  CNS myelin vesicles were 
purified from rat brain as previously described (Gaultier et al., 2009), solubilized in Triton X-
100, and incubated with CII-Fc or CIV-Fc.  Fc fusion proteins were precipitated with Protein A-
Sepharose and associated proteins were identified by LC-MS/MS (Gaultier et al., 2010).  MAG 
was identified as a candidate binding partner for CII-Fc and CIV-Fc, but not Fc alone (data not 
shown).   
 As a first approach to test whether MAG binds to full-length LRP1, the ectodomain of 
MAG was expressed as an Fc fusion protein (MAG-Fc) and incubated with extracts of mouse 
N2a neuroblastoma cells, which is a rich source of LRP1 (Figure 3.1b).  LRP1 was readily 
detected in MAG-Fc affinity-precipitates using a polyclonal antibody that detects the 85-kDa 
LRP1 β chain.  LRP1 did not co-precipitate with purified Fc, demonstrating specificity in the 
MAG-LRP1 interaction.  Next, we prepared extracts of rat brain and tested whether endogenous 
MAG associates with LRP1.  LRP1 co-immunoprecipitated (co-IPed) with MAG from brain 
extracts and MAG co-IPed with LRP1 (Figure 3.1c).  To test whether MAG binds to LRP1 in a 
purified system, full-length LRP1 was purified from rat liver as previously described (Gorovoy 
et al., 2010) and incubated with MAG-Fc or Fc.  LRP1 was detected in affinity precipitates with 
MAG-Fc but not Fc alone, providing evidence for a direct association of MAG with full-length 




Receptor-associated protein (RAP) is an LRP1 chaperone that binds to LRP1 and inhibits 
binding of other known LRP1 ligands (Strickland et al., 2002).  To test whether RAP inhibits 
binding of MAG to LRP1, MAG-Fc was incubated with extracts from the N20.1 cell line, which 
is an abundant source of LRP1, in the presence of either GST or GST-RAP.   MAG-Fc bound to 
LRP1 in N20.1 cell extracts and GST-RAP greatly reduced this interaction (Figure 3.1e).  
Additionally, MAG from CNS myelin affinity precipitated with CII-Fc and CIV-Fc, but not with 
Fc alone (Figure 3.1f), and MAG-Fc bound to immobilized CII-Fc and CIV-Fc in a purified 
system (Figure 3.1g).  These results validate our LC-MS/MS results, demonstrating that Fc 
fusion proteins, which contain ligand-binding sequences from LRP1, bind MAG. 
 
MAG shows high-affinity, sialic acid-independent binding to CII and CIV 
 In order to assess binding affinities for the MAG-LRP1 interaction, we utilized an 
established model system in which full-length MAG is expressed in COS-7 cells, as previously 
described (Dickendesher et al., 2012).  CII-Fc and CIV-Fc bound to cell-surface MAG and the 
level of binding was similar to that observed with NgROMNI-Fc (Figure 3.1h).  In NgROMNI-Fc, 
Fc is fused to a chimeric form of NgR1 and NgR2 that binds MAG with higher affinity than 
wild-type NgR1 (Robak et al., 2009).  Purified Fc did not bind to MAG-expressing COS-7 cells, 
indicating that binding of CII-Fc and CIV-Fc is specific.  As a control, we examined binding of 
CII-Fc and CIV-Fc to COS-7 cells that were transfected to express PirB, which, similar to MAG, 
is a member of the Ig superfamily.  As expected, neither CII-Fc nor CIV-Fc bound to PirB-
expressing cells (Figure 3.2a).  Importantly, GST-RAP almost completely inhibited binding of 





 To calculate binding affinities, MAG-expressing COS-7 cells were incubated with 
increasing concentrations of CII-Fc, CIV-Fc, and NgROMNI-Fc.  In initial studies, the fusion 
proteins were precoupled to alkaline phosphatase (AP)-conjugated anti-Fc antibody, allowing 
direct analysis of binding.  The results were most accurately fit by non-linear regression to 
sigmoidal curves, suggesting possible complexity in the binding interactions, beyond a simple 
single-site model (Figure 3.3a).  To estimate binding constants, we determined the concentration 
of ligand that yielded half-maximal saturation (Kd).  The Kds are as follows: NgROMNI-Fc - 5.7 ± 
0.1nM, CII-Fc - 8.1 ± 0.2nM, and CIV-Fc - 7.4 ± 0.2nM.  The equivalent data were also fit to 
rectangular hyperbolae, assuming a simple, single-site model.  The Kd values were largely 
unchanged, ranging from 5-15nM for all three fusion proteins.  Monomeric fusion protein 
binding (no precoupling) was also most accurately fit to sigmoidal curves, with Kds of 9.6 ± 
0.3nM for CII-Fc and 17 ± 3nM for CIV-Fc (Figure 3.2b-c). 
MAG is an Ig-family lectin, which binds to gangliosides and Nogo receptors in a sialic 
acid-dependent manner (Robak et al., 2009; Vyas et al., 2002).  To test whether the interaction of 
MAG with LRP1 is sialic acid-dependent, CII-Fc, CIV-Fc, and NgROMNI-Fc were pretreated with 
V. cholera neuraminidase (VCN), which removes terminal sialic acids on the cell surface (Robak 
et al., 2009; Venkatesh et al., 2007).  While pretreatment of NgROMNI-Fc with VCN abolished 
binding to MAG-expressing COS-7 cells, pretreatment of CII-Fc and CIV-Fc with VCN did not 
inhibit binding (Figure 3.3b).  Next, we examined binding of CII-Fc, CIV-Fc, and NgROMNI-Fc 
to COS-7 cells that express MAGR118A, a point mutation that greatly reduces lectin activity (Tang 
et al., 1997).  MAGR118A failed to bind NgROMNI-Fc, as previously demonstrated (Robak et al., 
2009); however, robust binding was observed to CII-Fc and CIV-Fc (Figure 3.3c).  These results 




LRP1 mediates the endocytosis of MAG 
 As LRP1 is a known endocytic receptor (Franchini and Montagnana, 2011), we 
investigated the possibility of MAG being internalized.  MAG-Fc was incubated at 4oC with N2a 
cells in the presence of GST or GST-RAP, followed warming of the cells to 37oC.  To ensure 
that only internalized MAG-Fc would remain cell-associated, a mild acid wash (pH 3.0) was 
performed.  Immunofluorescence microscopy revealed that MAG-Fc was internalized by the N2a 
cells and the degree of internalization was substantially reduced when GST-RAP was added 
(Figure 3.4a).  To show that the interaction of MAG-Fc with LRP1 is specific, we expressed the 
first three Ig-like domains of receptor protein tyrosine phosphatase sigma as an Fc fusion protein 
(RPTP-Fc) and studied uptake of this protein by N2a cells, in the presence or absence of GST-
RAP.  Although RPTP-Fc was internalized by N2a cells, the extent of internalization was not 
affected by GST-RAP (Figure 3.4a).  In additional control experiments, we incubated MAG-Fc 
with N2a cells at 4oC, but did not increase the temperature to 37oC before performing the mild 
acid wash.  Under these conditions, MAG-Fc binding was not detected (data not shown). 
 To further assess the role of LRP1 in the endocytosis of MAG, we developed a stable cell 
line in which LRP1 is silenced with shRNA in N2a cells.  By immunoblot analysis, LRP1 was 
undetectable in these cells (data not shown).  MAG-Fc was incubated with N2a cells in which 
LRP1 was silenced or with N2a cells that had been transfected with empty vector.  Following the 
mild acid wash, MAG-Fc internalization was much greater in the LRP1-expressing cells, 
compared with cells in which LRP1 was silenced.  Importantly, LRP1 gene silencing did not 
inhibit internalization of RPTP-Fc (Figure 3.4b-c).  Additionally, we examined the uptake of 
125I-labeled MAG-Fc by N2a cells, defined as the fraction of radioligand internalization inhibited 




MAG-Fc internalized 44 ± 4fmol MAG-Fc/mg of cellular protein per hour.  LRP1 gene silencing 
completely abolished specific internalization of 125I-MAG-Fc, providing further evidence that 
LRP1 is necessary for the endocytosis of MAG (Figure 3.4d). 
 
LRP1 is required for inhibition of neurite outgrowth by MAG   
 To test whether LRP1 is involved in the pathway by which MAG inhibits neurite 
outgrowth, PC12 pheochromocytoma cells and N2a cells were cultured on monolayers of CHO 
cells that express MAG or on control R2 CHO cells (Mukhopadhyay et al., 1994).  MAG-
expressing CHO cells strongly inhibited neurite outgrowth of both cell types and GST-RAP, but 
not GST, significantly reversed this inhibition (Figure 3.5a).  Importantly, MAG expression 
levels were not affected by RAP, as determined by immunoblot analysis (data not shown).  To 
confirm that LRP1 is required for inhibition of neurite outgrowth by MAG, we transiently 
silenced LRP1 gene expression in PC12 and N2a cells.  Control cells were transfected with non-
targeting control (NTC) siRNA.  LRP1 gene silencing was 80% and 85% effective in PC12 cells 
and N2a cells, respectively, as determined by RT-PCR.  Similar extents of gene silencing were 
evident by immunoblot analysis (data not shown).  LRP1 gene silencing significantly reversed 
MAG-mediated neurite outgrowth inhibition, suggesting that LRP1 expression in neuron-like 
cells is important for growth-inhibitory responses by MAG (Figure 3.5b). 
 To further test this hypothesis, we conducted neurite outgrowth experiments using 
primary cultures of rat cerebellar granule neurons (CGNs).  We took three approaches to 
neutralize LRP1 in CGNs that were plated on MAG-expressing or control R2 CHO cells.  First, 
cells were cultured in the presence of GST or GST-RAP.  Addition of GST-RAP, but not GST 




LRP1 expression was robustly silenced in CGNs using siRNA.  LRP1 protein levels were 
substantially decreased by gene silencing (data not shown), resulting in a significant reversal of 
neurite outgrowth inhibition on MAG-expressing CHO cells (Figure 3.6b).  Finally, CGNs were 
isolated from mice in which loxP sites flank part of the LRP1 promoter and the first two exons 
(LRP1loxP/loxP), allowing for Cre-mediated LRP1 gene deletion (Rohlmann et al., 1996).  These 
CGNs were transduced with herpes simplex virus-1 that encodes GFP and Cre (HSV-1-GFP-
Cre) or a HSV-1-GFP control.  Immunoblot analysis showed that HSV-1-GFP-Cre transduction 
caused substantial LRP1 gene deletion and a significant increase in CGN neurite length on 
MAG-expressing CHO cells when compared to CGNs infected with HSV-1-GFP (Figure 3.6c).  
Collectively, three different approaches show that functional ablation of LRP1 in primary 
neurons is sufficient to significantly attenuate MAG inhibition. 
 
Binding of MAG to LRP1 recruits p75NTR and activates RhoA 
 RhoA activation is critical for MAI-induced neurite outgrowth inhibition in both neurons 
and neuron-like cells (Kozma et al., 1997; Kuhn et al., 1999; Madura et al., 2004; Yamashita et 
al., 2002).  Blocking RhoA activation promotes neurite outgrowth (Jalink et al., 1994; Jeon et al., 
2012), even in cells plated on inhibitory substrata (Fu et al., 2007; Niederost et al., 2002; Tan et 
al., 2007).  To test the role of LRP1 in MAG-induced RhoA activation, N2a cells in which LRP1 
was silenced with shRNA were treated with MAG-Fc or Fc alone.  MAG-Fc significantly 
increased GTP-loaded RhoA in LRP1-expressing N2a cells; however, when LRP1 was silenced, 
MAG-Fc failed to induce this increase (Figure 3.7a).  As RhoA activation by MAIs requires 
p75NTR or TROY in some cell types (Park et al., 2005; Wang et al., 2002; Yamashita et al., 




peptide that binds to p75NTR and blocks Rho-GDI binding to p75NTR and p75NTR-dependent 
RhoA activation (Yamashita and Tohyama, 2003).  TAT-Pep5 blocked RhoA activation in 
response to MAG-Fc, suggesting that p75NTR and LRP1 may both contribute to MAG-induced 
RhoA activation (Figure 3.7b). 
 It has been reported that p75NTR is recruited into a complex with NgR1 or PirB when 
these receptors bind MAIs (Fujita et al., 2011; Shao et al., 2005; Wang et al., 2002).  To 
determine whether p75NTR forms a complex with LRP1, we performed co-IP experiments.  When 
N2a cells were treated with MAG-Fc, but not Fc alone, p75NTR was found to co-IP with LRP1 
(Figure 3.7c).  To test whether p75NTR regulates the binding of MAG to LRP1, p75NTR was 
partially silenced in N20.1 cells.  Total levels of LRP1, as well as the association of LRP1 and 
MAG-Fc, were not affected by p75NTR gene silencing (Figure 3.7d).  These results suggest that 
the binding of MAG to LRP1 does not require p75NTR, consistent with the results presented in 
Figure 3.1. 
 
LRP1 is required for myelin-mediated neurite outgrowth inhibition  
 Given that p75NTR can be recruited as a co-receptor following the binding of multiple 
MAIs (Wang et al., 2002), we next examined neurite outgrowth of CGNs plated on purified rat 
CNS myelin.  As expected, neurite outgrowth was strongly inhibited on myelin, and GST-RAP 
(Figure 3.8a) or LRP1 gene silencing (Figure 3.8b) significantly reversed this inhibition.  
However, addition of GST-RAP failed to reverse the inhibitory effects of another major group of 
CNS growth inhibitors, the chondroitin sulfate proteoglycans (CSPGs) (Figure 3.9). 
 As purified CNS myelin contains multiple MAIs in addition to MAG, including Nogo 




Nogo-A and LRP1 show an endogenous interaction in rat brain extracts (Figure 3.8c), Nogo-A 
and OMgp from purified rat CNS myelin co-IP with CII-Fc and CIV-Fc, but not Fc alone 
(Figure 3.8d-e), and AP-conjugated Nogo66 and OMgp bind to immobilized CII-Fc and CIV-Fc 
in a purified system (Figure 3.8f).  Overall, these qualitative binding studies demonstrate that 
LRP1 can interact with multiple MAIs, but further quantitative binding and functional studies 
will be necessary to understand the significance of these interactions. 
 
Soluble forms of LRP1 reverse MAI-mediated neurite outgrowth inhibition 
 We hypothesized that purified LRP1 and derivatives of LRP1 that include its ligand-
binding sites will compete with membrane-anchored LRP1 for MAI binding and therefore 
reverse the growth-inhibitory activity of MAIs.  Purified LRP1 derivatives may also compete 
with other membrane-anchored, MAI-binding receptors.  Indeed, purified, full-length LRP1 
significantly reversed the inhibition of CGN outgrowth observed on both MAG-expressing CHO 
cells (Figure 3.10a) and purified rat CNS myelin (Figure 3.10b).  
LRP1 is released from cells as a “shed” product by α-secretase and accumulates in the 
blood and cerebrospinal fluid (Liu et al., 2009).  As shed LRP1 retains the entire α-chain, ligand-
binding activity remains intact (Quinn et al., 1999).  Shed LRP1 was purified from human 
plasma, as previously described (Gorovoy et al., 2010), and was able to reverse the inhibitory 
effects of CNS myelin on CGN outgrowth (Figure 3.10c).  Furthermore, addition of either the 
CII-Fc or CIV-Fc fusion proteins significantly reversed MAG- and myelin-mediated neurite 






 A detailed understanding of the mechanisms by which MAIs inhibit neuronal growth is 
of considerable interest, both biologically and clinically.  Previously, NgR1 was reported to bind 
MAG, Nogo66, OMgp, and CSPGs; however, NgR1 mutant neurons are not disinhibited when 
plated on substrate-bound ligands, suggesting some degree of mechanistic redundancy in how 
growth inhibition is signaled (Chivatakarn et al., 2007; Dickendesher et al., 2012; Zheng et al., 
2005).  Another study identified PirB as a promiscuous receptor for MAG, Nogo66, and OMgp.  
Antagonism of PirB leads to a significant, yet incomplete release of neurite outgrowth inhibition 
in the presence of substrate-bound inhibitors or crude CNS myelin (Atwal et al., 2008).  The 
combined functional ablation of NgR1 and PirB is not sufficient to fully release MAG, Nogo66, 
or OMgp inhibition, suggesting the existence of other receptor mechanisms.  In addition to NgR1 
and PirB, MAG has been shown to bind to brain gangliosides, NgR2, and β1-integrins, and 
depending on the neuronal cell type examined, these interactions contribute to growth inhibition 
to various degrees (Goh et al., 2008; Mehta et al., 2007; Venkatesh et al., 2007; Worter et al., 
2009).  
 Herein, we report the identification of LRP1 as a novel receptor for MAG.  We initially 
identified MAG as an LRP1 binding partner from LC-MS/MS screening experiments.  We 
subsequently determined that MAG binds LRP1 directly and independently of its lectin activity.  
This is important, as the inhibitory effects of membrane-associated MAG on neurite outgrowth 
are known to occur independently of sialic acid binding (Tang et al., 1997).  To our knowledge, 
LRP1 is the first receptor to demonstrate this anticipated characteristic of a functional MAG 
receptor.  The association of MAG with LRP1 recruits p75NTR into a receptor complex and is 
coupled to MAG endocytosis.  In primary neurons, functional ablation of LRP1 attenuates 




supports interactions with Nogo66 and OMgp, although more detailed work will be necessary to 
elucidate whether these interactions are important for the mechanism by which myelin inhibits 
neurite outgrowth.  
NgR1 and NgR2 are GPI-anchored proteins and depend on interactions with membrane-
spanning receptors for cell signaling.  Lingo-1 and two members of the TNF receptor family, 
p75NTR and TROY, form complexes with NgR1 (Yiu and He, 2006).  A more recent study 
showed that PirB associates with p75NTR to signal growth inhibition (Fujita et al., 2011).  Similar 
to NgR1 and PirB, we show that LRP1 associates with p75NTR in the presence of MAG.  Because 
of the limited distribution of p75NTR in the mature CNS and the strong inhibition observed in 
MAI-treated p75NTR-/- neurons, additional signal transducing components remain to be discovered 
(Zheng et al., 2005, Venkatesh et al., 2007).  In addition to p75NTR, LRP1 may also associate 
with TROY or Lingo-1, and it will be interesting to examine whether NgRs, PirB, and LRP1 are 
part of a multicomponent receptor complex or if they function separately.  
Binding of tPA and α2M to neuronal LRP1, in the absence of MAIs, results in enhanced 
neurite outgrowth and neuronal survival (Hayashi et al., 2007; Qiu et al., 2004; Mantuano et al., 
2008; Shi et al., 2009).  These LRP1 ligands activate Src family kinases, transactivate Trk recep-
tors, and stimulate ERK and AKT in a Trk-dependent manner (Shi et al., 2009).  In addition to 
Trk receptors, NMDA receptors may also be involved in the pathway by which ERK is activated 
by tPA and α2M (May et al., 2004).  The signaling downstream of these LRP1 ligands is very 
different from that observed with MAIs and reported in this study.  We propose a model in which 
the activity of LRP1 in cell signaling is highly dependent on the co-receptors that are recruited to 
LRP1 by specific ligands.  We further propose that whether p75NTR or Trk receptors are recruited 




Joset et al. (2010) demonstrated that Nogo-A activates RhoA by a mechanism that 
requires Pincher-dependent macroendocytosis.  Although this pathway occurs independently of 
clathrin-coated pits, formation of the signalosome and vesicular transport of Nogo-A within the 
cell was pivotal for growth cone collapse.  Endocytosis of MAG by LRP1, possibly in combin-
ation with p75NTR and other members of the MAG receptor complex, may provide a related 
pathway for intracellular trafficking of myelin products and RhoA activation.  Interestingly, 
Steuble et al. (2010) found evidence of Nogo and LRP1 colocalization in early endosomes when 
growth cone vesicles were isolated. 
Both purified LRP1 and shed LRP1 from human plasma attenuated the inhibitory effects 
of MAG and purified myelin on neurite outgrowth.  We interpret these results to reflect 
competition with membrane-anchored LRP1 for MAI binding.  Purified and shed LRP1 may also 
competitively block binding of MAIs to other receptors, such as NgR1, NgR2, and PirB.  We 
propose that the activity of MAG and other MAIs may be neutralized by any soluble LRP1 
derivative that retains ligand-binding activity.  Shed LRP1 is generated by the α-secretase, 
ADAM17 (Gorovoy et al., 2010).  Inflammation increases LRP1 shedding and promotes the 
accumulation of shed LRP1 in the plasma (Gorovoy et al., 2010).  In CNS ischemia, shedding of 
LRP1 from perivascular astrocytes is significantly increased (Polavarapu et al., 2007).  It is not 
clear whether LRP1 shedding from neurons is regulated; however, our results suggest that shed 
LRP1 may serve as an endogenous antagonist of the growth-inhibitory activity of MAG and 
possibly other MAIs.  As such, LRP1 shedding in the brain may represent a previously 







 Recombinant and purified proteins: CII, which includes amino acids 804-1185 of 
mature human LRP1; CIV, which includes amino acids 3331-3778; and full-length rat MAG 
were cloned into pFuse-rFc2 (Invivogen) and expressed as Fc fusion proteins in CHO-K1 cells.  
NgROMNI-Fc and RPTP-Fc are previously described (Dickendesher et al., 2012; Robak et al., 
2009).  Fc fusion proteins were purified from conditioned culture medium by affinity 
chromatography on Protein A-Sepharose (GE Healthcare).  GST-RAP and GST were expressed 
in bacteria and purified as previously described (Gaultier et al., 2009).  Shed LRP1 was purified 
from human plasma by RAP affinity chromatography and molecular exclusion chromatography 
(Gorovoy et al., 2010).  Full-length LRP1 was purified from rat liver, as described (Gorovoy et 
al., 2010).  Homogeneity and integrity of LRP1 preparations were assessed by SDS-PAGE.  
OMgp-AP, AP-Nogo66, and AP-Fc were expressed in HEK293T cells as previously described 
(Dickendesher et al., 2012).  Conditioned medium was collected and used as a source of these 
fusion proteins. 
 
 Cell culture: CHO-K1 cells were cultured in high glucose Dulbecco’s Modified Eagle’s 
Medium (DMEM) with 10% fetal bovine serum (FBS) (Thermo Scientific), 10mg/L L-
glutamine, and 10 mg/L non-essential amino acid solution (Gibco).  For expression of 
recombinant proteins, transfected CHO-K1 cells were cultured in PowerCHOTM Chemically 
Defined Medium (Lonza).  MAG-expressing and R2 CHO cells were a generous gift from Dr. 
Mark Tuszynski (University of California San Diego).  These cells were maintained in DMEM 
with 10% FBS, 2mM glutamine, 40mg/L proline, 0.73mg/L thymidine, 1μM methotrexate, and 




GFP as described (Atwal et al., 2008; Robak et al., 2009).  PC12 cells were cultured in DMEM 
supplemented with 10% FBS, 5% heat-inactivated horse serum (Thermo Scientific), and 
penicillin/streptomycin (P/S; Thermo Scientific).  For neurite outgrowth experiments, PC12 cells 
were plated in serum-free medium (SFM) and treated with 50μg/ml NGF-β (R & D Systems).  
N2a cells were a generous gift from Dr. Katerina Akassoglou (Gladstone Institute of 
Neurological Disease, University of California San Francisco).  N2a cells were cultured in 
DMEM with 10% FBS and P/S, and plated in SFM for neurite outgrowth experiments.  Primary 
cultures of rat cerebellar granule neurons (CGNs) were isolated and cultured in DMEM with 
50mM glucose, 10% FBS, 25mM KCl, and P/S.  Primary cultures of mouse CGNs were isolated, 
purified in a discontinuous Percoll gradient, and cultured as previously described (Dickendesher 
et al., 2012).  N20.1 cells were a generous gift from Dr. Anthony Campagnoni (University of 
California Los Angeles) and were cultured as previously described (Wight and Dobretsova, 
1997). 
 
 Neurite outgrowth assays: MAG-expressing and R2 CHO cells were cultured on glass 
slides as previously described (Domeniconi et al., 2002).  When CHO cells were confluent, rat 
CGNs, PC12 cells, or N2a cells were added and grown for 48 hours, unless otherwise specified.  
For some experiments, CGNs from LRP1loxP/loxP mice (JAX® Mice and Services) were cultured 
for 24 hours on poly-D-lysine hydrobromide (PDL; 50μg/ml) before transduction with either 
herpes simplex virus-1 (HSV-1)-GFP or HSV-1-GFP-Cre (Viral Gene Transfer Core, McGovern 
Institute for Brain Research, MIT).  After an additional 72 hours, CGNs were either lysed 
directly in 2X SDS sample buffer (for immunoblotting with anti-LRP1 [Sigma] and anti-βIII-




CellstripperTM non-enzymatic cell dissociation solution (Corning) and re-plated on MAG-
expressing or R2 CHO cells for 24 hours before fixation and staining (Dickendesher et al., 2012).   
 As an alternative to the CHO cell system, culture surfaces were coated with PDL 
(50μg/ml) and, in some cases, subsequently coated with 8μg/ml purified myelin in 30μM HEPES 
pH 7.4, 10μg/ml BSA, or 10μg/ml chondroitin sulfate proteoglycan (CSPG) mix (Millipore) 
before coating with 2μg/ml laminin for 2 hours at room temperature.  When GST-RAP or GST 
(200nM) was added, these proteins were preincubated with the neural cells in suspension for 15 
minutes at the indicated concentration prior to plating.  For studies involving shed LRP1, 
purified LRP1, CII-Fc, or CIV-Fc, these proteins (or appropriate controls) were preincubated 
with the indicated substrate.  Neurite outgrowth was determined by immunofluorescence to 
detect βIII-tubulin (Promega) and quantified using ImageJ software. 
 
 Gene silencing: PC12 cells were transfected with LRP1-specific siRNA 
(CGAGCGACCUCCUAUCUUUUU) or with non-targeting control (NTC) siRNA (Thermo 
Scientific) using the Amaxa rat neuron nucleofector kit, according to the manufacturer’s 
instructions.  LRP1 was silenced in rat CGNs and mouse N2a cells using ON-TARGETplus 
LRP1-specific siRNA or with NTC siRNA (Thermo Scientific) and Lipofectamine® 2000 
(Invitrogen).  Stable LRP1 gene silencing was achieved in N2a cells using our previously 
described LRP1-specific shRNA, cloned into pSUPER (Oligoengine; Gaultier et al., 2008).  This 
construct (or empty vector) was transfected into N2a cells using Lipofectamine® 2000.  
Transfected cells were selected first with puromycin (1μg/ml) and then for 48 hours with 
Exotoxin A (200ng/ml; List Biological Laboratories; FitzGerald et al., 1995).  LRP1 gene 




performed using ON-TARGETplus p75NTR-specific siRNA or with NTC siRNA (Thermo 
Scientific) and Lipofectamine® 2000.  
 
 CNS myelin purification/mass spectrometry: Myelin vesicles were purified from 
mouse and rat brain, as described by Norton and Poduslo (Norton and Poduslo, 1973).  Briefly, 
adult rodent brains were homogenized in 0.32M sucrose, layered over 0.85M sucrose, and 
subjected to sucrose density gradient ultracentrifugation.  Myelin was then subjected to osmotic 
shock, recovered, and resuspended in 20mM sodium phosphate, 150mM NaCl, pH 7.4 (PBS).  
The purity of the preparation was determined by Coomassie Blue staining and by immunoblot 
analysis for myelin basic protein, as previously described (Gaultier et al., 2009). 
 Myelin-associated proteins were solubilized from purified myelin vesicles with RIPA 
buffer (100mM Tris-HCl, 150mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS 
supplemented with 1mM CaCl2, and protease inhibitor cocktail).  Protein extracts (2mg) were 
incubated with 1μM CII-Fc, CIV-Fc, or Fc overnight at 4°C.  The fusion proteins and associated 
proteins were recovered by incubation with Protein A-Sepharose for 1 hour at 20°C.  After 
extensive washing with RIPA buffer, proteins were digested with trypsin in the presence of 
ProteaseMAXTM Surfactant as described by the manufacturer (Promega).  Proteins associated 
with CII-Fc or CIV-Fc, but not with Fc, were identified as “specific interactors” by LC-MS/MS 
as previously described (Gaultier et al., 2010). 
 
 Immunoprecipitation analysis: Unless otherwise specified, protein extracts were 
prepared in 50mM HEPES pH 7.4, 1% Triton X-100, 150mM NaCl, 10% glycerol, 2mM EDTA, 




CII-Fc, CIV-Fc, MAG-Fc, or Fc were immobilized on Protein A-Sepharose prior to adding 
ligands or protein extracts.  In some studies, 200nM GST-RAP or GST was added to protein 
extracts prior to affinity precipitation.  Following a preclearing step with non-immune IgG, 
LRP1 was affinity precipitated using an LRP1-specific antibody (Sigma) coupled to Protein A-
Sepharose.  Nogo-A, MAG, and OMgp were identified in affinity precipitates by immunoblot 
analysis using the indicated antibody (R & D Systems).  p75NTR was detected using an antibody 
that recognizes the intracellular domain (Millipore).   
 For detection of endogenous LRP1 interactions, membrane preparations from adult rat 
brain were collected using sucrose gradient centrifugation, as previously described (Winters et 
al., 2011).  Membranes were incubated in lysis buffer containing 20mM Tris-HCl pH 7.5, 
150mM NaCl, 5mM EDTA, 1% NP-40, and protease inhibitor cocktail, before tumbling for 4 
hours at 4°C with antibodies against either LRP1 (Sigma), MAG (custom; Winters et al., 2011), 
or Nogo-A (R & D Systems).  Following precipitation with Protein G Plus/Protein A-Agarose 
overnight at 4°C, samples were rinsed six times with lysis buffer, and bound proteins were eluted 
with 2X SDS sample buffer.  Precipitates were analyzed by immunoblotting.   
 
 Binding assays: Fc fusion proteins, which were preclustered with anti-human or anti-
rabbit IgG, conjugated to alkaline phosphatase (AP), were incubated with COS-7 cells 
expressing MAG, MAGR118A, PirB, or GFP for 75 minutes.  Unbound fusion protein was 
removed by extensive rinsing with OptiMEM (Invitrogen). Cells were then fixed with 1% 
formaldehyde in 60% acetone solution, and rinsed three times in HEPES-buffered saline.  
Endogenous phosphatases were heat inactivated by incubation at 65°C for 90 minutes.  Binding 




5-bromo-4-chloro-3'-indolyphosphate (Sigma).  In some experiments, ligands were pretreated 
with either V. cholera neuraminidase (1mU/ml; Robak et al., 2009) or with GST-RAP (200nM) 
for 1 hour at 37°C.  Binding was quantified using ImageJ software.  For monomeric binding 
studies with no preclustering, anti-human IgG-AP or anti-rabbit IgG-AP were applied to cells 
following fusion protein incubation.  To determine binding isotherms, increasing concentrations 
of each Fc fusion protein were incubated with MAG-expressing COS-7 cells.  
 For dot blotting studies, 40pmol of CII-Fc, CIV-Fc, or Fc was immobilized on 
nitrocellulose (secured in a Bio-Rad Bio-Dot Apparatus).  Membranes were then rinsed in PBS 
and blocked in PBS with 5% BSA, followed by incubation with the indicated protein for 1 hour 
at room temperature.  After extensive washing in PBS, bound proteins were detected using the 
appropriate antibodies. 
 
 RhoA activation: N2a cells were cultured for 1 day and then serum starved for 1 hour.  
MAG-Fc or Fc was preincubated with an Fc-specific antibody (Jackson Immunoresearch 
Laboratories) at a 2:1 molar ratio and added to the N2a cells (20nM) for 10 minutes.  Cell 
extracts were prepared and GTP-loaded RhoA was affinity precipitated using the Rho binding 
domain of Rhotekin, which was expressed as a GST fusion protein, according to the 
manufacturer’s instructions (Millipore).  The levels of affinity-precipitated active RhoA and total 
RhoA were determined by immunoblot analysis using a RhoA antibody (Cell Signaling).  For 
quantification of RhoA activation in LRP1-expressing and -deficient N2a cells, the ratio of 
active/total RhoA was quantified by densitometric analysis.  For experiments using TAT-Pep5 




and Tohyama, 2003), cells were incubated with 500nM TAT-Pep5 for 30 minutes prior to the 
addition of MAG-Fc. 
 
 Endocytosis assays: LRP1-positive and -deficient N2a cells, as well as standard N2a 
cells in the presence of GST-RAP or GST (200nM), were plated on PDL-coated glass slides and 
allowed to grow overnight.  Cells were then differentiated in SFM for 4 hours, before being 
treated with 1ug/ml of an Fc receptor blocking antibody (BD Biosciences) for 30 minutes at 4°C, 
followed by 25nM MAG-Fc, RPTP-Fc, or Fc control for 60 minutes at 4°C.  For internalization, 
the cells were warmed to 37°C for 30 minutes.  Surface-associated Fc fusion proteins were 
removed by treatment with acetic acid/sodium acetate pH 3.0 for 4 minutes.  Cells were then 
rinsed with cold PBS, fixed with 4% paraformaldehyde in PBS for 10 minutes, permeabilized 
and blocked for non-specific binding by incubation with 0.1% Triton X-100 and 5% goat serum 
in PBS for 1 hour, and immunolabeled to detect the Fc tag of the fusion proteins.  For 
immunoblot analysis, proteins were extracted in RIPA buffer as previously described (Mantuano 
et al., 2008).  An equivalent amount of cellular protein (30μg per lane) was subjected to SDS-
PAGE and immunoblot analysis to detect levels of the Fc tag and tubulin. 
 In additional experiments, MAG-Fc was radioiodinated with 1 mCi of Na125I using 
Iodination Beads (Pierce, Rockford, IL, USA) and separated from free Na125I by molecular 
exclusion chromatography.  1x105 cells were plated in 12-well plates and equilibrated in DMEM 
with 25mM HEPES pH 7.4, 0.1% BSA, and an Fc receptor blocking antibody (BD Biosciences).  
125I-MAG-Fc (25nM) was incubated with cells for 2 hours at 37°C.  Unlabeled MAG (1.25μM) 
was added to some wells.  At the end of the incubation, cells were washed and treated with 




extracts were prepared in 0.1M NaOH and 1% SDS.  Cell-associated radioactivity was 
determined using a Wallac Wizard 1470 Gamma Counter (Perkin Elmer), and cellular protein 
levels were determined by a bicinchoninic acid assay (Pierce).  Specific MAG-Fc uptake was 
calculated as the fraction of total uptake that was inhibited by excess unlabeled MAG. 
 
 MAG expression analysis: To evaluate the effect of RAP treatment on the expression of 
MAG in MAG-CHO cells, confluent MAG-CHO cells were cultured with 200nM GST-RAP or 
GST for 24, 48, 72, or 96 hours.  Proteins were then extracted in RIPA buffer as previously 
described (Mantuano et al., 2008).  An equivalent amount of cellular protein was then subjected 
to SDS-PAGE and immunoblot analysis using an anti-MAG antibody (R & D Systems). 
 
 Data analysis: Data processing and statistical analysis were performed using GraphPad 
Prism 5.00 (GraphPad Software).  Data sets were analyzed using one-way ANOVA followed by 
Tukey’s post hoc comparisons.  P values <0.01 were considered statistically significant. 
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Figure 3.1: LRP1 is a MAG receptor.  (a) Schematic diagram showing the relationship of the 
CII-Fc and CIV-Fc fusion proteins to the intact structure of LRP1. (b) N2a cell extracts (or 
extraction buffer only) were incubated with MAG-Fc or Fc, which were immobilized on Protein 




Endogenous MAG and LRP1 were precipitated from adult rat membrane preparations using 
MAG- or LRP1-specific antibodies, followed by immunoblotting for both proteins. A non-
specific IgG was used as a control. (d) Recombinant MAG-Fc or Fc were immobilized on 
Protein A-Sepharose and incubated with purified LRP1 or with vehicle (PBS). Affinity-
precipitated proteins were subjected to immunoblot analysis for LRP1. (e) Protein extracts 
prepared from N20.1 cells were treated with 200nM GST-RAP (+RAP) or GST (-RAP) and then 
precipitated with MAG-Fc coupled to Protein A-Sepharose. Affinity-precipitated samples were 
subjected to immunoblot analysis for LRP1. (f) CII-Fc, CIV-Fc, or Fc were incubated with 
purified CNS myelin extracts followed by precipitation with Protein A-Sepharose. Immunoblot 
analysis was performed to detect MAG. (g) CII-Fc, CIV-Fc, or Fc (40pmol) were immobilized in 
duplicate on nitrocellulose membranes and incubated with MAG-Fc (10µg/ml) or vehicle (PBS). 
MAG binding was detected using a MAG-specific antibody. (h) COS-7 cells were transfected 
with either membrane-bound MAG or control (GFP), and then incubated with CII-Fc, CIV-Fc, 
NgROMNI-Fc, or Fc control. All fusion proteins were conjugated to alkaline phosphatase (AP), 
and bound proteins were detected by developing the AP reaction with nitro-blue tetrazolium and 
5-bromo-4-chloro-3'-indolyphosphate (NBT/BCIP). The graph represents the degree of binding 
relative to NgROMNI-Fc (mean ±SEM, n=5 independent experiments). (i) COS-7 cells were 
transfected with membrane-bound MAG, and then incubated with CII-Fc, CIV-Fc, or NgROMNI-
Fc in the presence of either 200nM GST-RAP (+RAP) or GST (-RAP). The graph represents the 























































Figure 3.2: Monomeric CII-Fc and CIV-Fc bind with high affinity to MAG, but not PirB.  
(a) COS-7 cells were transfected with membrane-bound PirB, and then incubated with CII-Fc, 
CIV-Fc, MAG-Fc (positive control), or Fc (negative control). All fusion proteins were 
conjugated to AP, and bound proteins were detected by developing the AP reaction with 
NBT/BCIP. (b) COS-7 cells were transfected with membrane-bound MAG, and then incubated 
(at increasing concentrations) with monomers of CII-Fc or CIV-Fc. Following fusion protein 
incubation, anti-IgG-AP conjugate was applied and bound proteins were detected by developing 
the AP reaction with NBT/BCIP. Binding from 4 independent experiments was quantified using 
ImageJ software, and then averaged to yield the presented data points (mean ±SEM). A 
sigmoidal line of best fit was used to assess binding affinities. (c) COS-7 cells were transfected 
with membrane-bound MAG, MAGR118A (a mutant with greatly reduced lectin activity), or 





















Figure 3.3: MAG binds to the CII and CIV domains of LRP1 in a sialic acid-independent 
manner.  (a) COS-7 cells were transfected with membrane-bound MAG, and then incubated (at 
increasing concentrations) with CII-Fc, CIV-Fc, or NgROMNI-Fc. All fusion proteins were 
conjugated to AP, and bound proteins were detected by developing the AP reaction with 
NBT/BCIP. Binding from 5 independent experiments was quantified using ImageJ software, and 
then averaged to yield the presented data points (mean ±SEM). A sigmoidal line of best fit was 
used to assess binding affinities. (b) MAG-expressing COS-7 cells were incubated with CII-Fc, 
CIV-Fc, or NgROMNI-Fc. In some cases, ligands were pretreated with 1mU/ml V. cholera 
neuraminidase (+VCN) for 1 hour before incubation with COS-7 cells. The graph represents the 
degree of binding relative to NgROMNI-Fc (mean ±SEM, n=4 independent experiments). (c) COS-
7 cells were transfected with either membrane-bound MAG or MAGR118A, before addition of 
CII-Fc, CIV-Fc, or NgROMNI-Fc. The graph represents the degree of binding relative to NgROMNI-





Figure 3.4: LRP1 is an endocytic receptor for MAG.  (a) N2a cells were treated with 200nM 
GST-RAP (+RAP) or GST (-RAP) prior to addition of 25nM RPTP-Fc, MAG-Fc, or Fc control. 
Surface-associated proteins were removed by mild acid washing before visualization of the 
internalized protein by immunofluorescent detection of the Fc tag. (b) N2a cells stably 
transfected with LRP1-specific shRNA or empty vector were incubated with 25nM RPTP-Fc, 
MAG-Fc, or Fc control prior to mild acid washing and immunofluorescent detection. (c) N2a 
cells stably transfected with LRP1-specific shRNA or empty vector were incubated with 25nM 
of fusion proteins prior to mild acid washing. Protein extracts were prepared and immunoblotted 
for the Fc tag, as well as tubulin (loading control). (d) To quantify the differences in MAG 
endocytosis, N2a cells stably transfected with LRP1-specific shRNA or empty vector were 
incubated with 25nM 125I-MAG-Fc, in the presence of a fiftyfold molar excess of unlabeled 
MAG-Fc. Specific MAG-Fc internalization was determined relative to the empty vector control 





















Figure 3.5: LRP1 inactivation enhances neurite outgrowth of neuron-like cells on MAG-
expressing CHO cells.  (a) PC12 cells (top) and N2a cells (bottom) were plated on R2 control or 
MAG-expressing CHO cells and allowed to grow for 48 hours in the presence of 200nM GST-
RAP (+RAP) or GST (-RAP). Neurite outgrowth was detected by immunofluorescent imaging of 
βIII-tubulin. Results were normalized to outgrowth on R2 control CHO cells (mean ±SEM, n=4 
independent experiments, ** P< 0.01). (b) PC12 cells (top) and N2a cells (bottom) were 
transfected with non-targeting control (NTC) or LRP1-specific (siLRP1) siRNA prior to plating 
on monolayers of R2 control or MAG-expressing CHO cells, and were allowed to grow for 48 
hours. Neurite outgrowth was detected by immunofluorescent imaging of βIII-tubulin. Results 
were normalized to outgrowth on R2 control CHO cells (mean ±SEM, n=5 independent 




Figure 3.6: LRP1 inactivation enhances neurite outgrowth of primary cerebellar granule 
neurons on MAG-expressing CHO cells.  (a) Cerebellar granule neurons (CGNs) pretreated 
with 200nM GST-RAP (+RAP) or GST (-RAP) were plated on monolayers of MAG-expressing 
or R2 control CHO cells and grown for 48 hours prior to immunofluorescent detection of βIII-
tubulin. The graph represents the mean neurite outgrowth (±SEM) per condition (n=5 
independent experiments, ** P< 0.001). (b) CGNs transfected with non-targeting control (NTC) 
or LRP1-specific (siLRP1) siRNA were plated on monolayers of MAG-expressing or R2 control 
CHO cells and grown for 48 hours prior to immunofluorescent detection of βIII-tubulin. The 
graph represents the mean neurite outgrowth (±SEM) per condition (n=4 independent 
experiments, * P< 0.01, ** P< 0.001). (c) Primary CGNs were isolated from LRP1loxp/loxp mice 




on monolayers of MAG-expressing or R2 control CHO cells. CGNs were grown on CHO cell 
feeder layers for 24 hours prior to immunofluorescent detection of βIII-tubulin. The extent of 
silencing was demonstrated by immunoblotting of HSV- and HSV-Cre-infected CGN lysates for 
LRP1 and βIII-tubulin (loading control). The graph represents the mean neurite outgrowth 












































Figure 3.7: LRP1 and p75NTR are required for MAG-mediated RhoA activation.  (a) N2a 
cells in which LRP1 was stably silenced with shRNA, as well as cells transfected with empty 
vector, were treated with 20nM MAG-Fc or Fc. GTP-loaded RhoA was then affinity precipitated 
using the Rho binding domain of Rhotekin, and relative RhoA activity was determined as a ratio 
of GTP-loaded RhoA to total RhoA. The graph represents the relative RhoA activity normalized 
to Fc-treated control cells (mean ±SEM, n=5 independent experiments, * P< 0.01, ** P< 0.001). 
(b) N2a cells were pretreated with TAT-Pep5 or vehicle (PBS), followed by treatment with 
20nM MAG-Fc or Fc. GTP-loaded and total RhoA levels were assessed by immunoblot. (c) N2a 
cells were treated with 20nM MAG-Fc or Fc, extracted, and sequentially immunoprecipitated 
with control IgG (IgG pre-clear) and then with a LRP1-specific antibody. Precipitated proteins 
were subjected to immunoblot analysis for p75NTR. (d) N20.1 cells were transfected with p75NTR-
specific (si-p75) or non-targeting control (NTC) siRNA and analyzed 48 hours later by affinity 
precipitation of LRP1 with MAG-Fc from cell extracts. Whole cell extracts were subjected to 






Figure 3.8: LRP1 inactivation enhances neurite outgrowth of primary cerebellar granule 
neurons on purified CNS myelin.  (a) CGNs pretreated with 200nM GST-RAP (+RAP) or GST 
(-RAP) were plated on laminin or laminin + myelin (8μg/ml) and grown for 48 hours prior to 
immunofluorescent detection of βIII-tubulin. The graph represents the mean neurite outgrowth 
(±SEM) per condition (n=4 independent experiments, ** P< 0.001). (b) CGNs transfected with 
non-targeting control (NTC) or LRP1-specific (siLRP1) siRNA were plated on laminin or 
laminin + myelin and grown for 48 hours prior to βIII-tubulin labeling. The graph represents the 
mean neurite outgrowth (±SEM) per condition (n=5 independent experiments, ** P< 0.001). (c) 




Nogo- or LRP1-specific antibodies, followed by immunoblotting for both proteins. A non-
specific IgG was used as a control. (d, e) CII-Fc, CIV-Fc, or Fc were incubated with purified 
CNS myelin extracts followed by precipitation with Protein A-Sepharose. Immunoblot analysis 
was performed to detect (d) Nogo-A or (e) OMgp. (f) CII-Fc, CIV-Fc, or Fc (40pmol) were 
immobilized in duplicate on nitrocellulose membranes and incubated with OMgp-AP or AP-




























Figure 3.9: LRP1 is not required for CSPG-mediated neurite outgrowth inhibition of 
primary cerebellar granule neurons.  Primary CGNs pretreated with 200nM GST-RAP 
(+RAP) or GST (-RAP) were plated on laminin + BSA (10μg/ml; -CSPG)  or laminin + 
chondroitin sulfate proteoglycan (CSPG) mix (10μg/ml; +CSPG) and grown for 24 hours prior to 
immunofluorescent detection of βIII-tubulin. The graph represents the mean neurite outgrowth 

























Figure 3.10: Soluble forms of LRP1 enhance neurite outgrowth of primary cerebellar 
granule neurons on myelin-associated inhibitors.  (a) Monolayers of MAG-expressing and R2 
control CHO cells were incubated for 15 minutes with purified LRP1 (p-LRP1) or vehicle 
control (PBS; veh) prior to addition of CGNs, which were grown for 48 hours before 




(±SEM) per condition (n=5 independent experiments, ** P< 0.001). (b) Surfaces coated with 
laminin or laminin + myelin (8μg/ml) were incubated for 15 minutes with purified LRP1 (p-
LRP1) or vehicle control (PBS; veh) prior to addition of CGNs, which were grown for 48 hours 
before βIII-tubulin labeling. The graph represents the mean neurite outgrowth (±SEM) per 
condition (n=4 independent experiments, ** P< 0.001). (c) Surfaces coated with laminin (-
myelin) or laminin + myelin (8μg/ml; +myelin) were incubated for 15 minutes with shed LRP1 
(purified from human plasma; LRP1shed) or vehicle control (PBS). CGNs were then plated and 
grown for 48 hours prior to immunofluorescent staining for βIII-tubulin. Neurite outgrowth was 
standardized to the vehicle control. The graph represents a scatter plot of neurite outgrowth per 
cell, with bars representing the mean neurite outgrowth per condition (* P< 0.01). (d) 
Monolayers of MAG-expressing and R2 control CHO cells were incubated for 15 minutes with 
1μM CII-Fc, CIV-Fc or Fc, prior to addition of CGNs. CGNs were grown for 48 hours before 
βIII-tubulin labeling. The graph represents the mean neurite outgrowth (±SEM) per condition 
(n=4 independent experiments, ** P< 0.001). (e) Surfaces coated with laminin or laminin + 
myelin (8μg/ml) were incubated for 15 minutes with 1μM CII-Fc, CIV-Fc or Fc, prior to addition 
of CGNs. CGNs were grown for 48 hours prior to immunofluorescent staining for βIII-tubulin. 
The graph represents the mean neurite outgrowth (±SEM) per condition (n=4 independent 
experiments, * P< 0.01, ** P< 0.001). Scale bars, 100μm. 
 
Figure 3.11: Soluble CII-Fc and CIV-Fc reverse both MAG- and myelin-mediated neurite 
outgrowth inhibition.  Representative images from the graphs presented in Figure 3.10d-e. (a) 
Images that correspond to the graph in Figure 3.10d. (b) Images that correspond to the graph in 
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Myelin-Associated Glycoprotein Utilizes Distinct Receptors and Signaling 
Pathways to Confer Growth Inhibition vs. Neuroprotection 
 
4.1 Abstract 
 The regenerative potential of injured axons in the adult mammalian central nervous 
system (CNS) is very limited.  Protein components associated with the damaged myelin sheath, 
including the myelin-associated glycoprotein (MAG), bind with high affinity to neuronal cell 
surface receptors and initiate signaling cascades that inhibit regrowth of these connections.  In 
addition to its role in growth inhibition, MAG has recently been shown to protect neurons from 
axonal degeneration and excitotoxicity.  Here we show that paired immunoglobulin (Ig)-like 
receptor B (PirB) and low-density lipoprotein receptor-related protein 1 (LRP1) mediate MAG-
induced growth inhibition of cultured neurons, whereas the Nogo66 receptor-1 (NgR1) mediates 
MAG-induced neuroprotection.  Loss of NgR1 results in increased vulnerability to acrylamide 
administration, as determined by rotarod performance and electrophysiological recordings of the 
sciatic nerve.  NgR1-/- mice also show increased susceptibility to kainic acid-induced seizures.  
Additionally, we provide evidence that the PI3K-AKT-mTOR pathway is a major target for 
MAG growth inhibition and identify a novel connection between MAG and calpain-induced 




comprehensive dissection of the growth-inhibitory and neuroprotective functions of MAG and 
identified distinct receptor-signaling systems that mediate these functions. 
   
4.2 Introduction 
 Following injury to the adult mammalian CNS, severed axons do not regenerate beyond 
the lesion site, often leading to permanent functional deficits.  A number of growth-inhibitory 
molecules associated with CNS myelin and glial scar tissue contribute to the non-permissive 
environment of the injured CNS (Akbik et al., 2012; Fawcett et al., 2012; Silver and Miller, 
2004).  The best characterized myelin-associated inhibitors (MAIs) are Nogo, MAG, and 
oligodendrocyte myelin glycoprotein (OMgp).  Nogo, which is a member of the reticulon family 
of proteins, exists in three isoforms (Nogo-A, -B, and -C), all of which contain an inhibitory 66 
amino acid loop (Nogo66).  Both NgR1 and PirB have been identified as functional receptors for 
Nogo66, MAG, and OMgp (Atwal et al., 2008; Domeniconi et al., 2002; Fournier et al., 2001; 
Liu et al., 2002; Wang et al., 2002). 
 MAG is a member of the sialic acid-binding Ig lectins, composed of an extracellular 
segment with five Ig-like domains, a transmembrane domain, and a cytoplasmic tail (Filbin, 
2003).  The lectin activity of MAG complexes with terminal sialic acids and critically depends 
on an arginine residue (Arg118) located in the first Ig-like domain (Kelm et al., 1994; Tang et 
al., 1997; Vyas and Schnaar, 2001).  In addition to NgR1 and PirB, MAG interacts with NgR2, 
LRP1, the gangliosides GD1a and GT1b, and β1-integrin (Collins et al., 1997; Goh et al., 2008; 
Stiles et al., 2013; Venkatesh et al., 2005; Vyas et al., 2002; Yang et al., 1996).  Structural 
studies have determined that while all known MAG interactors bind to Ig-like domains 1-3 (Goh 




inhibitory activity of MAG resides within Ig-like domain 5 (Cao et al., 2007; Robak et al., 2009; 
Tang et al., 1997). 
 While MAG is localized to the periaxonal membranes of Schwann cell and 
oligodendrocyte myelin sheaths, analysis of MAG-/- mice revealed that MAG is not necessary for 
myelination in vivo (Li et al., 1994; Montag et al., 1994; Quarles, 2007).  However, as MAG-/- 
mice age, they exhibit a peripheral neuropathy that includes degeneration of myelinated axons, 
decreased axonal caliber, reduced phosphorylation of neurofilament proteins, and reduction of 
neurofilament spacing (Yin et al., 1998).  In the CNS, progressive axonal degeneration, as well 
as decreases in axonal diameter and neurofilament spacing, has been noted in older MAG-/- mice 
(Loers et al., 2004; Pan et al., 2005; Nguyen et al., 2009).  Other abnormalities in the absence of 
MAG have been reported, including an irregular distribution of sodium channels at the nodes of 
Ranvier, dystrophic oligodendrocytes, the formation of redundant myelin, and doubly myelinated 
axons (Bartsch, 1996; Marcus et al., 2002; Weiss et al., 2000).   
 These subtle phenotypes in aging MAG-/- mice have led to the hypothesis that MAG 
influences axonal maintenance and stability.  Indeed, a recent study has shown that MAG 
promotes resistance to axonal injury and degeneration when confronted with a variety of stresses, 
including acrylamide, vincristine sulfate, and induction of experimental autoimmune 
encephalomyelitis (EAE), a mouse model of multiple sclerosis (Nguyen et al., 2009).  This 
protective function of MAG extends to the neuronal cell body, as MAG guards neurons from 
excitotoxic insults, including kainic acid and NMDA (Lopez et al., 2011).  Here we report on the 
identification of distinct receptors and novel signaling pathways that mediate the growth-






PirB and LRP1 participate in MAG-dependent growth inhibition 
 To determine the contribution of high-affinity MAG receptors to growth inhibition in 
vitro, primary neurons were cultured on either control CHO cells or CHO cells stably expressing 
MAG on the surface (Domeniconi et al., 2002).  When plated on MAG-CHO monolayers, 
postnatal day 7 (P7) cortical neurons, hippocampal neurons, and DRG neurons from mice 
lacking NgR1 (NgR1-/-) or PirB (PirB-/-) do not show enhanced neurite growth compared to wild-
type (WT) controls (Figure 4.1).  Because there is evidence of functional redundancy among 
MAG receptors (Atwal et al., 2008; Venkatesh et al., 2007; Worter et al., 2009), we repeated our 
outgrowth assays using neurons from mice lacking all NgRs (NgR123-/-) or from mice lacking 
NgR1, NgR2, and PirB combined (NgR12/PirB-/-).  Surprisingly, the combined loss of these 
receptors in cortical, hippocampal, and DRG neurons does not result in enhanced outgrowth 
(Figure 4.1).  In P7 CGNs and RGCs, however, the loss of PirB, but not NgRs, results in a 
significant (P< 0.01, one-way ANOVA, Tukey’s post hoc), yet incomplete release of growth 
inhibition (Figure 4.2).   
 As germline deletion of LRP1 results in embryonic lethality (Herz et al., 1992), we took 
three alternative approaches to disrupt LRP1 activity in primary neurons: (1) inhibition of MAG-
LRP1 binding by the LRP1 antagonist, receptor-associated protein (RAP) (Stiles et al., 2013; 
Strickland et al., 2002); (2) Cre-mediated deletion of LRP1 in LRP1f/f neurons by herpes simplex 
virus-1 (HSV-1-GFP-Cre) transduction (Rohlmann et al., 1996; Stiles et al., 2013); and (3) 
tissue-specific deletion of LRP1 in differentiated neurons of LRP1f/f mice using Synapsin I-Cre 
(Syn-Cre) (May et al., 2004).  In four of the five cell types tested (cortical neurons, hippocampal 




4.2), but not GST alone (Stiles et al., 2013; data not shown), enhances neurite outgrowth on 
MAG-CHO cells.  In a similar vein, transduction of these neuronal cell types with HSV-1-GFP-
Cre, but not HSV-1-GFP, results in increased neurite outgrowth on MAG-CHO cells (Figure 
4.3).  Only three of the cell types isolated from LRP1f/f; Syn-Cre mice (cortical neurons, 
hippocampal neurons, RGCs) show significant (P< 0.01, one-way ANOVA, Tukey’s post hoc) 
growth in the presence of MAG (Figure 4.4a-e).  This is likely explained by the fact that strong 
Syn-Cre expression is noted in multiple layers of the cortex and regions of the hippocampus, as 
well as in the RGC layer of the retina; however, limited expression is seen in the cerebellum and 
in subsets of DRG neurons (Figure 4.4f-m).  In total, these results argue for the existence of cell 
type-specific receptor mechanisms for MAG to exert its growth-inhibitory function (Mehta et al., 
2007; Perdigoto et al., 2011; Venkatesh et al., 2007).  Specifically, complete inhibition by MAG 
requires PirB and LRP1 in certain neuronal populations, but does not depend on the presence of 
NgR family members.   
 
RGC axon regeneration is not enhanced following deletion of high-affinity MAG receptors 
 To assess whether the role of PirB and LRP1 in RGC growth inhibition in vitro extends 
to an in vivo CNS injury model, we performed retro-orbital optic nerve crush injury in adult 
PirB-/- and NgR12/PirB-/- mutant mice.  Compared to injured wild-type controls, PirB-/- and 
NgR12/PirB-/- mice do not show any substantial RGC axon regeneration at two weeks post-injury 
(Figure 4.5a,c).  To delete LRP1 in RGCs, we performed an intravitreal injection of adeno-
associated virus 2 encoding GFP and Cre (AAV2-GFP-Cre) in adult LRP1f/f mice.  Similar to a 
previous study (Park et al., 2008), this procedure results in an almost 80% transduction 




(Figure 4.6c), and substantial knockdown of LRP1 protein levels in the retina, two weeks post-
injection (Figure 4.6d).  Two weeks post-injury, LRP1f/f mice with AAV2-GFP-Cre injection 
show no enhanced fiber regeneration compared to wild-type controls or LRP1f/f mice with 
AAV2-GFP injection (Figure 4.5a,c). 
 Because of the lack of optic nerve axon regeneration in PirB-/-, NgR12/PirB-/-, and 
LRP1f/f; AAV2-GFP-Cre mutant mice (Figure 4.5a,c), as well as NgR1-/-, NgR2-/-, and NgR12-/- 
mutants (Dickendesher et al., 2012), we performed  intravitreal injection of these mice with the 
yeast cell wall extract Zymosan to stimulate RGC growth potential (Leibinger et al., 2009; Yin et 
al., 2009).  It has been demonstrated that there are additive effects when extrinsic inhibitory cues 
are blocked while intrinsic growth programs are simultaneously activated (Dickendesher et al., 
2012; Fischer et al., 2004; Kadoya et al., 2009).  Zymosan-induced RGC axon regeneration, 
however, was comparable between all genotypes (Figure 4.5b,d).  Thus, there is a limited and/or 
redundant role for these receptors in growth inhibition following CNS injury in vivo.  
 
NgR1 participates in MAG-dependent neuroprotection 
 As NgR1 and NgR2 are not required for MAG-mediated longitudinal neurite outgrowth 
inhibition, we hypothesized that these receptors may be critical for a second function of MAG: 
resistance to axonal injury and excitotoxic damage.  To test this hypothesis, P7 mouse DRG 
explants were dissected and cultured for one week to allow extension of neurites, and subjected 
to vincristine treatment for 36 hours.  As expected, vincristine sulfate, a microtubule-
destabilizing drug broadly used as an anti-cancer treatment with peripheral neuropathy as a well-
established side effect (Jaggi and Singh, 2012), induces severe axonal degeneration (Figure 




culture medium leads to significant (P< 0.01, one-way ANOVA, Tukey’s post hoc), but partial, 
protection from degeneration, as assessed by class III β-tubulin labeling.  To determine if any of 
the known, high-affinity MAG receptors mediate this protective effect, the assay was repeated 
with receptor mutant DRG explants.  Strikingly, NgR1-/- DRG explants, but not NgR2-/- or PirB-/ 
explants, show a significant (P< 0.01, one-way ANOVA, Tukey’s post hoc) loss of MAG-
induced axon protection (Figure 4.7a).  This effect is not further enhanced in NgR12-/- or  
NgR12/PirB-/- explants, suggesting that NgR1 is the primary receptor to mediate MAG-induced 
protection from axonal degeneration.  It should be noted that loss of NgR1 does not completely 
abolish MAG protection, likely due to the continued MAG-ganglioside interaction (Mehta et al., 
2010; Nguyen et al., 2009).  Furthermore, reduction of LRP1 levels by HSV-1-GFP-Cre 
transduction of LRP1f/f DRG explants does not substantially affect MAG-induced axon 
protection from vincristine (Figure 4.8a). 
 In addition to protection from axonal degeneration, MAG has also been implicated in the 
protection of neuronal cell bodies from excitotoxicity and cell death (Lopez et al., 2011).  
Indeed, bath application of MAG-Fc to cultured mouse hippocampal neurons partially protects 
them from kainic acid-induced excitotoxic cell death after 36 hours (Figure 4.7b).  Loss of 
NgR1, but not NgR2, PirB, or LRP1, completely abolishes MAG-dependent protection (Figures 
4.7b, 4.8b), providing strong evidence that MAG utilizes NgR1 for multiple protective functions 
following toxic insult.  This effect is specific for MAG, as no protection from degeneration or 
cell death is seen with bath application of the MAIs Nogo-66 or OMgp (data not shown), or the 
structurally-related Ig lectin Siglec-3 (Figure 4.7c-d).  
 




 To further confirm the protective role of MAG-NgR1 from kainic acid-induced 
excitotoxicity, an alternative, membrane-bound source of MAG was provided.  CHO cell lines 
expressing full-length L-MAG (MAG Ig1-5-CHO), MAG with Ig-like domains 4 and 5 deleted 
(MAG Ig1-3-CHO), and MAG with Ig-like domains 1 and 2 deleted (MAG Ig3-5-CHO) were 
established.  Successful expression of the indicated MAG proteins was confirmed by 
immunoblotting of CHO cell line lysates with a custom-made MAG antibody directed against 
the L-MAG cytoplasmic portion (Figure 4.9a) (Winters et al., 2011), as well as immunostaining 
for surface-expressed MAG (Figure 4.9b).  P7 mouse hippocampal neurons were strongly 
inhibited when grown for 24 hours on MAG Ig1-5-CHO and MAG Ig3-5-CHO cell monolayers, 
but not on MAG Ig1-3-CHO cell lines (Figure 4.9b).  This is consistent with previous studies 
demonstrating that the growth-inhibitory activity of MAG resides within Ig-like domain 5 (Cao 
et al., 2007; Robak et al., 2009; Tang et al., 1997).  Similar to experiments with soluble MAG-Fc 
(Figures 4.7b, 4.8b), culturing hippocampal neurons on MAG Ig1-5-CHO feeder layers partially 
protects them from kainic acid-induced excitotoxicity, an effect that is reversed to an equal 
degree in NgR1-/-, NgR12-/-, and NgR12/PirB-/- neurons (Figure 4.9c).  Importantly, kainic acid 
does not induce cell death of the CHO feeder layers themselves (data not shown). 
 To determine the structural basis for MAG-mediated protection from excitotoxicity, 
hippocampal neurons were cultured on either MAG Ig1-5-CHO, MAG Ig1-3-CHO, or MAG 
Ig3-5-CHO cell lines, and treated with kainic acid for 36 hours.  Both the MAG Ig1-5 and MAG 
Ig1-3 cell lines, but not the MAG Ig3-5 line, confer significant (P< 0.01, one-way ANOVA, 
Tukey’s post hoc) and equal protection from cell death (Figure 4.9d).  Similar results were 
obtained using soluble forms of these MAG structural mutants.  Bath application of MAG Ig1-5-




vincristine-induced axonal degeneration (Figure 4.10a) and hippocampal neurons from kainic 
acid-induced excitotoxicity (Figure 4.10b).  In total, these results suggest that the growth-
inhibitory and protective functions of MAG can be dissociated, with the growth-inhibitory 
activity residing within Ig-like domain 5 (Cao et al., 2007; Robak et al., 2009; Tang et al., 1997) 
and the protective activity residing within Ig-like domains 1-3.  
 
Loss of NgR1 increases vulnerability to acrylamide-induced axonal degeneration and 
kainic acid-induced seizures 
 Given the critical role for NgR1 in MAG-dependent protection in vitro, we set out to 
establish the importance of these receptors when confronted with toxic insults in vivo.  To this 
end, adult mice were treated for two weeks with acrylamide, a neurotoxin that produces distal 
axonopathies of both sensory and motor nerves (Ko et al., 2000; Miller and Spencer, 1985).  On 
a congenic C57BL/6 background, adult MAG+/+ and MAG+/- mice display less severe gait 
abnormalities and hindlimb clasping behavior following acrylamide administration than age-
matched MAG-/- mice (data not shown).  Consistent with a previous study (Nguyen et al., 2009), 
administration of acrylamide to MAG-/- mice leads to a substantially lower retention time on the 
rotarod following a three day training period (Figure 4.11a).  Strikingly, acrylamide 
administration in NgR1-/- mice, but not in NgR2-/- or PirB-/- mice on the same genetic background, 
results in a similar phenotype and significantly (P< 0.01, one-way ANOVA, Tukey’s post hoc) 
impaired retention time on the rotarod (Figure 4.11b).  NgR1-/-, NgR12-/-, NgR1/PirB-/-, and 
NgR12/PirB-/- mice display comparable deficits in rotarod retention time, suggesting that NgR1 
is the major contributor for this protective effect.  Importantly, no significant (P> 0.05) changes 




acrylamide (Figure 4.11a-b).  As an independent confirmation of the increased susceptibility of 
MAG-/- and NgR1-/- mice to acrylamide administration, mice were also subjected to a performance 
test on a grid apparatus, as a measure of behavioral impairment (Tillerson et al., 2003).  Mice 
were lifted by their tail and placed in the center of the apparatus, before slow inversion of the 
grid to hang the mice upside down.  Two weeks following acrylamide intoxication, NgR1-/-, 
NgR12-/-, NgR1/PirB-/-, and NgR12/PirB-/- mice all show significant (P< 0.01, one-way ANOVA, 
Tukey’s post hoc) and comparable decreases in their latency to fall from the grid apparatus 
(Figure 4.11d).  While MAG-/- mice show a trend toward a decreased latency to fall compared to 
MAG+/+ or MAG+/- controls, this difference is not significant (P> 0.05) (Figure 4.11c).   
 To identify any corresponding physiological alterations in sciatic nerve function of  mice 
treated with acrylamide, compound action potentials (CAPs) were recorded from the tibial 
branch of the sciatic nerve of adult WT, NgR1-/-, NgR2-/-, PirB-/-, and NgR12/PirB-/- mice.  All 
mice show comparable CAP recordings of myelinated axons of the tibial branch (measured at 
37°C) prior to treatment, with no differences in either conduction velocity (>15m/s) or peak 
amplitude (>2mV) (Figure 4.12a,c,e-f).  Two weeks following acrylamide administration,  
NgR2-/- and PirB-/- mice display significant (P< 0.01, one-way ANOVA, Tukey’s post hoc)  
reductions in both conduction velocity (<15m/s)  and amplitude (<2mV), comparable to the 
reductions noted in WT mice (Figure 4.12b,e-f).  NgR1-/- and NgR12/PirB-/- mice, on the other 
hand, show an even further reduction in peak amplitude (<1mV) (Figure 4.12d-f).  Thus, 
administration of acrylamide on an NgR1-/- background results in a significant decrease of CAP 
amplitude, but not conduction velocity, when compared to WT controls, suggesting that NgR1 is 




 As an in vivo readout for susceptibility to excitotoxicity, MAG+/+, MAG+/-, and MAG-/- 
mice were given intraperitoneal injections of kainic acid, which is an epileptogenic and 
neuroexcitotoxic agent that acts as an agonist for ionotropic glutamate receptors.  In this role, 
kainic acid causes severe seizures in mice and neuronal cell death in the CA1 and CA3 regions 
of the hippocampus (Jin et al., 2009; Zheng et al., 2011).  Upon kainic acid injection, mouse 
seizure activity was recorded and then quantitatively scored on a 0-7 scale (Liu et al., 1999) for a 
period of seven hours.  The seizure onset time is decreased in MAG-/- animals, and the severity 
and duration of the seizures is greatly increased compared to MAG+/+ and MAG+/- mice (Figure 
4.13a-b), as previously reported (Nguyen et al., 2009).   MAG-/- animals reach higher seizure 
scores, including a 20% fatality rate, which is seen throughout the entire period of analysis.   
 Notably, NgR1-/- mice show an even greater response to kainic acid injection, with 
significantly (P< 0.01, one-way ANOVA, Tukey’s post hoc) higher seizure scores, a 50% 
fatality rate, a decreased seizure onset time, and a longer duration of seizure activity compared to 
WT controls on the same background (Figure 4.13c-d).  While NgR2-/- and PirB-/- mice show 
comparable seizure activity to WT controls, NgR12-/-, NgR1/PirB-/-, and NgR12/PirB-/- mice 
display similar activity to NgR1-/- mice.  These results are further supported by 
electroencephalogram (EEG) recordings performed on NgR1-/- and WT control mice.  Following 
kainic acid injection, the latency until the first sign of abnormal activity is decreased by more 
than half in NgR1-/- animals when compared to WT controls (average of 6 minutes vs. 16 
minutes), with NgR1-/- mice displaying synchronized, high-voltage, fast-spiking, generalized 
seizures much earlier than WT mice (average of 18 minutes vs. 43 minutes; Figure 4.13e).  
Interestingly, baseline EEG recordings (no kainic acid administration) reveal that NgR1-/- 




than WT controls (up to 11 discharges per hour vs. up to 1 discharge per hour; Figure 4.13f).  In 
NgR1-/- animals, but not WT controls, these discharges are often associated with myoclonic jerks, 
suggesting a general level of hyperexcitability in NgR1-/- mice. 
 
MAG antagonizes the PI3K-AKT-mTOR pathway to confer neurite outgrowth inhibition 
 Because MAG utilizes distinct receptors to mediate growth-inhibitory vs. protective 
responses, we examined whether this is also true for the downstream signaling pathways that are 
activated by MAG.  The PI3K-AKT-mTOR pathway is negatively regulated by a number of 
growth-inhibitory ligands and receptors, including myelin-associated inhibitors (Fujita et al., 
2011; Nie et al., 2010; Oinuma et al., 2010; Perdigoto et al., 2011; Raiker et al., 2010).  To 
examine whether acute treatment of primary neurons with MAG leads to regulation of PI3K-
AKT-mTOR, primary mouse CGNs were cultured for 14 days, followed by treatment with either 
AP-Fc or MAG-Fc for 30 minutes before cell lysis.  Strikingly, MAG-Fc treatment results in a 
substantial decrease of both phospho (p)-AKT (Ser473) and p-p70 S6 kinase (Thr389), but not p-
p44/42 ERK1/2 (Thr202/Tyr204), levels (Figure 4.14a).  This suggests that MAG is indeed 
suppressing the PI3K-AKT-mTOR pathway in cultured primary neurons.  To understand the 
functional relevance of MAG-mediated regulation of this pathway, primary CGNs were 
transfected with a siRNA construct targeting phosphatase and tensin homolog (PTEN), a 
negative regulator of PI3K, and subsequently analyzed for neurite outgrowth on CHO or MAG-
CHO feeder layers.  While knockdown of PTEN does not alter CGN growth on control CHO 
cells, it significantly (P< 0.01, one-way ANOVA, Tukey’s post hoc), but only partially, releases 
MAG-CHO-mediated growth inhibition (Figure 4.14b).  This effect depends on the mammalian 




release of growth inhibition.  As expected, transfection of CGNs with PTEN siRNA does reduce 
PTEN levels and increases p-p70 S6 kinase (Thr389) levels, a hallmark of increased mTOR 
activity (Figure 4.14c).  Importantly, treatment of CGNs with rapamycin strongly reduces the 
levels of p-p70 S6 kinase below baseline.   
 Because knockdown of PTEN influences a wide spectrum of downstream signaling 
pathways and is not specific to regulation of mTOR, we repeated our neurite outgrowth assay 
using a constitutively active form of the GTPase Rheb1 (CA Rheb1), which remains in its GTP-
bound state and drives sustained levels of mTOR and p-p70 S6 kinase (Figure 4.15b; Henry et 
al., 2012).  Similar to knockdown of PTEN, transfection of CGNs with CA Rheb1 significantly 
(P< 0.01, one-way ANOVA, Tukey’s post hoc) releases MAG inhibition in a rapamycin-
sensitive manner (Figure 4.15a).  Thus, the growth-inhibitory activity of MAG depends on the 
negative regulation of the PI3K-AKT-mTOR pathway.  To test if the same is true for MAG-
mediated protection from excitotoxicty, primary mouse hippocampal neurons, transfected with 
either PTEN siRNA or CA Rheb 1, were subjected to kainic acid treatment in the presence of 
AP-Fc or MAG-Fc.  While knockdown of PTEN alone or treatment with MAG-Fc alone both 
reduce the levels of kainic acid-induced cell death to a similar degree, there is no additive effect 
(Figure 4.15c).  Furthermore, despite being actively expressed in hippocampal neurons (Henry 
et al., 2012; data not shown), CA Rheb 1 has no effect on kainic acid-induced cell death under 
any of the conditions tested (Figure 4.15d).  As the reduction of cell death with PTEN 
knockdown is not sensitive to rapamycin treatment (Figure 4.15c) and CA Rheb 1 expression 
does not alter cell death levels (Figure 4.15d), it is likely that mTOR-independent pathways that 
are downstream of PI3K (and are not regulated by MAG) have protective activity (Asomugha et 




regulation of the PI3K-AKT-mTOR pathway by MAG is important for its growth-inhibitory, but 
not protective, function. 
 We next wanted to explore the mechanism by which MAG negatively regulates the 
PI3K-AKT-mTOR pathway in primary neurons.  Studies in non-neuronal cells have shown that 
PTEN is directly phosphorylated and activated by ROCK (Li et al., 2005).  It is well established 
that ROCK and its small GTPase activator, RhoA, are converging points for the majority of 
growth inhibitors, and that blockade of ROCK with a pharmalogical inhibitor, Y-27632, releases 
myelin-induced growth inhibition (McKerracher et al., 2012; Tonges et al., 2011).  We thus 
hypothesized that inhibition of mTOR activity will prevent the release of MAG-mediated growth 
inhibition seen with Y-27632 treatment in primary neurons.  Indeed, primary mouse CGNs are 
strongly inhibited on MAG-CHO feeder layers, an effect that is partially reversed in the presence 
of Y-27632 (Figure 4.16).  Concurrent treatment of CGNs with Y-27632 and rapamycin, 
however, completely blocks this reversal of MAG inhibition, suggesting a potential mechanism 
for MAG-mediated growth inhibition that involves the downstream activation of ROCK, which 
directly stimulates PTEN and thus negatively regulates PI3K-AKT-mTOR. 
 
MAG prevents calpain-induced cleavage of the cytoskeleton in an NgR1-dependent manner 
 In an effort to identify downstream components regulated by MAG in the context of 
protection during axonal degeneration and excitotoxicity, proteins known to be involved in both 
processes were investigated.  Of particular interest is the intracellular cysteine protease, calpain, 
which is activated by increased intracellular calcium levels and has the ability to cleave a number 
of substrates, including α-fodrin/spectrin (Nath et al., 1996), tubulin (Billger et al., 1988), 




and p35 (Patrick et al., 1999).  Calpain has been shown to mediate vincristine-induced axonal 
degeneration (Wang et al., 2000) and excitotoxic cell death in response to kainate receptor 
activation (Sanchez-Gomez et al., 2011).  Additionally, inhibition of calpains has been linked to 
neuronal protection from injury-induced death in vitro and in vivo (McKernan et al., 2007; Ryu 
et al., 2012).  To test whether calpain activity is altered in the presence of MAG, primary mouse 
hippocampal neurons were cultured for 14 days, pretreated with either Siglec-3-Fc or MAG-Fc 
for 30 minutes, and then subjected to kainic acid for 4 hours before cell lysis.  As expected, the 
cleavage product of a known calpain substrate and component of the cytoskeleton, α-fodrin, is 
substantially increased when treated with kainic acid (Figure 4.17a-b).  In the presence of 
MAG-Fc, however, cleavage of α-fodrin is largely abrogated, with a corresponding increase in 
the larger, unprocessed form.  Importantly, kainic acid-induced, α-fodrin cleavage is mostly 
prevented with pretreatment of the neurons with PD150606, a cell-permeable, non-competitive 
calpain inhibitor (Figure 4.17b), suggesting that MAG prevents α-fodrin cleavage by inhibiting 
the activity of calpain.  In addition, pretreatment of the neurons with the ROCK inhibitor          
Y-27632 does not alter MAG-mediated prevention of α-fodrin cleavage (Figure 4.17b).  Thus, 
while ROCK is necessary for MAG-mediated protection from axonal degeneration and 
excitotoxicity (Figure 4.17c-d; Lopez et al., 2011; Mehta et al., 2010), it is likely not acting by 
inhibiting calpain activity.  Similar results were obtained when vincristine sulfate was used to 
induce degeneration in these cultures (data not shown). 
 To determine which high-affinity receptor is critical for MAG-mediated prevention of 
cytoskeletal breakdown, the assay was repeated in NgR1-/-, NgR2-/-, PirB-/-, NgR12-/-,   
NgR1/PirB-/-, NgR2/PirB-/- and NgR12/PirB-/- hippocampal neurons.  Strikingly, cleavage of      




NgR12/PirB-/- neurons are used (Figure 4.17a), suggesting that a MAG-NgR1 pathway is 
responsible for inhibiting calpain activity in the presence of toxic insults.  While it remains to be 
tested if MAG inhibition of calpain activity is responsible for MAG-mediated protection from 
axonal degeneration and excitotoxicity, inhibition of calpain does significantly (P< 0.01, one-
way ANOVA, Tukey’s post hoc) reduce axonal degeneration and excitotoxic cell death to a 
similar degree as treatment with MAG-Fc, with no additive effect when MAG-Fc treatment and 
calpain inhibition are combined (Figure 4.17c-d).  As expected, inhibition of calpain has no 
effect on the ability of MAG to inhibit neurite outgrowth (data not shown).  
 
4.4 Discussion 
 In this study, we show that the growth-inhibitory and neuroprotective activities of MAG 
can be dissociated (Figure 4.18).  The neuroprotective activity resides within the N-terminal and 
the growth-inhibitory activity within the C-terminal portion of the MAG ectodomain.  Moreover, 
MAG-mediated neurite outgrowth inhibition of CGNs and RGCs depends, at least in part, on the 
presence of PirB and LRP1, but is independent of NgR1 and NgR2.  The neuroprotective 
function of MAG in hippocampal and DRG neurons is mediated by NgR1 and independent of 
NgR2, PirB, and LRP1.  Biochemical studies further reveal that MAG blocks activation of 
calpains and that direct inhibition of calpains mimics the MAG neuroprotective function toward 
acrylamide or vincristine.  Together these studies provide novel mechanistic insights into how 
MAG exerts neuroprotection and suggest that the growth-inhibitory and protective activity of 
MAG can be targeted separately for therapeutic applications following nervous system injury or 





MAG employs multiple receptors in a cell type-specific manner to inhibit neurite 
outgrowth 
 While there are a relatively small number of CNS growth-inhibitory ligands, it is 
becoming abundantly clear that their neuronal cell surface receptors are far more diverse and 
complex (Akbik et al., 2012; Fawcett et al., 2012).  MAG is known to participate in high-affinity 
interactions with NgR1, NgR2, PirB, and LRP1 (Atwal et al., 2008; Domeniconi et al., 2002; Liu 
et al., 2002; Stiles et al., 2013; Venkatesh et al., 2005); thus, we set out to explore which of these 
receptors mediate the growth-inhibitory function of MAG in cultures of primary mouse neurons.  
In CGNs and RGCs, the loss of PirB or LRP1 partially releases MAG inhibition, whereas in 
cortical and hippocampal neurons, only LRP1 plays a substantial role.  To our surprise, the loss 
of these receptors has no effect on MAG-mediated growth inhibition of DRG neurons.  These 
results support the growing notion that inhibitory ligands utilize multiple receptor complexes to 
signal inhibition, depending on the cell type (Mehta et al., 2007; Perdigoto et al., 2011; 
Venkatesh et al., 2007).  Our neurite outgrowth inhibition assays also reveal a limited role for 
members of the Nogo receptor family in longitudinal outgrowth inhibition by membrane-bound 
MAG.  This is consistent with previous reports (Chivatakarn et al., 2007; Venkatesh et al., 2007) 
that suggest a role for NgR1 in MAG-induced growth cone collapse but not inhibition of neurite 
extension, implying distinct receptor mechanisms for these two actions.  
 Because total release of MAG inhibition is not achieved with the loss of any receptor, and 
DRG neurons remain completely inhibited under all conditions, it is likely that (1) a substantial 
degree of functional redundancy exists between MAG receptors (Atwal et al., 2008; Venkatesh 
et al., 2007; Worter et al., 2009), and/or (2) additional MAG receptors have yet to be identified.  




(Mehta et al., 2007; Vyas et al., 2002), it is possible that the continued MAG-ganglioside 
relationship in our neuronal cultures prevents a total release of MAG inhibition.  It is also 
possible that there is an additive effect with deletion of multiple MAG receptors, as might be the 
case with the combined loss of PirB and LRP1 in CGNs and RGCs.  Still, structure/function 
analysis of MAG has demonstrated that Ig-like domain 5 is sufficient to convey growth 
inhibition (Cao et al., 2007; Robak et al., 2009), whereas NgR1, NgR2, gangliosides, and β1-
integrin all bind to Ig-like domains 1-3 (Goh et al., 2008; Robak et al., 2009; Vinson et al., 
2001).  Furthermore, we have found that PirB and LRP1 bind to MAG Ig-like domains 1-3 
(unpublished observations), implying the existence of a novel, neuronal binding partner for the 
MAG inhibitory site located in Ig-like domain 5.  Studies are currently underway to use MAG 
Ig1-5-, MAG Ig1-3-, and MAG Ig3-5-CHO cell lines as molecular handles to co-
immunoprecipitate, identify, and characterize novel MAG interactors.  
 
A novel, protective role for NgR1 in degeneration and excitotoxicity 
 In stark contrast to growth inhibition, MAG-mediated protection from axonal 
degeneration and neuronal excitotoxicity is conferred through Ig-like domains 1-3 and dependent 
on NgR1, but not NgR2, PirB, or LRP1.  Compared to controls, MAG-/- and NgR1-/- mice both 
show worsened performances on the rotarod when subjected to acrylamide intoxication and 
higher seizure scores when given injections of kainic acid.  However, NgR1-/- mice develop even 
greater deficiencies than MAG-/- mice when analyzed on the grid apparatus and higher fatality 
rates when seizures are induced.  Unfortunately, a direct comparison between MAG-/- and NgR1-/- 
mice cannot be made due to the fact that the mice are on different genetic backgrounds, an 




if MAG/NgR1-/- mice display a more severe phenotype than MAG-/- mice, it is tempting to 
speculate that other NgR1 ligands, such as Nogo66, OMgp, or chondroitin sulfate proteoglycans 
(CSPGs) (Dickendesher et al., 2012; Fournier et al., 2001; Wang et al., 2002), also mediate 
protection.  Indeed, Nogo and CSPGs have already been implicated in protection from toxin-
induced cell death (Okamoto et al., 1994a; Okamoto et al., 1994b; Teng and Tang, 2013).  
 
Distinct downstream signaling components for MAG growth inhibition vs. neuroprotection 
 Genetic manipulations that lead to increased mTOR activation, such as deletion of PTEN, 
are known to promote robust axon regeneration in both the injured optic nerve and spinal cord 
(Liu et al., 2010; Park et al., 2008).  It is thus believed that the PI3K-AKT-mTOR pathway is a 
key regulator of a “dormant” neuron intrinsic growth program in the adult mammalian CNS, but 
how this pathway itself is regulated upon injury is still not well understood.  Recent reports have 
shown that ephrins, semaphorins, and MAIs negatively regulate the PI3K-AKT-mTOR pathway 
to inhibit neurite outgrowth (Nie et al., 2010; Oinuma et al., 2010; Perdigoto et al., 2011).  More 
generally, MAIs and their receptors have the ability to antagonize the signaling pathways 
(including PI3K-AKT-mTOR) that are activated by growth factors (Fujita et al., 2011; Raiker et 
al., 2010), suggesting a pro-/anti-growth balancing act between these opposing protein systems.   
 Here we show that MAG reduces mTOR activation in primary neurons, and that 
increasing mTOR activity can partially override MAG-mediated growth inhibition, but not 
MAG-mediated protection from toxic insult.  Additionally, we provide evidence for the first time 
of a functional link between mTOR and the RhoA/ROCK pathway in cultured neurons.  As 
virtually all CNS growth inhibitors signal via RhoA/ROCK, and PTEN is known to be activated 




inhibitors negatively regulate the PI3K-AKT-mTOR pathway by means of their activation of 
ROCK, which directly activates PTEN.  Given that inhibition of ROCK, but not activation of 
mTOR, attenuates MAG-induced protection, it is probable that additional ROCK targets beyond 
PTEN are involved.  Future studies in primary neurons will need to be performed to elucidate the 
full connections and complexity of this signaling cascade. 
 We have also identified a novel role for MAG, by means of NgR1, in the prevention of 
calpain-induced cleavage of the neuronal cytoskeleton, a critical cellular response in both 
degeneration and excitotoxicity (Sanchez-Gomez et al., 2011; Wang et al., 2000; Wang et al., 
2012).  While further experiments are needed to determine if MAG protects from degeneration 
and excitotoxicity through inhibition of calpain activity, it remains a likely scenario as both 
MAG treatment and calpain inhibition (1) provide comparable levels of protection from axon 
degeneration and cell death to cultured neurons, and (2) stabilize components of the neuronal 
cytoskeleton (Dashiell et al., 2002; Lopez-Picon et al., 2006; Nguyen et al., 2009; Yin et al., 
1998).  Interestingly, vincristine-treated DRG explants in the presence of MAG show a 
substantial delay, but not a complete prevention, of axonal degeneration (Figure 4.7c), similar to 
effects noted with the Wallerian degeneration slow (WldS) transgene (Wang et al., 2012).  As 
axons isolated from the WldS mouse show resistance to calpain-mediated degradation of the 
cytoskeleton (Bernier et al., 1999), it remains an intriguing possibility that MAG- and WldS-
mediated protection are functioning through similar pathways.  
 
Implications for nervous system injury and disease 
 A wide spectrum of central and peripheral nervous system disorders (including traumatic, 




the fundamental problem of axonal degeneration and dropout.  These disorders include 
amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Guillain-Barré syndrome, and 
multiple sclerosis (Lingor et al., 2012).  Similarly, excitotoxicity-induced cell death poses a 
major clinical problem, particularly for neurodegenerative diseases such as Alzheimer’s disease, 
Huntington’s disease, and Parkinson’s disease (Dong et al., 2009).  While these disorders have a 
wide array of aetiologies and pathological diversity, it is likely that there are common molecular 
mechanisms that can be therapeutically targeted.  Because MAG is strikingly protective for 
neurons in the context of both degeneration and excitotoxicity, a better understanding of its 
receptor interactions and signaling pathways is warranted.  As with any potential therapeutic, 
however, it is crucial to examine all aspects of MAG function, in both the healthy and injured 
nervous system.   
 Here we have identified specific receptors and signaling components that mediate MAG 
growth inhibition vs. neuroprotection.  Our in vivo analysis of axon regeneration following optic 
nerve injury in MAG receptor mutants, coupled with recent regeneration studies in MAI or MAI 
receptor mutants (Cafferty et al., 2010; Fujita et al., 2011; Lee et al., 2010), suggests that 
targeting of these extrinsic inhibitors provides minimal axon growth following CNS injury.  If 
multiple inhibitory ligands or receptors are deleted, however, or if this approach is coupled with 
strategies to increase the intrinsic growth potential of the neuron, substantial growth may be 
achieved (de Lima et al., 2012; Dickendesher et al., 2012; Fischer et al., 2004; Winzeler et al., 
2011).  In this context, the growth-inhibitory function of MAG needs to be deleted while the 
protective function preserved, so as to not increase degeneration of the already injured axons.  A 
similar line of thinking needs to be applied in the context of introducing MAG or MAG receptor-




identification of distinct receptor-signaling systems for two critical MAG functions sheds light 
on fundamental pathways for nervous system injury and disease, and sets the foundation for 
future studies that will further unravel the triggers, connections, and targets of these pathways.  
 
4.5 Methods 
 Transgenic mice: All animal handling and surgical procedures were performed in 
compliance with local and national animal care guidelines, and were approved by the University 
of Michigan Committee on Use and Care of Animals (UCUCA).  LRP1f/f mice (Jackson 
Laboratory, 012604) were kindly provided by Steven L. Gonias (University of California, San 
Diego), MAG-/- mice (Li et al., 1994) were kindly provided by Ronald L. Schnaar (Johns Hopkins 
School of Medicine), NgR1-/- mice (Zheng et al., 2005) were kindly provided by Marc Tessier-
Lavigne (Rockefeller University), PirB-/- mice (Ujike et al., 2002) were kindly provided by Marc 
E. Rothenberg (Cincinnati Children's Hospital Medical Center), ROSA reporter mice (Jackson 
Laboratory, 003474) were kindly provided by Andrew P. Lieberman (University of Michigan 
Medical School), and Synapsin I-Cre mice (Jackson Laboratory, 003966)  were kindly provided 
by Geoffrey G. Murphy (University of Michigan Medical School).  NgR2-/- and NgR3-/- mice 
have been previously described (Dickendesher et al., 2012).  Mice listed above were bred 
together to generate the following genotypes: NgR12-/-, NgR123-/-, NgR1/PirB-/-, NgR2/PirB-/-, 
NgR12/PirB-/-, LRP1f/f; Synapsin I-Cre, and ROSA; Synapsin I-Cre.  For all experiments, control 
mice were of the exact same age and genetic background as mutant mice. 
 
 Neurite outgrowth assays: To assay MAG inhibition, 96-well plates were covered with 




(MAG-CHO; Mukhopadhyay et al., 1994).  CHO and MAG-CHO cells were cultured in DMEM 
(Invitrogen) with 10% dialyzed fetal bovine serum (FBS), 2mM glutamine, 40mg/L proline, 
0.73mg/L thymidine, and 7.5mg/L glycine.  After 24 hours, P7 mouse cortical neurons, 
hippocampal neurons, DRG neurons, CGNs, or RGCs (from control or mutant mice) were plated 
on top of the confluent CHO feeder layers at a density of 8,000 cells/well.  For some 
experiments, GST or GST-RAP (200nM), the ROCK inhibitor Y-27632 (15μM; Millipore), or 
rapamycin (25nM; Cell Signaling) were added to the wells at the time of plating.  Cells were 
cultured for 24 hours at 37°C in the appropriate neuronal medium (see below), and then fixed 
with 4% paraformaldehyde, blocked in 1% horse serum and 0.1% Triton X-100 in PBS, and 
stained with anti-class III β-tubulin (TuJ1; Promega).  Alexa Fluor-conjugated secondary 
antibodies (Invitrogen) were used for fluorescent labeling, and images were taken using an 
inverted microscope (IX71; Olympus) attached to a digital camera (DP72; Olympus).  To 
quantify neurite outgrowth, UTHSCSA ImageTool for Windows was used, and processes equal 
or longer to one cell body diameter were measured.   
 Primary neurons were isolated as follows: (1) P7 mouse cerebral cortex or hippocampus 
(with meninges removed) was dissected in Neurobasal medium (Invitrogen) on ice, trypsinized 
for 15 minutes and gently washed/triturated, and resuspended in Neurobasal medium with B-
27® supplement (Invitrogen), glutamine, and penicillin/streptomycin.  (2) P7 mouse DRG 
neurons were dissected, incubated in 0.05% trypsin and 0.1% collagenase for 40 minutes, and 
triturated before resuspension in Neurobasal medium with B-27® supplement, glutamine, 
penicillin/streptomycin, and 15ng/ml nerve growth factor (Venkatesh et al., 2005).  (3) P7 mouse 
cerebellum was dissected, trypsinized for 15 minutes/triturated, and CGNs were purified in a 




supplement, glutamine, glucose, and penicillin/streptomycin (Venkatesh et al., 2005).  (4) P7 
mouse retina was dissected, digested in papain (MP Biomedicals) for 30 minutes, washed, and 
plated onto 60mm culture dishes (Corning) that were precoated with goat anti-mouse IgM 
(Millipore) and anti-Thy1.2 (Sigma).  After 1 hour at room temperature, unbound cells were 
removed by several rinses in PBS, and bound cells were lifted using 0.125% trypsin/EDTA, 
washed, and resuspended in Neurobasal medium with B-27® supplement, glutamine, glucose, 
and penicillin/streptomycin (Venkatesh et al., 2007).   
 
 In vitro degeneration and excitotoxicity assays: To assess levels of axonal 
degeneration, 96-well plates were coated with poly-D-lysine hydrobromide (50μg/ml; Sigma) 
overnight, rinsed in water, and air dried.  P7 mouse DRG explants (from control or mutant mice)  
were then dissected and placed in the middle of each well (1 explant per well) in a minimal 
amount of medium (Neurobasal medium with B-27® supplement, glutamine, 
penicillin/streptomycin, and 15ng/ml nerve growth factor), allowing the explants to attach.  After 
an overnight incubation at 37°C, additional medium was added to the wells, and the explants 
were allowed to extend neurites for 7 days.  Some explants were then treated with 50nM 
vincristine sulfate (Sigma), as well as 50nM preclustered AP-Fc, Siglec-3-Fc, MAG-Fc, MAG 
Ig1-5-Fc, MAG Ig1-3-Fc, or MAG Ig3-5-Fc fusion proteins (Dickendesher et al., 2012; Robak et 
al., 2009), for 12-96 hours before all explants were fixed/stained for TuJ1/imaged as described 
above.  For certain experiments, explants were treated with the ROCK inhibitor Y-27632 (15μM) 
or the membrane-permeable calpain inhibitor, PD150606 (10μM; Sigma).  The percentage of 





 To assess levels of excitotoxicity-induced cell death, P7 mouse hippocampal neurons 
(from control or mutant mice) were cultured on poly-D-lysine hydrobromide-coated plates 
(50μg/ml) for 4 days at 37°C, in Neurobasal medium with B-27® supplement (Invitrogen), 
glutamine, and penicillin/streptomycin.  Some neurons were then treated with 200μM kainic acid 
(A.G. Scientific), as well as 50nM preclustered AP-Fc, Siglec-3-Fc, MAG-Fc, MAG Ig1-5-Fc, 
MAG Ig1-3-Fc, or MAG Ig3-5-Fc fusion proteins, for 12-96 hours.  For certain experiments, 
neurons were treated with Y-27632 (15μM) or PD150606 (10μM).  Medium from all cultures 
was then replaced with fresh medium containing 10μg/ml propidium iodide (Invitrogen) for 40 
minutes, and neurons were fixed/stained for TuJ1/imaged as described above.  The percentage of 
live cells (positive for TuJ1, negative for propidium iodide) was determined for each condition.  
For some experiments, neurons were cultured for 2 days on feeder layers of CHO cell lines (see 
below), as opposed to poly-D-lysine-coated plates.  These cultures did not receive treatment with 
Fc-fusion proteins. 
 
 Gene silencing/overexpression: To silence LRP1, LRP1f/f neurons/explants were 
cultured on poly-D-lysine hydrobromide-coated plates (50μg/ml) for 1 day (for neurite 
outgrowth assays, excitotoxicity assays) or 4 days (for degeneration assays) before transduction 
with either herpes simplex virus-1 (HSV-1)-GFP or HSV-1-GFP-Cre (Viral Gene Transfer Core, 
McGovern Institute for Brain Research, MIT).  Virus was removed 2 days post-transduction and, 
at 3 days post-transduction, one group of neurons/explants were lysed in 2X SDS sample buffer 
and subjected to immunoblotting with anti-LRP1 (Sigma) and anti-TuJ1 to confirm Cre-
mediated deletion of LRP1 (data not shown; also performed in Stiles et al., 2013).  A second 




while a third group of neurons were gently dislodged using CellstripperTM non-enzymatic cell 
dissociation solution (Corning) and re-plated on CHO or MAG-CHO cells for 24 hours (see 
above). 
 For knockdown of PTEN, CGNs or hippocampal neurons were transfected with siRNA 
targeted against mouse PTEN (siGENOME SMARTpool; Thermo Scientific) or with non-
targeting control siRNA (Thermo Scientific), using the Amaxa NucelofectorTM Kit for mouse 
neurons, according to the manufacturer’s instructions.  Transfected neurons were grown for 3 
days before (1) being lysed with 2X SDS sample buffer and subjected to immunoblotting with 
anti-PTEN (Cell Signaling), anti-p-p70 S6 kinase (Thr389; Cell Signaling), and anti-β-actin 
(Sigma) to confirm knockdown of PTEN and its activity, (2) being subjected to excitotoxicity 
assays (see above), or (3) being dislodged by CellstripperTM (Corning) and re-plated on CHO or 
MAG-CHO cells for 24 hours (see above).  Overexpression of Rheb1 was achieved in a similar 
manner, using either a plasmid containing a constitutively active form of Rheb1 (RhebQ64L; 
Henry et al., 2012) or a control plasmid containing GFP.  Immunoblotting was performed using 
anti-p-p70 S6 kinase (Thr389; Cell Signaling), and anti-β-actin to confirm Rheb1 activity.  All 
immunoblots were quantified by densitometric analysis (using ImageJ software - from a total of 
4 independent experiments), normalized to β-actin levels, and graphed as a percentage of the 
control. 
 
 Construction of cell lines: Standard PCR cloning using the Tth-DNA polymerase 
(Applied Biosystems) was performed to produce the following structural variants of rat MAG: 
MAG Ig1-5, MAG Ig1-3, and MAG Ig3-5.  Specifically, MAG Ig1-5 was created by amplifying 




MAG Ig1-3, the region from S17 until the end of Ig-like domain 3 (A325) was fused to the 
beginning of the transmembrane domain (K513) until K626.  For MAG Ig3-5, the region from 
the beginning of Ig-like domain 3 (L234) until K626 was amplified.  KpnI and BamHI restriction 
sites were introduced at the beginning and the end, respectively, of all variants to allow cloning 
into the multiple cloning site of the pSecTag2A vector (Invitrogen).  This vector allows proteins 
to receive the murine Ig κ-chain leader sequence at the N-terminus and the c-myc epitope and six 
tandem histidine residues (6HIS) at the C-terminus.  Following successful cloning into 
pSecTag2A, all MAG variants (with the Ig κ-chain leader sequence, c-myc epitope, and 6HIS 
residues included) were cloned into the pIRES2-EGFP vector (BD Biosciences) by introducing 
SacII and XmaI restriction sites.   
 After sequencing analysis, CHO cells were then transfected with these plasmids, using 
Lipofectamine® 2000 (Invitrogen), and multiple treatments with 400µg/ml of G418 sulfate 
(Invitrogen) were performed to select for stably-transfected cells.  To generate clonal cells, 
individual, EGFP-positive cells were picked and cultured in DMEM with 10% FBS, 2mM 
glutamine, 40mg/L proline, 0.73mg/L thymidine, and 7.5mg/L glycine.  This process was 
repeated several times to obtain ~95% clonal purity.  Fluorescence-activated cell sorting (FACS) 
was then performed on all cell lines, using anti-MAG, clone 513 (Millipore) for MAG Ig1-5-
CHO and MAG Ig1-3-CHO cell lines, or anti-MAG, extracellular (a generous gift from James L. 
Salzer) for MAG Ig3-5-CHO cell lines.  The top 3% of MAG-expressing cells for each cell line 
were collected, expanded, and continually maintained with 200µg/ml of G418 sulfate.  To 
confirm successful MAG expression and proper molecular weight of all MAG variants, the 
newly created CHO cell lines were lysed with 2X SDS sample buffer and subjected to 




expression of MAG was verified by immunostaining (without Triton X-100) with anti-MAG, 
clone 513 for MAG Ig1-5-CHO and MAG Ig1-3-CHO cell lines, or anti-MAG, extracellular for 
MAG Ig3-5-CHO cell lines.  To check the functionality of all cell lines, neurite outgrowth assays 
with P7 mouse hippocampal neurons were performed (see above). 
 
 Optic nerve injury: Adult mice (control or mutant; 6-8 weeks of age) were anesthetized 
with an intraperitoneal injection of Ketamine (100mg/kg; Fort Dodge Animal Health) and 
Xylazine (10mg/kg; Akorn, Inc.).  Without damaging the ophthalmic artery, the optic nerve was 
exposed and compressed for 10 seconds with angle jeweler’s forceps (Dumont #5; Fine Science 
Tools) at approximately 1mm behind the eyeball.  For intravitreal injection of Zymosan, 5µl of a 
suspension (12.5μg/μl in sterile PBS; Sigma) was injected using a Hamilton syringe with a 30 
gauge removable needle.  Following surgery, eyes were rinsed with sterile PBS and ophthalmic 
ointment was applied (Butler AHS).  All surgeries were performed under aseptic conditions 
(Dickendesher et al., 2012).  For deletion of LRP1 in LRP1f/f mouse RGCs, 2µl of AAV2-GFP 
(Vector Biolabs) was injected into the left eye and 2µl of AAV2-GFP-Cre (Vector Biolabs) was 
injected into the right eye, 14 days prior to optic nerve injury.   
 14 days following optic nerve injury, mice were given a lethal dose of anesthesia and 
perfused with PBS/4% paraformaldehyde.  Eyes with optic nerves attached were dissected, post-
fixed overnight at 4°C, and cryoprotected in 30% sucrose.  Optic nerves were then embedded in 
OCT Tissue-Tek Medium (Sakura Finetek) and 14μm longitudinal sections were stained with 
anti-GAP-43 (a generous gift from Larry I. Benowitz).  Alexa Fluor-conjugated secondary 
antibodies were used for fluorescent labeling, slides were mounted with Fluoromount-GTM 




positive axons at prespecified distances from the injury site was counted in at least 3 sections per 
nerve.  These numbers were converted into the number of regenerating axons per nerve as 
previously described (Fischer et al., 2004).   
 
 Histochemical studies: To evaluate expression levels of Cre recombinase under the 
Synapsin I promoter, 3-week-old ROSA; Synapsin I-Cre mice were perfused with PBS/4% 
paraformaldehyde, and the following tissues were dissected, post-fixed (overnight), and 
cryoprotected: eye, brain, spinal cord, and DRGs.  Tissues were embedded and cryosectioned 
(20μm sections), and slides were washed for 15 minutes with PBS + 0.02% NP-40 (repeated two 
additional times).  Stain solution [5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 2mM MgCl2, 0.01% 
sodium deoxycholate, 0.02% NP-40, and 1mg/ml X-Gal (Sigma) in PBS] was added to the slides 
for an overnight incubation at room temperature.  Slides were then post-fixed in 4% 
paraformaldehyde for 20 minutes, washed, and mounted with Fluoromount-GTM before imaging.  
For expression analysis of AAV2-GFP-Cre, 6-week-old ROSA reporter mice received 
intravitreal injections of AAV2-GFP in the left eye and AAV2-GFP-Cre in the right eye.  14 
days later, mice were perfused and retina was stained with X-Gal as described above. 
 To confirm successful injection of AAV2-GFP and AAV2-GFP-Cre into LRP1f/f mice, 
these mice were perfused with PBS/4% paraformaldehyde at 14 days post-injection.  Eyes were 
removed and post-fixed overnight at 4°C, and retinal “cups” were dissected out and fixed in 4% 
paraformaldehyde for 30 minutes at 4°C.  Retinas were washed with PBS, blocked in 10% goat 
serum and 0.2% Triton X-100 for 1 hour, incubated with primary antibodies (anti-GFP, 
Invitrogen; anti-TuJ1) for 1-2 days at 4°C, and washed with PBS.  Following overnight 




of washing, retinas were mounted onto slides for imaging.  Transduction efficiency was 
calculated as the percentage of GFP/TuJ1-double positive cells, divided by the total number of 
TuJ1-positive cells.   
   
 Biochemical analysis: P7 mouse CGNs were cultured at a high density (800,000 
cells/well) on poly-D-lysine hydrobromide-coated (50μg/ml), 6-well plates.  After 14 days of 
growth in Neurobasal medium with B-27® supplement, glutamine, glucose, and 
penicillin/streptomycin medium, cultures were treated for 30 minutes with 50nM of preclustered 
AP-Fc or MAG-Fc in OptiMEM (Invitrogen).  Cells were lysed for 30 minutes on ice using Brij 
lysis buffer (10mM potassium phosphate, pH 7.2; 1mM EDTA; 10mM magnesium chloride; 
50mM β-glycerophosphate; 0.5% NP-40; 0.1% Brij® 35; 1mM Na3V04; and 1:100 protease 
inhibitor cocktail - Sigma), followed by centrifugation at 4°C (Raiker et al., 2010).  Supernatants 
were collected and protein concentration was determined using the BCA Protein Assay Kit 
(Thermo Scientific).  For immunoblot analysis, 10μg of protein lysate was loaded, separated by 
SDS-PAGE, transferred onto nitrocellulose membranes, and probed for p-AKT (Ser473; Cell 
Signaling), total AKT (Cell Signaling), p-p70 S6 kinase (Thr389; Cell Signaling), total p70 S6 
kinase (Cell Signaling), p-p44/42 ERK1/2 (Thr202/Tyr204; Cell Signaling), total p44/42 
ERK1/2 (Cell Signaling), and anti-β-actin (Sigma).  This experiment was repeated four times, 
with both treatments performed in duplicate for each experiment.   
 To assess levels of calpain activation, P7 mouse hippocampal neurons (from control or 
mutant mice) were cultured in a similar fashion for 14 days, followed by pretreatment for 30 
minutes with 50nM of preclustered Siglec-3-Fc or MAG-Fc, with or without Y-27632 (15μM) or 




for 4 hours, and then all cells were lysed and subjected to immunblotting as mentioned above.  
Membranes were probed for α-fodrin (Enzo Life Sciences) and TuJ1.  Results were confirmed 
from 3-5 independent experiments, depending on the conditions.  
 To confirm reduction of LRP1 in LRP1f/f mice with AAV2-GFP-Cre (but not AAV2-
GFP) injection, retinas were dissected from these mice at 14 days post-injection.  Retinas were 
lysed (on ice) in RIPA Buffer (Sigma) with 1mM Na3V04 and 1:100 protease inhibitor cocktail 
for 30 minutes, followed by centrifugation at 4°C and supernatant collection.  For immunoblot 
analysis, 10μg of lysate was loaded, and blots were probed for LRP1 and β-actin.  Quantification 
of relative protein levels was determined by densitometric analysis (using ImageJ software - 
from a total of 4 independent experiments), normalized to β-actin levels, and graphed as a 
percentage of the AAV2-GFP control.  
 
 Rotarod/grid apparatus performance: Adult mice (control or mutant; 6-8 weeks of 
age) were trained for 3 consecutive days (1 trial per day) on an accelerating rotarod (Ugo Basile), 
using a protocol that starts at 1 rotation per 38 seconds and ends at 1 rotation per 2 seconds.  On 
the fourth day, the rotarod performance was recorded and mice began to receive acrylamide (400 
parts per million; Sigma) in their drinking water for 2 weeks.  11 days into the treatment, mice 
were trained on the rotarod for another 3 days (1 trial per day), and the performance was 
recorded on the fourth day (14 days into acrylamide treatment).  For all rotarod experiments, the 
retention time before falling (in seconds) was measured, beginning at the start of the 
acceleration.  A “fall” was considered either (1) an actual fall from the accelerating rod, or (2) a 




 In a separate set of experiments, adult mice (control or mutant; 6-8 weeks of age) were 
tested for 1 day (3 trials - spaced 2 hours apart) on a grid apparatus (Tillerson et al., 2003), 
before receiving 2 weeks of acrylamide treatment.  14 days into the treatment, mice were again 
tested.  To perform the test, a mouse was lifted by its tail and placed in the center of the 
apparatus.  Once the mouse comfortably gripped the horizontal grid mesh, the apparatus was 
slowly inverted, thus hanging the mouse upside down.  At this point, the latency of the mouse to 
fall from the apparatus (in seconds) was measured.  Importantly, the apparatus was constructed 
to the specifications of the original study (Tillerson et al., 2003).  For all rotarod and grid 
apparatus experiments, the tester was blind to the genotypes. 
 
 Electrophysiology: 6-8-week-old mice (control or mutant; with or without 2 weeks of 
acrylamide treatment) were killed by CO2 inhalation.  Both sciatic nerves were dissected on ice 
and immediately transferred to a temperature-controlled recording chamber held at 37 ± 0.4°C, 
with oxygenated artificial CSF (ACSF).  Nerves less than 10mm in length were not used.  ACSF 
contains the following: 125mM NaCl, 1.25mM NaH2PO4, 25mM glucose, 25mM NaHCO3, 
2.5mM CaCl2, 1.3mM MgCl2, and 2.5mM KCl (saturated with 95% O2/5% CO2).  Each end of 
the nerve was drawn into the tip of a suction pipette electrode.  The stimulating electrode was 
connected to a constant-current stimulus isolation unit (WPI) driven by AxonTM pClamp® 10.3 
software, and a stimulating pulse (50µs) was applied to the proximal (toward the spinal cord) end 
of the nerve.  The recording electrode was applied to the distal (tibial branch) end of the nerve 
and connected to the input of a differential alternating current amplifier (custom-made).  In 
addition, the other amplifier input was connected to a pipette that was placed near the recording 




artifact from the recordings.  Signals were sampled at 100 kHz and fed into the data acquisition 
system (AxonTM Digidata 1440A, AxonTM pClamp® 10.3).  All recordings were done blind to 
the genotype.  
 The resistance of the recording pipette was measured before (R1) and after (R2) the nerve 
was inserted.  Similar to CAP area (Stys et al., 1991), we have found that CAP amplitude is a 
linear function of R2.  We have also determined that the amplitude of the signal is independent 
of the glass pipette used (to within ~5%) if the CAP is measured with the ratio R2/R1 constant.  
Therefore, in order to normalize the data, all amplitude measurements were made with 
R2/R1=1.7.  Data analysis was performed using Clampfit software, with conduction velocity 
taken as the length of the nerve divided by the time-to-peak.  
 
 Kainic acid-induced seizures/electroencephalogram recordings: Adult mice (control 
or mutant; 6-8 weeks of age) were given an intraperitoneal injection of kainic acid (25mg/kg in 
PBS) and were monitored for 7 hours, in order to assess their seizure onset/duration and seizure 
severity score.  Seizure severity scores are based upon a 0-7 scale (Liu et al., 1999), and can be 
summarized as follows: (0) normal behavior; (1) exploring, sniffing, and grooming have ceased 
and the animal is motionless; (2) forelimb and/or tail extension, giving the appearance of a rigid 
posture; (3) myoclonic jerks of the head and neck, with brief twitching or repetitive movements; 
(4) forelimb clonus and partial rearing; (5) forelimb clonus, rearing, and falling; (6) generalized 
tonic-clonic activity; and (7) death.  For all experiments, the tester was blind to the genotypes.  
 For EEG recordings, six electrodes were properly positioned (two frontal electrodes, two 
parietal electrodes, one ground electrode, and one reference electrode) using a mounting screw 




electrode holder, and a head cap was made using dental cement.  After a recovery period of 5 
days, mice were recorded using EEG hardware (Bio-Logic) for 48 hours to obtain baseline 
activity.  Following an intraperitoneal injection of kainic acid (15mg/kg in PBS), mice were 
recorded for an additional 24 hours (or until death).  Recordings were sampled at 400 Hz and 
filtered at 1Hz (high-pass)/70Hz (low-pass).  Concurrent video was obtained and analyzed 
together with the EEG recordings by an observer blind to the genotypes. 
 
 Statistical analysis: With the exception of Figure 4.6d (unpaired t-test), data were 
analyzed using one-way analysis of variance followed by Tukey’s post hoc comparisons.  All 
statistics were performed using SigmaStat 3.5 for Windows (Systat Software), and P< 0.01 was 
considered significant.   
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Figure 4.1: Antagonism of LRP1 partially releases MAG growth inhibition of cortical and 
hippocampal, but not DRG, neurons.  (a) In vitro, WT P7 cortical neurons are strongly 
inhibited when plated on MAG-CHO cell feeder layers. NgR1-/-, PirB-/-, NgR123-/-, and 
NgR12/PirB-/- cortical neurons show no substantial release of MAG inhibition; however, addition 
of GST-RAP (200nM) leads to a significant, yet incomplete release of growth inhibition. On 
control CHO cells, neurite length of all groups is comparable. (b) Similar to cortical neurons, 
WT, NgR1-/-, PirB-/-, NgR123-/-, and NgR12/PirB-/- P7 hippocampal neurons are equally inhibited 
on MAG-CHO cells.  Addition of GST-RAP (200nM), however, partially releases growth 
inhibition. (c) For DRG neurons, all groups are equally inhibited on MAG-CHO cells. 
Importantly, addition of 200nM GST has no effect on neurite outgrowth when these cell types 
are plated on CHO or MAG-CHO cells (data not shown). At least 150 neurites of TuJ1-labeled 
cells were counted per condition (n=5 independent experiments for cortical neurons, n=5 
experiments for hippocampal neurons, n=7 experiments for DRG neurons). Results are presented 
as mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (CHO); black 













Figure 4.2: Antagonism of LRP1 or genetic deletion of PirB partially releases MAG growth 
inhibition of CGNs and RGCs.   (a) In vitro, WT P7 CGNs are inhibited when plated on MAG-
CHO cell feeder layers. NgR1-/- and NgR123-/- CGNs show no release of MAG inhibition; 
however, loss of PirB (PirB-/-, NgR12/PirB-/-) or addition of GST-RAP (200nM) leads to a 
significant, yet incomplete release of growth inhibition. On control CHO cells, neurite length of 
all groups is comparable. (b) Similar to CGNs, WT, NgR1-/-, and NgR123-/- P7 RGCs are equally 
inhibited on MAG-CHO cells. Loss of PirB (PirB-/-, NgR12/PirB-/-) or addition of GST-RAP 
(200nM), however, partially releases growth inhibition. Importantly, addition of 200nM GST has 
no effect on neurite outgrowth when these cell types are plated on CHO or MAG-CHO cells 
(data not shown). At least 150 neurites of TuJ1-labeled cells were counted per condition (n=8 
independent experiments for CGNs, n=6 experiments for RGCs). Results are presented as mean 
±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (CHO); black bars (MAG-















































Figure 4.3: HSV-Cre transduction of LRP1f/f neurons releases MAG inhibition in a cell 
type-specific manner.  (a) When infected with HSV-1-GFP-Cre, LRP1 floxed cortical neurons 
(LRP1f/f; HSV-Cre) show a significant release of MAG-mediated growth inhibition compared to 
neurons infected with HSV-1-GFP (LRP1f/f; HSV). On control CHO cells, neurite length of both 
groups is comparable. Similar results are seen in (b) hippocampal neurons, (d) CGNs, and (e) 
RGCs. (c) LRP1f/f DRG neurons, however, are as equally inhibited on MAG with HSV-1-GFP-
Cre infection as with HSV-1-GFP infection. Importantly, LRP1 levels are substantially 
decreased in all five cell types when HSV-1-GFP-Cre is added (data not shown). At least 80 
neurites of TuJ1-labeled cells were counted per condition (n=4 independent experiments for 
cortical neurons, n=3 experiments for hippocampal neurons, n=4 experiments for DRG neurons, 
n=4 experiments for CGNs, n=3 experiments for RGCs). Results are presented as mean ±SEMs. 





Figure 4.4: LRP1f/f; Syn-Cre neurons show release of MAG inhibition in a cell type-specific 




(LRP1f/f; Syn-Cre) show a significant release of MAG growth inhibition compared to LRP1f/f 
control neurons. On control CHO cells, neurite length of both groups is comparable. Similar 
results are seen in (b) hippocampal neurons and (e) RGCs, but not in (c) DRG neurons or (d) 
CGNs. At least 100 neurites of TuJ1-labeled cells were counted per condition (n=4 independent 
experiments for cortical neurons, n=4 experiments for hippocampal neurons, n=3 experiments 
for DRG neurons, n=4 experiments for CGNs, n=3 experiments for RGCs). Results are presented 
as mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (CHO); black 
bars (MAG-CHO). (f-m) X-Gal labeling of tissue from 3-week-old ROSA; Synapsin I-Cre mice 
reveals strong Cre expression in coronal sections of the brain, including (f-g) multiple layers of 
the cortex and (h) the dentate gyrus and CA3 regions of the hippocampus.  Note the lack of 
expression in the white matter; in particular, the corpus callosum. (i) Strikingly, the cerebellum 
shows miminal levels of Cre expression. (j) The RGC layer of the retina, (k) a small subset of 
DRG neurons, and (l-m) a large number of cells in the gray matter of the spinal cord [including 
motor neurons of the anterior horn – best visualized in (m)] show expression as well. Scale bar: 














































































Figure 4.5: Loss of multiple MAG receptors is not sufficient to enhance axon regeneration 
following retro-orbital optic nerve crush injury.  (a) 2 weeks following optic nerve injury, 




sections. GAP-43 immunolabeling of injured optic nerve from WT, PirB-/-, and NgR12/PirB-/- 
mice fails to identify regenerative growth of axons beyond the lesion site (asterisk). Similarly, 
LRP1f/f mice with intravitreal injections of AAV2-GFP or AAV2-GFP-Cre show no substantial 
axon regeneration. (b) To test whether growth-activated RGCs show an additive regenerative 
effect when combined with genetic ablation of MAG receptors, a separate group of animals 
received an intravitreal injection of Zymosan at the time of optic nerve injury. Following 
Zymosan injection, PirB-/-, NgR12/PirB-/- LRP1f/f; AAV2-GFP, and LRP1f/f; AAV2-GFP-Cre 
mice do not show enhanced regeneration compared to WT mice with Zymosan. (c) 
Quantification of the number of GAP-43-positive axons at 0.2 to 0.8mm distal to the lesion site. 
Light gray bars (WT, n=5); black bars (PirB-/-, n=6); purple bars (NgR12/PirB-/-, n=5); dark gray 
bars (LRP1f/f; AAV2-GFP, n=6); blue bars (LRP1f/f; AAV2-GFP-Cre, n=6). (d) Quantification of 
the number of GAP-43-positive axons at 0.2 to 1.2mm distal to the lesion site in Zymosan-
injected mice. Light gray bars (WT, n=5); black bars (PirB-/-, n=5); purple bars (NgR12/PirB-/-, 
n=5); dark gray bars (LRP1f/f; AAV2-GFP, n=6); blue bars (LRP1f/f; AAV2-GFP-Cre, n=5). 






















Figure 4.6: Intravitreal injection of AAV2-GFP-Cre reduces LRP1 levels in LRP1f/f mice.  
(a) 2 weeks following intravitreal injection of AAV2-GFP-Cre, retinal whole-mount preparations 
of LRP1f/f mice reveal several TuJ1-positive RGCs that are also GFP-positive. (b) Quantification 
of the RGC transduction efficiency of AAV2-GFP (gray bar) and AAV2-GFP-Cre (black bar). 
Transduction efficiency is calculated as the percentage of GFP/TuJ1-double positive cells, 
divided by the total number of TuJ1-positive cells. At least 500 TuJ1-labeled cells were counted 
per condition (n=4 eyes for AAV2-GFP, n=4 eyes for AAV2-GFP-Cre). Results are presented as 
mean ±SEMs. (c) X-Gal labeling of retina from LRP1f/f mice reveals strong Cre expression in the 
RGC layer when AAV2-GFP-Cre, but not AAV2-GFP, is injected into the eye. (d) 
Quantification of LRP1 protein levels in retinas from LRP1f/f mice receiving intravitreal injection 
of either AAV2-GFP (gray bar) or AAV2-GFP-Cre (black bar). Densitometric analysis of LRP1 
bands was performed from 4 independent experiments and then normalized to β-actin levels. 
Results are presented as mean ±SEMs, and are shown as a percentage of the AAV2-GFP control. 

















Figure 4.7: NgR1 mediates MAG protection from axonal degeneration and excitotoxicity.  
(a) 36 hours following treatment with 50nM vincristine sulfate, TuJ1-labeled DRG explants 
show signs of substantial axonal degeneration. In the presence of preclustered MAG-Fc, 
degeneration is significantly reduced in WT, NgR2-/-, and PirB-/- explants. NgR1-/-, NgR12-/-, and 
NgR12/PirB-/- explants, however, are partially resistant to MAG-induced protection. The graph 
represents the percentage of axons with signs of degeneration (fragmentation or “blebbing”). At 
least 140 axons were counted per condition (n=6 independent experiments). Results are 
presented as mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars 
(Untreated); black bars (Vincristine). (b) 36 hours following treatment with 200μM kainic acid, 
TuJ1-labeled hippocampal neurons show signs of excitotoxicity and cell death. Neurons are also 
visualized for incorporation of propidium iodide (not shown). In the presence of preclustered 
MAG-Fc, cell death is significantly reduced in WT, NgR2-/-, and PirB-/- neurons. NgR1-/-,  
NgR12-/-, and NgR12/PirB-/- neurons, however, are partially resistant to MAG-induced protection 
from cell death. The percentage of live cells (positive for TuJ1, negative for propidium iodide) 
was determined for each condition. At least 300 cells were counted per condition (n=5 




ANOVA, Tukey’s post hoc). Gray bars (Untreated); black bars (Kainic Acid). Importantly, all 
genotypes show comparable levels of (a) vincristine-induced degeneration and (b) kainic acid-
induced excitotoxicity in the presence of AP-Fc (data not shown). (c) Time course of vincristine-
mediated axonal degeneration (50nM concentration) from 0-96 hours, in the presence of either 
preclustered AP-Fc, Siglec-3-Fc, or MAG-Fc.  While there is no significant difference in 
degeneration between the AP-Fc and Siglec-3-Fc conditions, the addition of MAG-Fc is 
protective from 24-72 hours post-treatment with vincristine.  At least 80 axons were counted per 
condition (n=4 independent experiments). Results are presented as mean ±SEMs. * P< 0.01 
(one-way ANOVA, Tukey’s post hoc; comparison between AP-Fc + Vincristine and MAG-Fc + 
Vincristine). Green line (AP-Fc + Vincristine); red line (Siglec-3-Fc + Vincristine); blue line 
(MAG-Fc + Vincristine). (d) Time course of kainic acid-mediated cell death (200μM 
concentration) from 0-96 hours, in the presence of either preclustered AP-Fc, Siglec-3-Fc, or 
MAG-Fc.  While there is no significant difference in cell death between the AP-Fc and Siglec-3-
Fc conditions, the addition of MAG-Fc is protective from 24-48 hours post-treatment with kainic 
acid.  At least 150 cells were counted per condition (n=4 independent experiments). Results are 
presented as mean ±SEMs. * P< 0.01 (one-way ANOVA, Tukey’s post hoc; comparison 
between AP-Fc + Vincristine and MAG-Fc + Vincristine). Green line (AP-Fc + Kainic Acid); 
red line (Siglec-3-Fc + Kainic Acid); blue line (MAG-Fc + Kainic Acid). Scale bar, 120μm. 































Figure 4.8: LRP1 is not necessary for MAG-mediated protection from axonal degeneration 
and excitotoxicity.  (a) 36 hours following treatment with 50nM vincristine sulfate, LRP1 
floxed DRG explants infected with HSV-1-GFP (LRP1f/f; HSV) or HSV-1-GFP-Cre (LRP1f/f; 
HSV-Cre) show comparable levels of degeneration.  The addition of preclustered MAG-Fc 
reduces degeneration to a similar extent for both groups. The graph represents the percentage of 
axons with signs of degeneration (fragmentation or “blebbing”). At least 100 axons were counted 
per condition (n=4 independent experiments). Results are presented as mean ±SEMs. ** P< 0.01 
(one-way ANOVA, Tukey’s post hoc). Gray bars (Untreated); black bars (Vincristine). (b) 36 
hours following treatment with 200μM kainic acid, LRP1f/f; HSV and LRP1f/f; HSV-Cre 
hippocampal neurons show comparable levels of cell death.  The addition of preclustered MAG-
Fc reduces cell death to a similar extent for both groups. The percentage of live cells (positive for 
TuJ1, negative for propidium iodide) was determined for each condition. At least 200 cells were 
counted per condition (n=4 independent experiments). Results are presented as mean ±SEMs. ** 
P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (Untreated); black bars (Kainic Acid). 
Scale bar, 120μm. 

















































Figure 4.9: CHO cells expressing MAG Ig-like domains 1-5 or 1-3 confer protection from 
excitotoxicity.  (a) Confirmation of MAG protein in CHO cell lines expressing variants of 
membrane-bound MAG. Immunoblotting of CHO cell lysates with a custom-made MAG 




5-CHO cell lysates are compared to the MAG Ig1-5-CHO cell lysates. Green circle (Ig-like 
domain 1); blue circle (Ig-like domain 2); orange circle (Ig-like domain 3); red circle (Ig-like 
domain 4); purple circle (Ig-like domain 5). (b) (Top) High levels of MAG are expressed on the 
surface of all CHO cell lines, as revealed by MAG immunostaining in the absence of Triton X-
100. (Bottom) MAG Ig1-5-CHO and MAG Ig3-5-CHO cells, but not MAG Ig1-3-CHO cells, 
substantially inhibit outgrowth of TuJ1-labeled, P7 mouse hippocampal neurons. (c) When 
grown on MAG Ig1-5-CHO (but not CHO) feeder layers, kainic acid-induced cell death is 
significantly reduced in WT, NgR2-/-, and PirB-/- hippocampal neurons. NgR1-/-,  NgR12-/-, and 
NgR12/PirB-/- neurons, however, are completely resistant to MAG-induced protection from cell 
death. The percentage of live cells (positive for TuJ1, negative for propidium iodide) was 
determined for each condition. At least 200 cells were counted per condition (n=3 independent 
experiments). Results are presented as mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s 
post hoc). Gray bars (Untreated); black bars (Kainic Acid). (d) WT hippocampal neurons grown 
on MAG Ig1-5-CHO and MAG Ig1-3-CHO cells, but not CHO or MAG Ig3-5-CHO cells, are 
equally protected from kainic acid-induced cell death. The percentage of live cells (positive for 
TuJ1, negative for propidium iodide) was determined for each condition. At least 250 cells were 
counted per condition (n=3 independent experiments). Results are presented as mean ±SEMs. ** 
P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (Untreated); black bars (Kainic Acid). 





























































Figure 4.10: MAG Ig-like domains 1-5 and 1-3, but not 3-5, are sufficient to confer 
protection from axonal degeneration and excitotoxicity.  (a) WT DRG explants treated with 
MAG Ig1-5-Fc or MAG Ig1-3-Fc, but not AP-Fc or MAG Ig3-5-Fc, are equally protected from 
vincristine sulfate-induced axonal degeneration. At least 100 axons were counted per condition 
(n=4 independent experiments). Results are presented as mean ±SEMs. ** P< 0.01 (one-way 
ANOVA, Tukey’s post hoc). Gray bars (Untreated); black bars (Vincristine). (b) WT 
hippocampal neurons treated with MAG Ig1-5-Fc or MAG Ig1-3-Fc, but not AP-Fc or MAG 
Ig3-5-Fc, are equally protected from kainic acid-induced cell death. The percentage of live cells 
(positive for TuJ1, negative for propidium iodide) was determined for each condition. At least 
200 cells were counted per condition (n=3 independent experiments). Results are presented as 
mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (Untreated); black 









Figure 4.11: MAG-/- and NgR1-/- mice show increased susceptibility to acrylamide-induced 
behavioral deficits.  (a) MAG-/- (but not MAG+/+ or MAG+/-) mice display substantially reduced 
retention times on an accelerating rotarod (post-training), following 2 weeks of acrylamide 
administration (400 parts per million). MAG+/+ (WT): n=7 mice, MAG+/-: n=5 mice, MAG-/-: n=9 
mice. (b) Similarly, NgR1-/-, NgR12-/-, NgR1/PirB-/-, and NgR12/PirB-/- mice, but not NgR2-/- or 
PirB-/- mice, display reduced retention times following acrylamide treatment when compared to 
WT controls. WT: n=8 mice, NgR1-/-: n=11 mice, NgR2-/-: n=8 mice, PirB-/-: n=10 mice,   
NgR12-/-: n=7 mice, NgR1/PirB-/-: n=11 mice, NgR12/PirB-/-: n=4 mice. Results are presented as 
mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (Before Treatment); 
black bars (Acrylamide Treatment). (c) MAG+/+, MAG+/-, and MAG-/- mice have comparable 
performances on the grid apparatus (measured as the latency to fall), following 2 weeks of 
acrylamide administration. It should be noted, however, that MAG-/- mice show a trend toward a 
decreased latency to fall. MAG+/+ (WT): n=6 mice, MAG+/-: n=7 mice, MAG-/-: n=9 mice. (d) 
NgR1-/-, NgR12-/-, NgR1/PirB-/-, and NgR12/PirB-/- mice, but not NgR2-/- or PirB-/- mice, show a 
decreased latency to fall from the grid apparatus following acrylamide treatment when compared 




NgR12-/-: n=7 mice, NgR1/PirB-/-: n=9 mice, NgR12/PirB-/-: n=5 mice. Results are presented as 
mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (Before Treatment); 
black bars (Acrylamide Treatment). In (a-d), there are no differences between the genotypes 






















































































Figure 4.12: NgR1-/- mice show increased susceptibility to acrylamide-induced degeneration 
of the sciatic nerve.  (a-d) Representative compound action potential (CAP) recordings of the 
sciatic nerve (tibial branch) from a (a) WT mouse, (b) WT mouse with 2 weeks of acrylamide 
treatment (400 parts per million), (c) NgR1-/- mouse, and (d) NgR1-/- mouse with acrylamide 
treatment. The first spike represents the artifact, while the major peak represents the myelinated 
component of the nerve. (e) While a significant decrease in conduction velocity is seen in all 




Conduction velocity is calculated as the length of the nerve divided by the time-to-peak. (f) All 
animals show a significant decrease in peak amplitude with acrylamide administration; however, 
NgR1-/- and NgR12/PirB-/- mice, but not NgR2-/- or PirB-/- mice, display an even further reduction 
than WT controls. At least 3 animals were used for every condition (1 or 2 nerves recorded per 
mouse). No Treatment - WT: n=4 nerves, NgR1-/-: n=4 nerves, NgR2-/-: n=3 nerves, PirB-/-: n=4 
nerves, NgR12/PirB-/-: n=4 nerves. Acrylamide Treatment - WT: n=4 nerves, NgR1-/-: n=5 
nerves,  NgR2-/-: n=3 nerves, PirB-/-: n=4 nerves, NgR12/PirB-/-: n=3 nerves. Results are 
presented as mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (No 





























Figure 4.13: MAG-/- and NgR1-/- mice show increased susceptibility to kainic acid-induced 
seizures.  (a) Following intraperitoneal injection of 25mg/kg kainic acid, MAG-/- mice (n=10) 
develop higher seizure severity scores than MAG+/+ mice (n=14). The percentage of mice that 
reach a given seizure score as their maximum is shown. Scores are rated as follows: (0) normal 
behavior; (1 - red) exploring, sniffing, and grooming have ceased and the animal is motionless; 
(2 - red) forelimb and/or tail extension, giving the appearance of a rigid posture; (3 - red) 




forelimb clonus and partial rearing; (5 - blue) forelimb clonus, rearing, and falling; (6 - gray) 
generalized tonic-clonic activity; and (7 - black) death. (b) Comparison of seizure scores for the 
period of 7 hours following 25mg/kg kainic acid injection. MAG-/- mice (blue line, n=10) show a 
significant increase in seizure scores at multiple time points when compared to MAG+/+ (green 
line, n=14) or MAG+/- mice (red line, n=8). Results are presented as mean ±SEMs. * P< 0.01 
(one-way ANOVA, Tukey’s post hoc; comparison between MAG-/- mice and MAG+/+ mice). (c) 
Following injection of kainic acid, NgR1-/- mice (n=12) develop higher seizure severity scores 
than WT controls (n=12). (d) Comparison of seizure scores for the period of 7 hours following 
25mg/kg kainic acid injection. NgR1-/- (red line, n=11), NgR12-/ - (purple line, n=8), NgR1/PirB-/- 
(light green line, n=12), and NgR12/PirB-/- mice (light blue line, n=9), but not NgR2-/- (blue line, 
n=11) or PirB-/- mice (orange line, n=12), show a significant increase in seizure scores at 
multiple time points when compared to WT controls (green line, n=12). Results are presented as 
mean ±SEMs. * P< 0.01 (one-way ANOVA, Tukey’s post hoc; comparison between NgR1-/- 
mice and WT mice). (e) Representative EEG traces from an NgR1-/- and WT control mouse, 20 
minutes following injection of 15mg/kg kainic acid. The NgR1-/- animal, but not the WT control, 
displays synchronized, high-voltage (>750µV), fast-spiking waves (generalized seizures). (f) 
Representative, baseline EEG traces from an NgR1-/- and WT control mouse. The NgR1-/- animal 
displays semi-periodic epileptiform discharges exceeding 750µV (second and third traces), often 

































Figure 4.14: Silencing of PTEN significantly releases MAG-mediated inhibition of CGNs.  
(a) Treatment of primary mouse CGNs (cultured in vitro for 14 days) with MAG-Fc results in a 
substantial decrease of p-AKT (Ser473) and p-p70 S6 kinase (Thr389) levels, but not p-p44/42 
ERK1/2 (Thr202/Tyr204) levels. Total levels of these proteins remain unchanged. β-actin is 
shown as a loading control for all CGN lysates. This experiment was repeated four times, with 
both treatments performed in duplicate for each experiment. (b) CGNs expressing PTEN siRNA, 
but not CGNs expressing a non-targeting control siRNA, show a significant release of MAG 
inhibition when plated on MAG-CHO feeder layers, an effect that is reversed with rapamycin 
treatment (25nM). All groups show comparable growth on control CHO feeder layers. At least 
200 neurites of TuJ1-labeled cells were counted per condition (n=5 independent experiments). 
Results are presented as mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray 
bars (CHO); black bars (MAG-CHO). (c) Immunoblotting analysis from CGN lysates confirms 
that PTEN siRNA-transfected cells show a significant decrease in PTEN levels and subsequent 
increase in p-p70 S6 kinase levels. While rapamycin (Rap) treatment does not affect PTEN 
levels, it does significantly decrease p-p70 S6 kinase levels. For quantification, densitometric 
analysis of PTEN bands and p-p70 S6 kinase bands from 4 independent experiments was 
performed and then normalized to β-actin levels. Results are presented as mean ±SEMs, and are 
shown as a percentage of the control siRNA condition. ** P< 0.01 (one-way ANOVA, Tukey’s 









Figure 4.15: MAG negatively regulates the PI3K-AKT-mTOR pathway to inhibit neurite 
outgrowth, but not to protect from excitotoxicity.  (a) CGNs expressing a constitutively active 
form of Rheb1 (CA Rheb1), but not CGNs expressing a GFP control, show a significant release 
of MAG inhibition when plated on MAG-CHO feeder layers, an effect that is reversed with 
rapamycin treatment (25nM). All groups show comparable growth on control CHO feeder layers. 
At least 150 neurites of TuJ1-labeled cells were counted per condition (n=4 independent 
experiments). Results are presented as mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s 
post hoc). Gray bars (CHO); black bars (MAG-CHO). (b) Immunoblotting analysis from CGN 
lysates confirms that CA Rheb1-transfected cells show a significant increase in p-p70 S6 kinase 
levels, while rapamycin (Rap) treatment significantly decreases p-p70 S6 kinase levels. For 
quantification, densitometric analysis of p-p70 S6 kinase bands from 4 independent experiments 
was performed and then normalized to β-actin levels. Results are presented as mean ±SEMs, and 
are shown as a percentage of the GFP control condition. ** P< 0.01 (one-way ANOVA, Tukey’s 
post hoc). Gray bars (GFP Control); black bars (GFP Control + Rap); purple bars (CA Rheb1); 
dark gray bars (CA Rheb1 + Rap). (c) In the presence of MAG-Fc, kainic acid-induced cell death 
of mouse hippocampal neurons is significantly reduced. Similarly, hippocampal neurons 
expressing PTEN siRNA show a significant reduction in cell death, which is not additive with 
MAG-Fc or affected by rapamycin treatment (25nM). The percentage of live cells (positive for 
TuJ1, negative for propidium iodide) was determined for each condition. At least 200 cells were 
counted per condition (n=4 independent experiments). Results are presented as mean ±SEMs. ** 
P< 0.01 (one-way ANOVA, Tukey’s post hoc). Gray bars (AP-Fc); black bars (AP-Fc + Kainic 
Acid); blue bars (MAG-Fc); red bars (MAG-Fc + Kainic Acid). (d) Hippocampal neurons 
expressing CA Rheb show no change in kainic acid-induced cell death. The percentage of live 
cells (positive for TuJ1, negative for propidium iodide) was determined for each condition. At 
least 200 cells were counted per condition (n=4 independent experiments). Results are presented 
as mean ±SEMs. Gray bars (AP-Fc); black bars (AP-Fc + Kainic Acid); blue bars (MAG-Fc); 

































Figure 4.16: Rapamycin treatment blocks the release of MAG growth inhibition by           
Y-27632.  (a) WT P7 CGNs are strongly inhibited when plated on MAG-CHO cell feeder layers; 
however, addition of the ROCK inhibitor Y-27632 (15μM) leads to a substantial release of 
growth inhibition. Concurrent treatment with rapamycin (Rap; 25nM) completely blocks this 
release. On control CHO cells, neurite length of all groups is comparable. (b) Quantification of 
neurite length. At least 200 neurites of TuJ1-labeled cells were counted per condition (n=6 
independent experiments). Results are presented as mean ±SEMs. ** P< 0.01 (one-way 














Figure 4.17: MAG inhibits calpain-induced cleavage of α-fodrin during toxic insult.  (a) 
Treatment of primary mouse hippocampal neurons (cultured in vitro for 14 days) with 200μM 
kainic acid for 4 hours results in substantial cleavage of α-fodrin (arrow). Pretreatment of 
neurons with MAG-Fc for 30 minutes, however, largely prevents cleavage, leaving more of the 
unprocessed form (top band). NgR1-/-, NgR12-/-, NgR1/PirB-/-, and NgR12/PirB-/- hippocampal 
neurons, but not NgR1+/-, NgR2-/-, PirB-/-, or NgR2/PirB-/- neurons, show substantial restoration 
of α-fodrin cleavage in the presence of MAG-Fc. (b) Inhibition of calpain with 10μM PD150606 
largely prevents kainic acid-induced cleavage of α-fodrin. Inhibition of ROCK with 15μM Y-
27632, however, has no effect on MAG-mediated prevention of α-fodrin cleavage. TuJ1 is 
shown as a loading control for all hippocampal neuron lysates. The results shown in (a) were 
confirmed from 3 independent experiments, and the results shown in (b) were confirmed from 5 
independent experiments. (c) Treatment of WT DRG explants with 10μM PD150606 
significantly reduces vincristine-induced axonal degeneration, similar to treatment with MAG-
Fc. MAG-Fc-mediated protection, however, is largely abrogated with addition of 15μM Y-27632 
to the cultures. The graph represents the percentage of axons with signs of degeneration 
(fragmentation or “blebbing”). At least 100 axons were counted per condition (n=4 independent 
experiments). Results are presented as mean ±SEMs. ** P< 0.01 (one-way ANOVA, Tukey’s 
post hoc). Gray bars (Untreated); black bars (Vincristine). (d) Similar results to (c) are seen 
when these experiments are repeated in the context of kainic acid-induced cell death of WT 
hippocampal neurons. The percentage of live cells (positive for TuJ1, negative for propidium 
iodide) was determined for each condition. At least 200 cells were counted per condition (n=4 
independent experiments). Results are presented as mean ±SEMs. ** P< 0.01 (one-way 






Figure 4.18: Summary of findings.  Our studies have revealed that MAG utilizes distinct 
receptor systems and signaling pathways to mediate neuronal growth inhibition vs. protection 
from toxic insults. While LRP1 and PirB have cell type-specific roles for MAG growth 
inhibition in vitro, there is a limited role for these receptors in the context of axon regeneration 
following CNS injury. NgR1 has a role in MAG protection against axonal degeneration and 
excitotoxicity in vitro, and also plays a substantial role in protection against acrylamide-induced 
degeneration and kainic acid-induced seizures in vivo. Additionally, MAG antagonizes the PI3K-
AKT-mTOR pathway to mediate growth inhibition, while it prevents calpain-dependent cleavage 
of the cytoskeleton during degenerative or excitotoxic insults.  While it is known that the growth-
inhibitory activity of MAG resides in the 5th Ig-like domain of the extracellular region, we have 
identified the protective activity to reside in Ig-like domains 1-3. Although previous studies have 
suggested that gangliosides and β1-integrin also mediate these MAG-dependent functions, our 
results show a limited role for NgR2. Note - This illustration was generously provided by 
Yevgeniya A. Mironova, and was modified for the purpose of this figure.  The original figure 
appeared in: Mironova YA, Giger RJ (2013) Where no synapses go: gatekeepers of circuit 
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 Taken together, the work presented in this dissertation provides new insights into the 
molecular and cellular mechanisms that inhibit long-distance axon regeneration of injured 
neurons in the adult mammalian CNS.  Most relevant to the field of nervous system injury and 
repair is our (1) identification of novel ligand-receptor interactions that function in neuronal 
growth inhibition, (2) innovative approach of deleting receptors for extrinsic growth-inhibitory 
cues combined with boosting the intrinsic growth potential of neurons to promote axon 
regeneration, and (3) discovery of distinct receptor mechanisms and signaling pathways that 
differentiate the multiple functions of CNS regeneration inhibitors.  These points, along with a 
frank assessment of the current state of the field of CNS repair and its future, are further 
discussed below.   
 
Is blockade of extrinsic inhibitory barriers enough to promote long-distance axonal 
regeneration following injury? 
 While the growth-inhibitory properties of injured adult mammalian CNS tissue are well 
established, the underlying molecular mechanisms of neuronal growth inhibition (ligands, 
receptors, signaling pathways) have only recently started to come to light.  Santiago Ramón y 




following injury.  However, when injured CNS axons of the optic nerve are presented with a 
peripheral graft from the sciatic nerve, these axons are now able to regenerate (Ramón y Cajal, 
1928).  Over sixty years later, Albert Aguayo and colleagues confirmed that specific populations 
of adult CNS fiber tracts have the capacity to regenerate for several centimeters into peripheral 
nerve grafts, while injured axons of the sciatic nerve are not able to grow through grafts of the 
optic nerve (Aguayo et al., 1978; Aguayo et al., 1981; David and Aguayo, 1981; Richardson et 
al., 1980).  These seminal experiments established the founding principles of the field of 
mammalian axon regeneration: the PNS environment, but not the CNS environment, is favorable 
for regrowth of injured adult axons.  Furthermore, the intrinsic ability to regrow axons is found 
in at least some populations of adult CNS neurons.   
 As discussed extensively in this dissertation, we now have a much clearer, but still 
incomplete, picture of the inhibitory proteins that are present in the injured CNS environment, 
including the myelin-associated inhibitors (MAIs) and chondroitin sulfate proteoglycans 
(CSPGs).  Here we have identified two members of the Nogo receptor family, NgR1 and NgR3, 
as high-affinity receptor components for CSPGs (Chapter II; Figure 5.1).  As NgR1 is a well-
established receptor for multiple MAIs (Domeniconi et al., 2002; Fournier et al., 2001; Liu et al., 
2002; Wang et al., 2002), our results show for the first time that MAIs and CSPGs utilize 
common receptor components for neuronal inhibition, thus suggesting common pathways for 
therapeutic targeting.  Indeed, our in-depth analysis reveals a functionally redundant role for 
these receptors in growth inhibition of select populations of primary neurons in vitro, as well as 
in limiting axon regeneration following optic nerve injury in vivo.  Because Nogo receptors are 
GPI-anchored proteins, further work is still needed to identify the signal-transducing components 




the presence of CSPG ligands, and preliminary evidence from our laboratory suggests that NgR1 
and NgR3 also interact with RPTPσ, another established CSPG receptor (personal 
communication with Yevgeniya A. Mironova).  It thus remains a possibility that RPTPσ is the 
transmembrane co-receptor for NgR1 and NgR3 to convey CSPG inhibition, and that growth-
inhibitory ligands mediate their activity through large, multi-component signaling platforms. 
 Additionally, we have identified a novel interaction between MAG (a known MAI) and 
LRP1 (Chapter III; Figure 5.1).  While this interaction is high affinity and has a functional 
consequence for neurite outgrowth inhibition in vitro, the in vivo significance for axon 
regeneration is underwhelming (Chapter IV).  In fact, the majority of mouse genetic studies 
from the past decade have pointed to a somewhat disappointing conclusion: the targeting of 
growth inhibitors or their receptors individually is not sufficient to promote substantial, long-
distance axon regeneration in the injured adult mammalian CNS (Ji et al., 2008; Kim et al., 2004; 
Nakamura et al., 2011; Zheng et al., 2003; Zheng et al., 2005).  While acute blockage of myelin 
inhibitors with anti-Nogo-A or soluble NgR(310)-Fc, as well as degradation of CSPG side chains 
with chondroitinase ABC (Ch’aseABC), leads to a modest but significant increase in axonal 
growth (Bradbury et al., 2002; Harvey et al., 2009; MacDermid et al., 2004; Moon et al., 2001; 
Peng et al., 2009; Wang et al., 2006; Zorner and Schwab, 2010), claims of long-distance 
regeneration and functional recovery following CNS injury in genetic targeting studies have been 
highly controversial and not consistently reproducible (Cafferty et al., 2007; Kim et al., 2003; 
Simonen et al., 2003; Steward et al., 2007; Zheng et al., 2003).  For this reason, studies with 
combined deletions of multiple inhibitory ligands have been conducted, but have also been 
largely ineffective in mammalian spinal cord injury (SCI) models (Cafferty et al., 2010; Lee et 




regeneration in vivo.  While we found that NgR13-/-, NgR123-/-, and NgR13/RPTPσ-/- mice show 
significant regeneration following optic nerve crush (Chapter II), the same is not true for 
NgR12-/- and NgR12/PirB-/- mice (Chapter II, Chapter IV).  In total, it is possible that (1) there 
is substantial functional redundancy for growth inhibition, (2) injured axons also need intrinsic 
growth programs to turn back on, and (3) these receptors are critical for other functions of CNS 
growth inhibitors, as discussed below.  
 
Combined manipulations of extrinsic and intrinsic factors to boost regenerative potential 
 In addition to blockade of growth-inhibitory factors, another approach to increasing 
regenerative growth is to change the intrinsic growth state of the neuron.  Following arrival of 
axons to their proper targets during development, CNS neurons downregulate the majority of 
growth pathways to allow for the proper formation of synaptic connections (Yang and Yang, 
2012).  As a result, injured adult CNS neurons are at an immediate disadvantage, as the critical 
signaling cascades that helped them grow and navigate during development are no longer active.  
Furthermore, injury to peripheral nerve axons induces transcription-dependent changes that 
promote regeneration by enhancing the intrinsic growth capacity of these neurons (Abe and 
Cavalli, 2008).  Pathways including JAK/STAT, PI3K-AKT-mTOR, and cAMP/PKA/CREB are 
active in injured PNS neurons, in stark contrast to injured CNS neurons (Abe and Cavalli, 2008; 
Hannila and Filbin, 2008; Park et al., 2008; Qiu et al., 2005; Yang and Yang, 2012).  Thus, it is 
not surprising that manipulations which lead to increased activation of these pathways in CNS 
neurons result in robust axon regeneration following injury (de Lima et al., 2012; Park et al., 




 A particularly elegant example of this difference in intrinsic growth potential is found in 
the dorsal root ganglion (DRG) neuron, which has both a peripheral branch (that does 
regenerate) and a central branch (that does not regenerate).  Interestingly, if the peripheral branch 
is injured before the central branch, both branches will show regeneration (Neumann and Woolf, 
1999).  This effect is known as the conditioning lesion, as the peripheral branch injury increases 
the intrinsic state of the DRG neuron and thus drives regeneration of the central branch.  It is 
important to mention that while the initial experiments of Ramón y Cajal and Aguayo showed 
that certain populations of injured CNS axons have some intrinsic growth potential, this is 
limited to a small subset of CNS neurons (Aguayo et al., 1978; Aguayo et al., 1981; David and 
Aguayo, 1981; Ramón y Cajal, 1928; Richardson et al., 1980).   
 A central finding of our studies is that the combination of (1) genetic deletion of multiple 
extrinsic inhibitory receptors and (2) activation of intrinsic growth programs by intraorbital 
injection of the yeast cell wall extract Zymosan has a substantial additive effect on regeneration 
of injured retinal ganglion cell (RGC) axons following optic nerve injury (Chapter II).  
Zymosan, which is a mixture of proteins, lipids, carbohydrates, and metabolites, is known to 
promote an inflammatory response in the vitreous of the eye and increase the regenerative state 
of RGCs (Yin et al., 2003).  Specifically, it has been proposed that Zymosan administration leads 
to the release of growth-promoting factors, including oncomodulin (Yin et al., 2009), ciliary 
neurotrophic factor, and leukemia inhibitory factor (Leibinger et al., 2009), which act directly on 
RGCs to increase their intrinsic growth potential.  While genetic deletion of multiple CSPG 
receptors had a significant but relatively minor effect on RGC regeneration, Zymosan injection 
resulted in substantially more RGC growth.  The effect of combining these two manipulations, 




great deal of promise for future studies.  It will be of great interest to examine RGC axon 
regeneration in NgR13/RPTPσ-/- mice with Zymosan (or with knockdown of PTEN - see 
Chapter II) at longer time points following injury, to determine if there is a limit to the 
regenerative growth of these fibers.  Of more clinical relevance is to administer Zymosan at the 
time of, or a day after, optic nerve crush to see if robust regeneration is still observed, as well as 
to try these strategies in a SCI model.  Furthermore, functional assays to measure compound 
action potentials in regenerating RGC fibers need to continued (see Chapter II), in the hope of 
demonstrating that these combined strategies result in both anatomical and functional 
regeneration.  Ultimately, our findings and other recent studies (de Lima et al., 2012; Lu et al., 
2012; Sun et al., 2011) suggest that a combination approach to axon regeneration has a great deal 
of potential.  These combinations include (1) neutralization of extrinsic growth inhibitors, their 
receptors, or signaling pathways, (2) activation of intrinsic growth programs, (3) application of 
growth factor cocktails, and (4) grafting of neural stem cells.  
 
The optic nerve as a CNS injury model 
 Throughout this dissertation, the optic nerve crush injury model is used as an in vivo 
assessment of axon regeneration in the mammalian CNS.  This model is becoming an 
increasingly popular alternative to rodent SCI models, as it offers a simpler approach that is 
easier to interpret, while still maintaining the most essential properties of injured axons in the 
spinal cord (Benowitz and Yin, 2008).  Importantly, the optic nerve is a part of the CNS, the 
RGCs that send their axons through the nerve have similar properties to other CNS axons, and 
the post-injury environment of the optic nerve is comparable to the spinal cord.  Specifically, a 




CSPG production.  Damaged oligodendrocytes are also present, exposing MAIs to cell surface 
receptors on injured RGCs (Ohlsson et al., 2004).  Most critically, injured RGC axons fail to 
regenerate past the lesion site, similar to the injured spinal cord (Tuszynski and Steward, 2012).   
 The advantages of the optic nerve injury model all stem from its simplicity.  Unlike the 
spinal cord, which contains numerous ascending and descending fibers at every level, the optic 
nerve consists of one set of axonal fibers.  Additionally, the injured axons are in close proximity 
to their retinal cell bodies and it is relatively easy to achieve a complete crush of all fibers 
(Benowitz and Yin, 2008).  Thus, unlike the spinal cord, where significant controversies have 
erupted over the possibility of spared fibers or fibers from other tracts being misinterpreted as 
regenerating axons (Cafferty et al., 2007; Steward et al., 2007), there is little question if axons 
are regenerating in the injured optic nerve.  This is a major benefit to the model, as a definitive 
answer on regenerative potential can be given within a few weeks of the injury.  Furthermore, the 
ease of access to the eye and optic nerve allows for minimally invasive methods to manipulate 
the system; for example, growth-promoting compounds or fluorescent tracers can be introduced 
by intravitreal injection, drugs can be directly applied to the optic nerve through the use of 
gelfoam, etc (Barry et al., 2008; Benowitz and Yin, 2008).   
 While these are substantial advantages, the simplicity of the optic nerve crush injury 
model is also its downside.  One of the greatest challenges for almost all CNS injuries, including 
spinal cord injury, is the complexity of the injury site and the fact that axons have to navigate 
through long distances of inappropriate targets before arriving at the correct one.  Additionally, 
spinal cord injury models have established measures of functional recovery, including the Basso-
Beattie-Bresnahan (BBB) locomotor rating scale and electrophysiological measurements 




has proposed functional assessments of RGC axon regeneration, including the optomotor 
response, depth perception, and circadian photoentrainment (de Lima et al., 2012).  Thus, the 
optic nerve is a great model for trying to decipher the molecular and cellular mechanisms that 
underlie CNS growth inhibition (as we have done in our studies), but ultimately the identified 
targets of these studies will need to be tested in SCI models before proceeding to any type of 
clinical setting. 
 
CNS growth inhibitors as multifunctioning molecules in physiology and pathology  
 While most attention has focused on the role of MAIs (including Nogo, MAG, and 
OMgp) and CSPGs in growth inhibition, increasing evidence suggests that these proteins and 
their receptors have critical roles in a variety of other physiological and pathological processes.  
Nogo and CSPGs, as well as NgR1 and PirB, have been shown to be key components for the 
maintenance of neuronal networks that occurs after experience-dependent refinement in the 
visual cortex (the critical period) is completed (McGee et al., 2005; Pizzorusso et al., 2002; 
Syken et al., 2006).  Additionally, Nogo, OMgp, and CSPGs are expressed on or near neurons 
and localize to the synapse, as do their receptors (Mironova and Giger, 2013).  Their synaptic 
roles are complex, and include the regulation of dendrite complexity and spine 
morphology/density (Lee et al., 2008; Wills et al., 2012; Zagrebelsky et al., 2010), the inhibition 
of synaptogenesis (Wills et al., 2012), and influence over Hebbian forms of synaptic plasticity 
(Delekate et al., 2011; Lee et al., 2008; Raiker et al., 2010).  MAG, on the other hand, has been 
shown to mediate axonal maintenance and stability over time, as well as protect neurons and 
their processes from a variety of toxic insults (Lopez et al., 2011; Nguyen et al., 2009).  Here we 




and protection (Chapter IV).  We identified distinct receptors and signaling pathways for these 
functions, suggesting the possibility of targeting one without influencing the other.  In the 
context of injury or disease, the ability to introduce therapeutic agents that are as specific as 
possible and have minimal side effects is essential. 
 Of particular interest is our finding that MAG negatively regulates the mTOR pathway 
for its growth-inhibitory, but not protective, activity (Chapter IV).  Mounting evidence suggests 
that CNS growth inhibitors and neurotrophic factors have an antagonistic relationship, in which 
the inhibitors restrict levels of synaptogenesis and synaptic plasticity in order to limit exuberant 
growth during development, while the neurotrophic factors promote these processes (Mironova 
and Giger, 2013).  One potential pathway to mediate these effects is the PI3K-AKT-mTOR 
pathway, as growth inhibitors and neurotrophic factors have opposite effects on the regulation of 
mTOR-dependent protein translation (Fortin et al., 2012; Peng et al., 2011).  Furthermore, the 
dramatic increases in AKT and mTOR activation that are seen with neurotrophic factor 
application, such as brain-derived neurotrophic factor (BDNF), are strongly attenuated in the 
presence of either crude myelin or the Nogo66 (Raiker et al., 2010).  This antagonistic 
relationship also applies directly to growth inhibition, as pretreatment of primary neurons with 
BDNF substantially reduces neurite outgrowth inhibition by myelin (Cai et al., 1999).  In the 
context of both development and axonal injury, a delicate balance needs to be struck between 
allowing enough time for sufficient growth or regrowth of axons and preventing an excess of 
growth or sprouting.  Indeed, without the necessary restrictions on synapse formation and 
plasticity, severe consequences for neurologic function may result, including epilepsy, memory 





Final thoughts and future strategies for SCI repair 
 Considering the biological complexity of a SCI, the development of new strategies that 
promote nervous system tissue regeneration and lead to a significant reduction of injury-inflicted 
disabilities remains a challenging task.  A major goal of SCI research is to develop therapeutic 
strategies that lead to greatly improved behavioral outcomes in spinal cord-injured rodents and 
non-human primates.  Subsequently, the most promising strategies are tested in clinical trials for 
their therapeutic efficacy in human subjects suffering from SCI.   
 Reproducibility of these strategies, however, has been problematic, as evidenced by a 
recent program by the National Institute of Neurological Disorders and Stroke, called Facilities 
of Research Excellence - Spinal Cord Injury (FORE-SCI) (Steward et al., 2012).  The purpose of 
the FORE-SCI program was to replicate the most promising reports related to regeneration.  Of 
the 11 studies that were replicated, only 1 confirmed the original findings, while 6 of the studies 
resulted in a complete failure of replication.  Given the incredible cost in time, effort, and money 
to test these potential therapeutics at the primate level or for clinical trials, this is a worrisome 
trend.  Future studies must be held accountable for their validity, robustness, choice of animal 
models, proper controls, blinded analyses, and delivery strategies, targets, and doses. 
 Successful repair of damaged nervous tissue depends on a series of critical steps.  
Following moderate to severe injury of the spinal cord, some degree of axonal growth will be 
necessary to achieve substantial repair.  While enormous progress has been made in our 
understanding of how neuronal growth is regulated, long-distance axonal growth in an injured 
adult mammalian CNS remains a challenge.  If axons regenerate in significant numbers, their 
growth needs to be directed, appropriate targets recognized, and new synapses formed.  




likely that task-specific training will be necessary to shape the connectivity of newly formed 
networks in a meaningful manner.  Indeed, mounting evidence suggests that experience-
dependent plasticity in the juvenile nervous system and injury-induced neuronal plasticity are 
regulated by similar mechanisms.  Furthermore, neuronal networks will need to be supported by 
glia.  Newly grown axons need to be myelinated to ensure axonal health and allow for rapid 
propagation of electrical impulses.   
 Additionally, scalability may become a problem when some of the most exciting findings 
in the rodent SCI field are translated to non-human primates and human patients.  The first step, 
growth of new axons, takes weeks in rodent SCI models.  If long-distance axonal regeneration 
can be achieved in human patients, it may take months to years in order to re-innervate distal 
targets in the injured spinal cord.  Any future treatment will likely have to be combined with 
some form of exercise or skilled training in order to “teach” newly formed networks in an 
experience-dependent manner.  There will be no “simple fix” for SCI; however, the greatly 
accelerated pace of which our mechanistic understanding of neuronal repair is growing raises 




















Figure 5.1: The major ligand-receptor interactions for axonal growth inhibition in the 
injured CNS.  Arrows in black refer to established ligand-receptor interactions, while arrows in 
blue refer to the novel interactions identified during the course of this dissertation. Note - This 
illustration was generously provided by Yevgeniya A. Mironova, and was modified for the 
purpose of this figure.  The original figure appeared in: Mironova YA, Giger RJ (2013) Where 
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Analysis of Tmem125: A Novel Oligodendrocyte-Specific Membrane Protein 
 
 Multiple lines of evidence show that demyelination causes alterations in axonal transport, 
axonal degeneration, and axonal loss (Chandran et al., 2008; Quarles, 2007).  Examples include a 
number of heritable demyelinating diseases of the central and peripheral nervous systems (Trapp 
and Nave, 2008; Zhou and Griffin, 2003).  Remyelination is often incomplete in demyelinating 
diseases such as multiple sclerosis (MS), a cause of neurological disability that primarily affects 
young adults (Franklin and Ffrench-Constant, 2008).  Mechanistic insights into the process of 
developmental myelination, as well as remyelination following injury or disease, are thus of 
critical importance to help understand why remyelination fails in MS and in other demyelinating 
diseases and how it might be enhanced therapeutically.  Here we have taken a genetic approach 
to study the function of a novel, CNS myelin-specific protein called transmembrane protein 125 
(Tmem125) in vivo.  
 To study cell type-specific gene expression profiles in the CNS, the laboratory of our 
collaborator, Ben A. Barres, isolated different cell types to high purity between postnatal day 1 
(P1) and P30 from mouse forebrain (Cahoy et al., 2008).  Affymetrix GeneChip Arrays with a 
total of more than 20,000 genes were used to identify gene products expressed in cell type-




comparative analysis of the transcriptome of acutely isolated neurons, oligodendrocytes, and 
astrocytes (Cahoy et al., 2008).  
 Genes regulated during oligodendrocyte differentiation are of particular interest for 
processes such as myelination, the biology of axon-glia interactions, myelin sheath stability, and 
white matter disorders in general.  To study gene expression in the oligodendrocyte lineage, 
oligodendrocyte progenitor cells (OPCs), newly differentiated oligodendrocytes, and myelinating 
oligodendrocytes were isolated and subjected to GeneChip analysis.  While a number of 
oligodendrocyte lineage-specific genes have been previously characterized, several novel genes 
that are expressed in an oligodendrocyte-specific manner were identified (Cahoy et al., 2008).  
Many of these genes are presumptive membrane-associated proteins, perhaps not surprising 
given the highly specialized function of these cells in the formation of myelin membranes.  
 Genes that are likely to be important for myelination, remyelination, or myelin stability 
are expected to be (1) strongly expressed in myelinating and mature oligodendrocytes (but not 
OPCs), (2) associated with the cell membrane, and (3) not expressed in neurons or astrocytes.  
As an additional search criterion, we focused on genes that do not have structurally-related 
family members, thus reducing the risk for potential compensatory mechanisms following 
germline ablation of the gene of interest.  Given these search criteria, Tmem125 stands out from 
the transcriptome analysis, as it is exceptionally abundant in myelinating oligodendrocytes (with 
comparable levels to myelin basic protein, myelin-associated glycoprotein, and proteolipid 
protein) but is also a completely novel gene.  
 Tmem125 (also known as 6330530A05Rik) is a protein consisting of 220 amino acid 
residues, with 4 predicted transmembrane domains and several regions that are highly conserved 




molecules did not identify any potential Tmem125 family members in human, rat, mouse, or 
chicken, suggesting that it has a unique function.  In the nervous system, Tmem125 is selectively 
expressed by myelinating and mature oligodendrocytes (Cahoy et al., 2008).   
 To address the functional significance of Tmem125 in vivo, we targeted the mouse 
Tmem125 locus to generate germline mutants.  The mouse Tmem125 gene is composed of four 
exons.  The open reading frame is encoded by exon 4; thus, it was deleted (along with exon 3) by 
homologous recombination using the targeting vector shown (Figure A1.1a).  To identify 
embryonic stem (ES) cells that underwent homologous recombination at the Tmem125 locus, 
Southern blot analysis was performed, using probes that distinguish between the Tmem125 wild-
type and mutant locus (Figure A1.1a-b).  Successfully targeted ES cells were injected into a host 
blastocyst, embryos were transferred to a pseudopregnant recipient female mouse, and the 
resulting chimeric mice were bred with wild-type mice to achieve germline transmission.  PCR 
genotyping from tail DNA confirms that Tmem125-/- mice were generated (Figure A1.1c).  
 To our surprise, Tmem125-/- mice do not display any noticeable phenotypes suggestive of 
defective myelin development or stability, such as generalized tremors, seizures, impaired motor 
coordination, or shortened lifespan, as has been noted for several mutants that are incapable of 
proper myelination (Chow et al., 2007; Ikenaka and Kagawa, 1995; Readhead and Hood, 1990).  
However, on a mixed genetic background (129/C57BL/6), Tmem125-/- mice show a striking 
“excessive grooming” behavior, resulting in a substantial loss of fur along their face and back 
(Figure A1.1d).  This type of behavior has been linked to mouse models of obsessive-
compulsive disorder, a neuropsychiatric disorder characterized by intrusive thoughts and 
ritualistic behaviors (Yang and Lu, 2011).  Our analysis shows that Tmem125-/- mice, but not 




beginning around ~6 weeks of age and continuing throughout their life.  Interestingly, a number 
of studies have suggested that deficiencies in myelination are related to various neuropsychiatric 
disorders (reviewed in Bartzokis, 2012). 
 Ongoing work in our laboratory is aimed at characterizing these behavioral abnormalities 
of Tmem125-/- mice.  As the mice are on a mixed background, they are first being backcrossed 
onto a C57BL/6 background for behavioral studies.  Additionally, commercial antibodies for 
Tmem125 are currently being tested by immunoblot analysis, to confirm deletion of the 
Tmem125 protein in Tmem125-/- mice.  Immunoblot analysis is also being used to determine 
levels of myelin marker proteins (myelin basic protein, myelin-associated glycoprotein, 
proteolipid protein, etc.) in Tmem125-/- mice, during and after the process of CNS myelination.  
Similarly, myelin structure and axon density are being assessed by Toluidine Blue staining and 
electron microscopy.  Preliminary evidence suggests that there are no major differences in the 
number of myelinated axons or the thickness of the myelin sheath (at 6 months of age) in 
Tmem125-/- mice, when compared to Tmem125+/+ control littermates.  This appears to be true in 
the sciatic nerve (as expected, given that Tmem125 is not expressed in the peripheral nervous 
system - data not shown), the spinal cord, and the optic nerve (Figure A1.1e-f; data not shown).  
It is possible that, similar to the myelin-associated glycoprotein (see Chapter IV), Tmem125-/- 
mice do not display substantial deficits in developmental myelination, but instead show a loss of 
myelin stability over time or when subjected to injury or insult.  Thus, we are also investigating 
myelin structure and axonal dropout in older Tmem125-/- mice, as well as the levels of 
demyelination (and remyelination) induced by cuprizone, lysolecithin, and experimental 
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Figure A1.1: Generation and preliminary analysis of Tmem125-/- mice.  (a) Targeting 




position of DNA probes (5' and 3' probes) and XbaI restriction sites used for Southern blotting 
are shown. The targeting vector is designed to delete E3 and E4 of the Tmem125 locus. After 
gene targeting, ES cells were subjected to positive (Neo; neomycin) and negative (TK; thymidine 
kinase) selection. ES cells that underwent homologous recombination were identified by 
Southern blotting, and the properly targeted gene was subjected to Cre-mediated recombination 
to delete the Neo cassette. (b) Southern blot analysis of several ES cells, using XbaI digestion 
and the 3’ probe. Many successfully targeted ES cells were identified. (c) PCR genotyping of tail 
DNA from Tmem125+/+ (lane 2), Tmem125+/- (lanes 3, 4, 5, 7), and Tmem125-/- (lanes 6, 8) mice. 
Primers were designed to produce a ~250bp wild-type allele product and a ~525bp null allele 
product. (d) Representative examples of adult Tmem125-/- mice with substantial loss of their fur, 
as a result of excessive grooming. (e-f) At 6 months of age, Toluidine Blue labeling of epon-
embedded Tmem125+/+ and Tmem125-/- (e) sciatic nerve and (f) spinal cord cross sections 
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Development of a Transgenic Mouse to Investigate Semaphorin3A Function 
 
 Semaphorins are a large family of evolutionally conserved glycoproteins, best known for 
their repulsive (and sometimes attractive, depending on the context) roles in developmental axon 
guidance (Pasterkamp and Giger, 2009).  The secreted semaphorin, Sema3A, was the first 
vertebrate semaphorin to be described, and has powerful repellent and growth gone collapsing 
activities toward a number of peripheral and central nervous system neurons (Luo et al., 1993; 
Pasterkamp and Kolodkin, 2003).  These include populations of sympathetic neurons, sensory 
neurons, motoneurons, cortical neurons, and hippocampal neurons (reviewed in Raper, 2000).  In 
vivo, loss of Sema3A has been reported to result in a multitude of phenotypes, including 
inappropriate projections of trigeminal, facial, vagus, accessory, and glossopharyngeal nerves 
(Taniguchi et al., 1997).  Improper orientation of pyramidal neurons in the neocortex and axon 
defasciculation of several neuronal populations has also been noted in Sema3A-/- mice (Behar et 
al., 1996; Polleux et al., 1998; Taniguchi et al., 1997).  To exert its function, Sema3A requires 
Neuropilin-1 (Npn1) as a co-receptor in order to signal through its transmembrane receptors, any 
member of the class A plexins (PlexinA1, PlexinA2, PlexinA3, or PlexinA4) (Pasterkamp and 
Giger, 2009). 
 While Sema3A has been extensively investigated for its roles in axon guidance, its 
expression continues long beyond the time of neuronal outgrowth and target navigation, 




regulation of dendritic spine density, coordination of synaptic transmission in the CA1 region of 
the hippocampus, and inhibition of axon regeneration following injury (reviewed in Pasterkamp 
and Giger, 2009).  Furthermore, roles for Sema3A in other tissues, including the bone, kidney 
and heart, have been suggested (Behar et al., 1996; Reidy and Tufro, 2011).  A major goal of our 
laboratory is to understand the plethora of functions that canonical axon guidance molecules 
perform (beyond axon guidance), using mouse genetic tools and gain- or loss-of-function 
approaches.  Thus, as a tool for future studies, we generated a transgenic mouse to allow 
overexpression of Sema3A in a cell type-specific and/or temporal fashion.  
 In order to visualize the cells that are overexpressing Sema3A, we constructed a 
tdTomato-Semaphorin3A (tdT-Sema3A) fusion protein using sequences from tdT and rat 
Sema3A (Figure A2.1a).  The entire tdT sequence was fused to Sema3A with a HindIII 
restriction site and then cloned into the pSecTag2A vector (Invitrogen).  More specifically, the 
end of tdT (the lysine residue immediately preceding the stop codon) was fused to the beginning 
of Sema3A (the 23rd residue - alanine - following the start codon).  As a control, a second protein 
was constructed in the exact same manner, except that the tdT stop codon was included.  Thus, 
this protein (referred to as tdT) consists of an expressed tdT and non-expressed Sema3A.    
 tdT-Sema3A and tdT expression were confirmed in transiently transfected HEK293T 
cells.  Conditioned cell culture supernatants were collected and concentrated using centrifugal 
filter units.  The expression levels and size of tdT-Sema3A and tdT in cell lysates were assessed 
by immunoblotting using anti-DsRed antibody (Clontech), as well as anti-β-actin (Sigma) as a 
loading control.  Indeed, tdT-Sema3A and tdT are expressed at the correct molecular weight 
(Figure A2.1b) and produce bright red fluorescence in HEK293T cells (Figure A2.1c).  To 




transfected with either pIRES-EGFP (GFP) or full-length rat Neuropilin-1 in pIRES-EGFP 
(GFP-Npn1).  24 hours later, the cells were incubated with 5nM of either tdT or tdT-Sema3A for 
90 minutes, before washing and fixation.  As expected, the tdT-Sema3A fusion protein shows 
robust binding (based on red fluorescence) to GFP-Npn1, but not to GFP only (Figure A2.1d). 
 To assess the bioactivity of tdT-Sema3A, a neurite repulsion assay with embryonic day 
18 dorsal root ganglion (DRG) explants was performed.  HEK293T cells were transiently 
transfected with either tdT-Sema3A or tdT.  24 hours later, the cells were trypsinized and 
collected in “hanging droplets”, and the droplets were incubated for 5 hours at 37°C to form cell 
aggregates.  In a collagen matrix, a DRG explant was placed in close proximity to aggregated 
HEK293T cells, and the co-cultures were incubated at 37°C for 48 hours.  The cultures were then 
fixed, washed, and immunolabeled with 2H3 anti-neurofilament antibody (Developmental 
Studies Hybridoma Bank, University of Iowa).  While DRGs exposed to tdT-expressing 
HEK293T cells grew long processes directly into the cells, DRGs exposed to tdT-Sema3A-
expressing cells were significantly repulsed (P< 0.001, unpaired t-test) (Figure A2.1e-f).   
 Following successful confirmation of tdT-Sema3A expression and activity (see above), 
we next cloned the entire tdT-Sema3A construct (with the Ig κ-chain leader sequence from 
pSecTag2A included) into the STOP-eGFP-ROSA26TV vector (Stratagene).  This vector 
contains loxP sites surrounding a STOP cassette, which is followed by the gene of interest.  
Thus, tdT-Sema3A will only be expressed when Cre is present and the STOP cassette is 
removed, allowing overexpression of the fusion protein in select cell types and/or at specific 
times of development or adulthood.  This final construct was then used for development of a 
transgenic mouse expressing tdt-Sema3A following Cre recombination.  PCR genotyping has 




studies are currently underway to confirm expression of tdT-Sema3A in mice that are also 
expressing nestin-Cre or in mice that have received intraorbital injection of AAV2-GFP-Cre.  
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Figure A2.1: Expression and functionality of a tdTomato-Semaphorin3A fusion protein.  
(a) Schematic of the tdTomato-Semaphorin3A secreted fusion protein (tdT-Sema3A). The end of 
tdTomato (1 amino acid before the stop codon - red) was fused to the beginning of rat Sema3A 
(23 amino acids after the start codon - blue) by inserting a HindIII restriction site (black) and 
cloning into the psectag2A vector. Sema=amino-terminal semaphorin domain, PSI=plexin-
semaphorin-integrin domain, Ig=immunoglobulin-like domain, Basic=basic C-terminal domain. 
(b-c) Confirmation of tdT-Sema3A expression in HEK293T cells. In (b), western blotting using 
conditioned media from HEK293T cells transfected with either tdT or tdT-Sema3A revealed the 
expected protein sizes when probed with an anti-DsRed antibody (actin shown as a loading 
control). In (c), HEK293T cells transfected with either tdT or tdT-Sema3A display strong tdT 
fluorescence. (d-f) Confirmation of tdT-Sema3A functionality. In (d), HEK293T cells were 
transfected with either GFP or GFP-Neuropilin-1 (GFP-Npn1), and binding of tdT or tdT-
Sema3A was assessed 24 hours later. Binding is only observed between the tdT-Sema3A fusion 
protein and GFP-Npn1-transfected cells. In (e), E18 rat DRG explants were co-cultured in a 
collagen matrix with HEK293T cells expressing either tdT or tdT-Sema3A and grown for 48 
hours. DRG axonal projections were labeled with 2H3 anti-neurofilament antibody. DRG axons 
are repelled by the tdT-Sema3A-expressing HEK293Ts, but not by the tdT-expressing cells. (f) 
Quantification of the repulsion assay shown in (e). The length of axonal projections on the 
proximal (P) and distal (D) sides of the DRG explant was measured and used to calculate the P/D 
value. 16 explants were analyzed for each condition (from 3 independent experiments). Gray bar 
(tdT); black bar (tdT-Sema3A). Results are presented as mean ± SEM. * P< 0.001 (unpaired t-
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VEGF Shows Its Attractive Side at the Midline 
 
 The following commentary was written as a preview for two articles appearing in a 2011 
issue of Neuron: 
 
 The assembly of a highly organized network of neuronal connections is a key 
developmental process and essential for all neural function, ranging from simple movement to 
complex cognitive processes.  Research focused on the cellular strategies and molecular 
mechanisms that orchestrate neural network assembly led to the discovery of a wide variety of 
axon guidance molecules and receptors (Kolodkin and Tessier-Lavigne, 2010).  Many guidance 
molecules are evolutionarily conserved and, based on their mode of action, are categorized into 
short- or long-range guidance cues that influence growth cone steering in a positive (attractive) 
or negative (repulsive/inhibitory) manner.  We now know that the activity of an individual 
guidance cue is not absolute, but instead interpreted by the neuronal growth cone in a context-
dependent manner.  Important conceptual advances in deciphering the molecular language of 
axon guidance and network assembly include the discovery of hierarchies among guidance cues, 
the identification of molecular switches that when flipped turn an attractive cue into an inhibitory 
one (or vice versa), and the existence of diverse receptor complexes that facilitate cell type-




wiring of the developing nervous system provides insight into the molecular logic that allows a 
relatively small set of guidance cues to initiate the assembly of complex neural networks with 
myriad interconnected circuits.  In this issue of Neuron, Erskine et al. (2011) and Ruiz de 
Almodovar et al. (2011) now provide new evidence that a key angiogenic factor, VEGF-A, 
exhibits angiogenesis-independent chemoattractive effects on spinal commissural and retinal 
ganglion cell axons at the CNS midline. 
 It is not by chance that analysis of nervous system midline development has been 
particularly successful in the discovery of guidance cues and the elucidation of axon pathfinding 
mechanisms.  Axons extending toward the CNS midline during development must make an 
important decision: to cross and find a synaptic partner on the contralateral side of the nervous 
system (relative to their cell body) or not to cross and remain confined to the ipsilateral side.  
Extensive work in fruit flies, worms, fish, chicks, and mice has established that the midline is a 
rich source of chemoattractants and chemorepellents (Figure A3.1a) (Dickson and Zou, 2010).  
Vertebrate Netrin-1 is a robust chemoattractant for spinal commissural axons and is secreted by 
floor plate cells located at the ventral midline.  Despite its strong and long-range attractive 
capabilities, Netrin-1 collaborates with several additional cues to direct precrossing commissural 
axons toward the floor plate.  Chemorepellents, including BMPs and Draxin, are released by the 
roof plate and initially “push” commissural axons ventrally into an increasing Netrin-1 gradient. 
 The floor plate also secretes the morphogen Sonic Hedgehog (Shh).  Like Netrin-1, Shh is a 
chemoattractant for precrossing commissural axons.  Once at the floor plate, commissural axons 
lose their interest in Netrin-1 and Shh, and acquire responsiveness to floor plate-derived 
repellents, including Slits and Semaphorins, allowing them to exit the floor plate and move on to 




commissural neurons exposed to a Netrin-1-deficient floor plate in the presence of Shh signaling 
inhibitors show residual attraction, indicating the existence of additional, unidentified floor plate 
attractant(s) (Charron et al., 2003). 
 In the developing visual system, retinal ganglion cell (RGC) axons arriving at the chiasm 
face the same challenge as precrossing axons in the ventral spinal cord: to cross or not to cross 
the midline.  As they approach the optic chiasm, RGCs segregate into ipsilaterally and 
contralaterally projecting fibers (Figure A3.1b).  Proper crossing, or decussation, at the chiasm 
is essential for organisms with prominent binocular vision.  The mouse has laterally positioned 
eyes and limited binocular vision.  A large population of RGC axons cross the midline, and a 
relatively small population does not cross and project ipsilaterally.  Seemingly quite different 
molecular strategies have evolved for proper growth cone navigation at the optic chiasm and 
spinal cord midline structures.  Molecular gatekeepers such as Netrin-1 and Slits are either 
absent from the optic chiasm or do not directly participate in midline crossing of RGCs.  Growth 
inhibitory cues, on the other hand, are abundant (Erskine and Herrera, 2007).  These include the 
midline repellent EphrinB2, an established guidance cue at the mouse optic chiasm.  EphB1 is 
expressed by ipsilaterally projecting RGCs and EphrinB2 is necessary for the proper formation 
of these projections.  More recent evidence suggests that Shh repels ipsilateral RGC axons at the 
optic chiasm via its receptor Boc (Fabre et al., 2010).  Semaphorin5A and Slits are molecules 
that define the boundary of the optic pathway but do not directly participate in midline crossing 
(Erskine and Herrera, 2007).  Much less is known about the molecular mechanisms that promote 
midline crossing at the chiasm.  In zebrafish, the secreted semaphorin Sema3D is expressed at 
the midline and is thought to provide inhibitory signals at the chiasm midline to help channel 




molecule NrCAM is expressed at the mouse chiasm and also in a small subset of late born RGCs, 
and it promotes their midline crossing in vivo (Williams et al., 2006).  Cell culture experiments 
raised the possibility that a growth-promoting factor that mediates RGC axon crossing at the 
midline is present at the optic chiasm, suggesting that decussation is not a default mechanism but 
an active process involving unknown chemoattractive cue(s) (Tian et al., 2008). 
 A pair of exciting new studies (Erskine et al. [2011] and Ruiz de Almodovar et al. 
[2011]) demonstrate for the first time that vascular endothelial growth factor (VEGF)-A released 
at the CNS midline functions as a chemoattractant for spinal commissural and RGC axons 
in vivo.  Erskine et al. show that in the mammalian visual system, VEGF functions as a growth-
promoting factor that promotes extension of contralaterally projecting RGC axons across the 
midline, while Ruiz de Almodovar et al. find that in the spinal cord, VEGF secreted from the 
floor plate is an attractant for precrossing spinal commissural axons.  VEGF is best known for its 
proangiogenic function during blood vessel growth in vivo, and recent studies have revealed that 
VEGF also promotes neural progenitor proliferation, survival, migration, and differentiation 
(Greenberg and Jin, 2005).  However, these present studies demonstrate the versatility of  
VEGF-A, expanding its repertoire to include chemoattractant function essential for proper 
nervous system wiring. 
 In their search for guidance cues that function as chemoattractants at the mammalian 
optic chiasm, Erskine and colleagues initially observe that mice lacking Neuropilin-1 (Npn-1), a 
transmembrane receptor for class 3 Semaphorins and select isoforms of VEGF-A (Adams and 
Eichmann, 2010), display increased ipsilateral projections at the optic chiasm at embryonic day 
(E)14.5 in vivo.  No defects at the chiasm were observed in mice deficient for the related 




appears to develop normally, and no changes in expression of EphrinB2 or Slits were observed.  
Furthermore, the ventrotemporal domain of the retina that gives rise to most ipsilateral RGC 
projections is not enlarged in Npn-1 mutants.  When coupled with the strong expression of   
Npn-1 on contralaterally projecting RGC axons, this phenotype suggested a role for Npn-1 in 
promoting RGC axon midline crossing.  Interestingly, expression of class 3 Semaphorin family 
members (Sema3s) at the chiasm is not observed, or is extremely low, at the time when RGCs 
cross.  To rule out potential influences from more remote Sema3 sources, mice carrying a Npn-1 
point mutation that abolishes Sema3, but not VEGF, signaling (Npn1Sema−/−) (Gu et al., 2003) 
were analyzed.  Similar to wild-type mice, Npn1Sema−/− mice show no midline crossing defects at 
the optic chiasm.  With a vital role for Sema3s eliminated, Erskine et al. (2011) turned their 
attention to isoforms of VEGF-A, a second class of Npn-1 ligands.  VEGF-A is strongly 
expressed at the embryonic optic chiasm in the mouse.  To explore the possibility that VEGF is 
the Npn-1 ligand that promotes contralateral RGC axon growth, Erskine et al. (2011) analyzed 
Vegfa120/120 mice, which cannot produce the Npn-1-binding isoforms VEGF164 or VEGF188, 
but do express VEGF120, which does not bind Npn-1 and supports blood vessel formation.   
Similar to Npn-1 null mice, Vegfa120/120 mice display increased ipsilateral projections and 
decreased contralateral projections, supporting the idea that VEGF/Npn-1 interactions promote 
RGC axon crossing at the optic chiasm.  Vegfa120/120 mice survive to birth, so retrograde DiI 
labeling was employed to independently assess ipsilaterally projecting RGC axons and determine 
the origin of misrouted axons within the retina.  In wild-type mice, ipsilateral RGCs are 
primarily restricted to the ventrotemporal region of the retina (Figure A3.1b).  In Vegfa120/120 
mice, however, retrogradely labeled RGCs were found throughout the temporal and nasal retina.  




to a VEGF164 gradient.  Consistent with a previous study showing that VEGF promotes 
regenerative growth of axotomized RGCs in culture (Bocker-Meffert et al., 2002), VEGF164 
was found to act as a selective attractant for dorsotemporal RGC growth cones (neurons that give 
rise to contralateral projections) but not for ventrotemporal RGC growth cones (neurons that give 
rise to ipsilateral projections).  Collectively, these studies show that VEGF164 functions as a 
chemoattractant to promote midline crossing of Npn-1-expressing RGC axons at the optic 
chiasm in vivo. 
 VEGF also functions as an attractant for spinal commissural axons, as reported in the 
study by Ruiz de Almodovar et al. (2011).  VEGF is expressed at the floor plate at the time when 
spinal commissural axons cross the midline (Figure A3.1a).  Mice lacking function of a single 
VEGF allele specifically in the floor plate (Vegf FP+/−) secrete less VEGF and exhibit 
concomitant abnormal pathfinding of precrossing commissural axons.  While most Robo3-
positive commissural axons reach the floor plate in Vegf FP+/− mice, labeled commissural axons 
in embryonic spinal cord sections are observed to be defasciculated, and they often project to the 
lateral edge of the ventral spinal cord.  Important control experiments show that the defects 
observed are not secondary to altered expression of Netrin-1 or Shh in the floor plate of         
Vegf FP+/− mice.  In vitro, an attractive response by commissural axons to a gradient of VEGF-A 
was observed in the Dunn chamber assay.  Interestingly, VEGF-A attraction was completely 
abolished in the presence of a function blocking, anti-Flk1 (KDR/VEGFR2) antibody or by 
pharmacological inhibition of Src family kinases.  Anti-Npn1 in this same assay had no effect 
on VEGF-A attraction.  Immunolabeling of precrossing commissural axons revealed 
coexpression of Flk1 and Robo3, and conditional ablation of Flk1 in commissural neurons 




levels of Netrin-1 and Shh in the floor plate in Flk1CN-ko mice are comparable to wild-type 
littermates, indicating that Flk1 cell-autonomously controls VEGF-mediated attraction of 
precrossing commissural axons in vivo. 
 Taken together, these studies are the first to report that VEGF is essential for proper axon 
guidance at the CNS midline in vivo.  VEGF-A functions as a midline-derived chemoattractant 
for RGC axons in the diencephalon and functions similarly for commissural axons in the 
developing spinal cord.  In the visual system, Npn-1 is an obligatory receptor for VEGF 
attraction, while in the developing spinal cord, Flk1 is required for the VEGF-mediated attractive 
response.  No significant expression of Flk1 or Flt1 is detected in developing RGCs (Erskine 
et al., 2011), and conversely, Npn-1 is not expressed by precrossing spinal commissural neurons 
(Ruiz de Almodovar et al., 2011).  Although Flk1 mutants have not been examined for RGC 
midline crossing defects, the current data suggest that RGCs and spinal commissural neurons 
employ distinct and independent signaling mechanisms for VEGF attraction. 
 How does VEGF signal attraction in RGCs?  Npn-1 is a type-1 transmembrane protein 
with a short cytoplasmic domain, and one possibility is that Npn-1 signals attraction through its 
cytoplasmic domain, independent of a coreceptor(s).  Alternatively, Npn-1 might form a 
complex with a coreceptor to form a holoreceptor complex that signals VEGF attraction.  
NrCAM has been shown to regulate neuropilin signaling in response to Sema3s during 
commissural axon guidance in the anterior commissure (Falk et al., 2005).  When coupled with 
NrCAM's role in promoting RGC axon midline crossing in vivo, it is possible that NrCAM is 
part of a Npn-1/VEGF receptor complex which promotes midline crossing.  Arguing against this 
possibility, however, are the distinct temporal requirements for NrCAM and Npn-1/VEGF for 




mutant mice is observed as early as E14, while defects in NrCAM mutants are observed only late 
in visual system development, from E17.5 onward (Williams et al., 2006).  Recent evidence 
suggests that Flk1 functions as the signal transducing receptor component for Sema3E, providing 
additional evidence for shared mechanisms involving Sema3s and VEGF (Bellon et al., 2010).  
These present studies do not address whether VEGF influences guidance in a Plexin-dependent 
manner.  Npn-1 forms a complex with Plexin receptors, and Plexins are regulators of both 
attractive and repulsive axon guidance (Kolodkin and Tessier-Lavigne, 2010).  Genetic tools are 
available, and it will be interesting to examine whether Plexin mutants show guidance defects at 
the CNS midline related to impaired VEGF function. 
 The identification of VEGF as a novel midline attractant released by the floor plate begs 
the question as to how VEGF might fit in with previously identified spinal commissural axon 
guidance mechanisms.  For precrossing, Flk1-positive axons, VEGF released by the floor plate 
presumably collaborates with Netrin-1 and Shh in commissural axon attraction.  While most 
Robo3-positive axons reach the floor plate in Vegf FP+/− mice, some of these axons stall and are 
misrouted into a more lateral trajectory.  The most noticeable phenotype in Vegf FP+/− mice is 
axon defasciulation.  Defects observed in Vegf FP+/− mice are similar to those observed in mice 
deficient for the Shh receptor Boc and the Shh signaling component Smoothened (Charron et al., 
2003; Okada et al., 2006).  However, these phenotypes are less pronounced than the Netrin-1 
phenotype, since the majority of precrossing commissural axons are able to reach the midline.  In 
Netrin-1 mutants on the other hand, most precrossing commissural axons stall and fail to enter 
the ventral spinal cord.  This suggests that in the absence of Netrin-1, the ventral spinal cord may 
be nonpermissive for commissural axon growth.  Thus, Shh and VEGF may function primarily in 




Consistent with this idea, Shh and VEGF attract precrossing commissural axons, but exhibit no 
growth-promoting effects in vitro (Charron et al., 2003; Ruiz de Almodovar et al., 2011). 
 Next on the agenda will be questions concerning how commissural axons cope with 
VEGF attraction after they have entered the floor plate.  Are there mechanisms in place that 
modulate or silence VEGF attraction, similar to those reported for Netrin-1 and Shh?  
Alternatively, is loss of Netrin-1 attraction, in conjugation with acquisition of Slit and Sema3 
inhibition, sufficient to prevent postcrossing commissural axons from recrossing the midline as 
they travel rostrally, despite continuing VEGF attraction?  Ultimately, a detailed understanding 
of growth cone navigation at the midline requires a combination of tools that allow temporal and 
spatial regulation of guidance cues, their receptors, and downstream effectors.  When combined 
with live imaging of commissural axon subpopulations, this approach will reveal insights into the 
contributions of individual cues as they promote proper axon navigation at the CNS midline.  
The identification of VEGF as a midline attractant by Erskine et al. (2011) and Ruiz de 
Almodovar et al. (2011) represents an important advancement toward this goal. 
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Figure A3.1: Axon guidance mechanisms at the CNS midline.  (a) Embryonic spinal cord 
showing trajectory of commissural axons. Precrossing spinal commissural axons are initially 
pushed ventrally by roof plate-derived inhibitory cues, including BMPs and Draxin (red 
gradient). Chemoattractants secreted by the floor plate include Netrin-1, Shh, and VEGF (green 
gradient). After crossing the midline, commissural axons lose attraction to Netrin-1 and Shh. 
Conversely, factors such as Slits and Sema3B, which have no effect on commissural axons 
before crossing, become potent repellents after crossing. (b) In vertebrates with frontally located 
eyes, subpopulations of RGC axons are segregated at the optic chiasm to project to targets on 
both the ipsilateral and contralateral side of the brain. EphrinB2 and Shh at the chiasm midline 
are repellents for EphB1- and Boc-expressing RGCs destined for the ipsilateral optic tract. 
NrCAM expressed by RGCs is required in a small subset of late born neurons to form 
contralateral projections. The VEGF-A isoform VEGF164 is expressed at the midline where it 
functions as a chemoattractant for Npn-1-positive RGCs to instruct contralateral growth. D, 
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